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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
1 NEEDLE-FREE VACCINATION TARGETING THE SKIN 
The world health organization (WHO) recently reported that vaccination prevents 
estimated two to three million deaths every year in all age groups from infectious 
diseases as diphtheria, tetanus, pertussis and measles [1]. Hence, vaccination is still 
the most effective and cost efficient method to advert infectious diseases. 
Vaccination dates back to the early success of the smallpox vaccine [2, 3]. Since 
then mass vaccination campaigns reduced significantly the incidence of many 
diseases, and herd immunity offers the protection of individuals who cannot be 
vaccinated. Recommendations for vaccination schedules are regularly outlined by 
public authorities. Future projects comprise the use of therapeutic vaccines in the 
treatment of non-curable diseases such as AIDS (acquired immunodeficiency 
syndrome), Alzheimer disease and cancer [4, 5]. A remarkable progress was 
achieved by the establishment of the Human Papillomavirus vaccine (HPV), 
Cervarix® (GSK) and Gardasil® (MSD), preventing cervical, vulvar and vaginal 
cancers [6-8]. 
There are many factors to consider for optimal vaccination, such as route of delivery, 
targeting of specialized immune cells and stimulation of humoral and cellular 
immunity [2]. Moreover, an ideal vaccine should be chemically stable, safe and 
effective and, in the best case, economical in order to facilitate a widespread use. 
The delivery of the vaccine should ideally be easy to handle, so that vaccine 
administration may be carried out after minimal operator training, already [9].  
Despite of the progress made in research of new vaccination technologies, the 
conventional administration of vaccines is still mostly carried out by injecting a liquid 
vaccine formulation subcutaneously or intramuscularly using needles and syringes. 
However, this implicates also the risk of needle stick injuries and re-use of needles. 
Extensive cross-contamination with HIV (human immunodeficiency virus), HBV 
(Hepatitis B virus) and other blood borne diseases was reported to be a result of re-
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use of needles particularly in developing countries. [10-14]. Furthermore, vaccination 
via needles and syringes is especially for children very stressful [15, 16]. Hence, 
needle-free delivery systems may therefore result in a better patient compliance [2]. 
Needle-free approaches for vaccine delivery have gained public interest in the last 
years as they offer a non-invasive alternative to conventional needle and syringe 
applications. The target areas for needle-free vaccine delivery are the oral, mucosal 
or dermal route. Especially the skin is a very attractive target area for vaccination as 
it comprises a dense network of immunocompetent cells and is easily accessible [17-
23]. 
In addition to its mechanical barrier function, the skin is able to respond to foreign 
antigens and to regulate the nature and magnitude of the resulting immune 
responses, due to the presence of specialized antigen presenting cells, so called 
Langerhans cells [24-26], in the epidermis. Furthermore, the lack of vasculature and 
the low density of sensory nerve endings in the epidermal layer of the skin provide 
the opportunity for painless vaccine administration. The combination of a needle-free 
application together with the use of dry vaccine powders instead of a liquid vaccine 
formulation offer in addition the potential for enhanced stability and cold chain 
independent logistics [19, 27, 28]. The effectiveness of low doses of intradermal 
vaccines was shown to be comparable to full doses of conventional intramuscular 
vaccines [29-40].  
The application of dry vaccine powders through the skin using needle-free powder 
injectors showed adequate immune responses in preclinical and clinical studies [41-
43]. Despite of the demonstrated potential of needle-free powder injection systems 
using powdered vaccine formulations for immunization, they did not gained market 
approval for human use.  
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2 VACCINES  
Vaccines are biological products which are applied to humans or animals in order to 
provide immunity to a certain disease. Live attenuated vaccines induce a strong 
cellular and antibody response and offer long term protection as they are non-
pathogenic but possess all pathogenic features [44]. Examples for live attenuated 
vaccines are the measles, mumps and rubella vaccine [45]. 
Inactivated vaccines are regarded as safer as live attenuated vaccines as they 
cannot revert back to virulence [3-5]. However, they are also not as effective in 
comparison to live attenuated vaccines but provoke more inflammatory immune 
responses than subunit vaccines. An example for an inactivated vaccine is the 
Hepatitis A vaccine [46]  
Subunit vaccines comprise one or more components of a pathogen, mostly 
recombinant peptides, proteins or polysaccharides. They are well defined and offer 
high purity and safety [47, 48]. One drawback of subunit vaccines is their low 
immunogenicity, and hence the need for co-administration of adjuvants. Examples for 
subunit vaccines are toxoid vaccines against diphtheria, tetanus, and pertussis. The 
subunit vaccine against hepatitis B that is composed of only the surface protein of the 
virus and the HPV vaccine, a virus like particle (VLP) composed of the viral major 
capsid protein [49]. 
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3 ADJUVANTS 
The administration of vaccines does not always lead to an effective immune 
response. Therefore, adjuvants are often necessary to enhance the specific immune 
responses towards the applied antigen [50]. They can also be used to reduce the 
amount of antigen or to improve the efficacy of vaccines [51, 52].  
There are different approaches to classify adjuvants. One of the oldest goes back to 
Edelman [53]. According to him, adjuvants can be classified into three groups: (i) 
active immunostimulants, which increase the immune response to an antigen, (ii) 
carriers, consisting of immunogenic proteins and supporting T-cells and (iii) oily 
emulsions or liposomes, stimulating the immune response and serving as matrix for 
antigens. Other systems to classify adjuvants are according to their administration 
route, their origin, their mode of action [54] or certain physicochemical properties [50, 
55-58].  
Alum based compounds are the most commonly used adjuvants approved for human 
use [59, 60].  
One of the most potent known adjuvants is Freund’s complete adjuvant, consisting of 
an emulsion of water and mineral oil containing killed mycobacteria [61]. However, 
due to severe local reactions only Freund’s incomplete adjuvant, without added 
mycobacteria, is approved for human use [62, 63].  
Further examples for oil in water emulsions are MF59 (based on squalene) [64, 65] 
and AS03 (based on squalene and α-tocopherol) [66, 67], which are both approved 
for human use in influenza vaccines. 
Currently adjuvants for mucosal immunization are in the focus of vaccine 
development, enabling the uptake of antigen through mucosal routes. Alum salts 
failed to enhance specific immune response when administered by the oral or nasal 
route [68]. However, Maa et al. showed that alum adjuvanted vaccines were well 
tolerated and immunogenic after the administration via the skin (by epidermal powder 
immunization) in a guinea pig model [69]. Bacterial derivatives like cholera toxin, the 
B subunit of cholera toxin, diphtheria toxoid or tetanus toxoid were shown to be 
highly effective mucosal adjuvants [3, 48, 70-77]. Diphtheria toxoid was also explored 
via epidermal powder injection in mice and showed promising results [75]. Synthetic 
or inactivated delivery systems, including synthetic polymeric particles [78, 79], 
alginates, gelatin, liposomes and ISCOMS, are another group of adjuvants suitable 
for the mucosal route [47, 50, 80, 81].  
CHAPTER 1 
 
5 
 
However, the efficacy of adjuvants and also the likelihood of side-effects depend on 
the route of administration [82], and hence, have to be taken into consideration. 
 
 
4 DRY VACCINE FORMULATIONS 
4.1 DRY POWDER VACCINE FORMULATIONS 
Efficient vaccination using ballistic needle-free devices implicate the development of 
dry vaccine formulations. The development of solid-state or dry vaccine formulations 
is a feasible approach to achieve room temperature stability of the formulations [83, 
84].  
Powdered vaccine formulations provide enhanced stability of the vaccine. They are 
less dependent on cold-chains and therefore particularly desirable for vaccination 
programs in the developing world, offering higher stability and facilitated storage 
conditions [28, 85].  
Vaccine particles intended for intradermal injection have to exhibit certain 
characteristics in order to be delivered to the target area by ballistic acceleration. The 
sizes of the particles, as well as their density determine significantly the velocity of 
particles upon acceleration as well as the particle distribution and penetration depth 
into the skin. Particles based on sugar formulations need a particle size of about 
20 to 70 µm in order to penetrate into the skin, as they have to compensate their low 
density, which is in general of about 1.5 g/cm³ or lower [75, 86-88]. However, the size 
of the particles is also a limiting factor for intradermal injection, as particles larger 
than 100 µm can cause pain and bleeding at the site of injection [89].  
A sugar excipient formulation composed of trehalose, mannitol and different polymers 
(dextran, polyvinylpyrrolidone, hydroxyethylstarch or polyethylene glycol) for the 
formation of particles by spray freeze-drying or spray drying was extensively studied 
for its suitability for intradermal injection [90-95]. It was shown that sugar particles 
were successfully delivered into the skin using a powder injection device, and were 
retrieved mostly in the extracellular space of the epidermis [87]. A cheap and easy 
manufacturing process of vaccine loaded sugar particles, a high loading capacity of 
the sugar matrix with antigen, as well as the possibility to store the formulation at 
room temperature are major advantages of this approach. Preclinical and clinical 
studies showed an adequate immune response after injection of vaccine loaded 
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powders into the skin [41-43]; however, local site reactions like erythema, petechiae, 
oedema and skin discoloration were prominent at the site of injection [89].  
 
4.2 PARTICULATE SYSTEMS AS CARRIERS FOR VACCINES 
Apart from sugar based vaccine formulations, other particulate systems were 
evaluated as carrier particles for vaccines intended for intradermal injection like silica 
nanoparticles embedded in sugar microparticles [96], agarose beads [91], aluminium 
salts [69, 92] and gold particles [87, 97, 98].  
The use of gold particles has been extensively studied for the delivery of DNA 
vaccines using a supersonic particle injection device. As particle penetration into the 
skin is a function of size, density and velocity, gold particles with a particle size of 1 to 
3 µm can be delivered successfully to the skin by ballistic approaches and are mainly 
deposited intracellularly [98]. Thereby, immunocompetent cells in the epidermal 
layers of the skin can be efficiently targeted [87, 97, 99]. However, it was also 
reported that cell death can occur due to the direct impact of the gold particles due to 
stress and shock waves within the tissue [100, 101]. By using this technology, only a 
low amount of DNA vaccine is necessary to transfect the cells with a high transfection 
efficiency [97, 102, 103]. Limitations of this system are given by the amount of DNA 
that can be precipitated on the particle surface and hence, in some cases, the need 
of multiple shots at multiple delivery sites in order to deliver the require payload [87, 
104, 105]. From an economical view of sight, the use of gold particles may be too 
costly for mass vaccination campaigns. It was observed in preclinical vaccination 
studies, that DNA vaccine coated on gold microparticles was able to elicit antibody 
responses, however, this was only achieved with the highest dose levels [98, 104, 
106]. 
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5 DRYING TECHNIQUES FOR THE GENERATION OF VACCINE POWDER 
FORMULATIONS 
Drying techniques such as spray drying, spray freeze drying and air drying 
(desiccation) have been explored to create particles suitable for epidermal powder 
immunization using a supersonic device developed by PowderJect Technologies [42, 
69, 85, 90-95]. 
Furthermore, other technologies like supercritical fluid drying were used for the 
generation of stable vaccine products. For example microparticulate powder 
formulations containing diphtheria toxoid for pulmonary vaccination and inhalable 
powders of live attenuated measles virus vaccine were generated using this 
technology [107, 108]. 
Freeze drying is a gentle method to create a porous cake by preserving the stability 
of sensitive vaccine products [84, 109-112]. By applying this method a subsequent 
particle formation, e.g. milling, is required in order to generate particles in the 
appropriate size range suitable for ballistic powder injection [41, 85]. 
The controlled collapse of lyophilizates [113, 114] as well as products obtained by 
vacuum foam drying [27] offer sugar matrices with a highly reduced surface area in 
comparison to conventional lyophilizates. A reduced surface area of the sugar matrix 
implicates a dense and mechanical robust cake, which is a vital prerequisite for 
ballistic injection of vaccine powders [115]. Hence, these techniques, combined with 
a second particle formation step, are of interest for the generation of particles suitable 
for ballistic powder delivery.  
 
5.1 FREEZE-DRYING AND COLLAPSE FREEZE DRYING 
Freeze drying is a preferred method to convert vaccines into the solid state. In brief, 
the fluid formulation is frozen and subsequently dried by the removal of water by 
sublimation, directly from the solid state to gas under reduced pressure [111, 116, 
117]. After removal of all water, the biopharmaceutical compound is embedded in a 
dry sugar glass, with a glass transition temperature depending on the excipients 
used. The obtained product is a highly porous cake with a high specific surface area 
which can easily be reconstituted, offering stability advantages [28, 85]. The choice of 
stabilizers determines decisively the preservation of vaccine quality during freezing, 
drying and subsequent storage [110, 116].  
GENERAL INTRODUCTION 
 
8 
 
A controlled collapse of the lyophilizates due to a modified lyophilization cycle 
performed by Schersch et al. was shown to result in a highly dense sugar matrix, 
comprising a low specific surface area whilst the stability of the incorporated 
biopharmaceuticals was preserved [113]. In addition, enhanced protein stability 
during storage could be shown by applying the collapse freeze-drying cycle [118]. 
Thus, by combining the process with a subsequent milling step, and, if required, a 
sieving step, collapse freeze-drying offers a promising option to generate powder 
particles with desirable characteristics for ballistic injection.  
Whilst jet-milling of pharmaceutical powders is already commonly used for the 
preparation of inhaled biopharmaceuticals [119], only little is known about milling of 
biopharmaceuticals intended for intradermal application [85]. Though, Chen et al. 
proved evidence of immunogenicity in mice of a recombinant envelope protein 
rgp120 (rgp120), a human immunodeficiency virus (HIV) component, when 
administered by epidermal powder immunization after manually grinding of the 
powder formulation with a pestle and mortar [41]. Another pulverization method, cryo-
milling, will be explored in detail in this thesis. 
 
5.2 SPRAY FREEZE DRYING 
Spray freeze drying is technological process to produce pharmaceutical powders of 
small and large scale particles or powders. Spray freeze drying is a two-step process 
combining the atomisation of a liquid formulation into a cloud of small droplets and 
subsequent lyophilization. In the first step, a liquid formulation containing antigens 
and excipients is atomized through a high frequency ultrasonic nozzle to generate 
fine liquid droplets that are flash frozen in liquid nitrogen. In a second step, the frozen 
droplets are lyophilizated, generating a dry powder formulation [93, 95, 120]. 
Spray freeze drying offers an extremely rapid vitrification process due to the 
enormous surface area for heat transfer generated during the atomization in the 
spraying process and the direct contact of the liquid droplets with the freezing 
medium. Using this process, it is also possible to produce particles with adjustable 
sizes due to variations in process parameters [85]. The dry particles obtained by 
spray freeze-drying are suitable for epidermal powder immunization as shown by 
Dean et al. with a trivalent influenza vaccine embedded in an excipient solution 
composed of mannitol, trehalose and dextran [89]. Similarly, Hepatitis B antigens in a 
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formulation based on trehalose were successfully spray freeze-dried and showed 
excellent stability without a loss of vaccine potency in accelerated stability studies 
[83, 91]. 
 
5.3 SPRAY DRYING 
Spray drying is a drying method suitable to convert biopharmaceuticals into a dry and 
solid state. A liquid sugar formulation containing a biopharmaceutical is atomized in 
the hot air of a spray dryer into a cloud of small droplets. The droplet surface is 
moisture saturated and water evaporates in an endothermic process so that the 
droplet temperature remains significantly lower than the hot air temperature. The 
sugar concentration of the droplet increases during evaporation of the water and the 
droplet temperature begins to rise. At a certain concentration the sugar becomes 
solid. Water molecules evaporate under conditions that the solution is in 
thermodynamic equilibrium. If the evaporation rate of the water is fast enough, the 
sugar has no sufficient time to crystallize and turns into a dry amorphous glassy state 
[121, 122].  
Oxygen sensitive materials and solvents require drying with nitrogen gas. The 
incorporation of the biopharmaceutical into a glassy sugar matrix protects it from 
degradation during the spray drying process. However, heat denaturation can occur if 
process parameters are not well chosen. The biopharmaceutical is rapidly vitrified by 
using a large liquid-gas interface at elevated temperature and rapid moisture 
removal. The air-water interfacial stress and the shear stress induced by the 
atomisation can lead to degradation of the biopharmaceutical. The addition of 
surface-active agents reduces the interfacial stress induced by the spray drying 
process and improves the stability of the biopharmaceutical [85]. An example of 
stable vaccine powder formulations generated by spray drying is an influenza subunit 
vaccine powder stabilized using the oligosaccharide inulin. The obtained particles 
were spherical and smooth with an average particle size of 3 µm and maintained the 
antigen’s immunogenicity in vivo [28]. 
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5.4 DESICCATION/AIR DRYING 
The process of drying using a hygroscopic substance in a sealed desiccator is called 
desiccation. A small amount of material is dried on a shelf above a drying agent like 
silica gel or anhydrous caustic soda. The process is carried out at room temperature 
and takes several hours [28]. Desiccation is very time consuming method 
incorporating a high risk of sugar crystallization and phase separation and 
subsequent denaturation of the biopharmaceutical. 
Chen et al. prepared a split vaccine powder formulation by air drying. The vaccine 
was desiccated in a trehalose solution overnight using an N2 purge. Whether the 
integrity of the vaccine compound in the dry product was affected, was not 
investigated, however the performed immunization studies were successful [41, 123].  
 
5.5 VACUUM DRYING  
Vacuum drying describes the process of drying at a certain pressure and constant 
temperature so that the boiling point of water is lowered below the sample 
temperature [124, 125]. The constant addition of heat prevents the sample to cool 
from heat loss by evaporation of the water. The sugar solution is saturated at a 
certain point, so that it starts to precipitate simultaneously with the evaporation of the 
water molecules, when the solution is in thermodynamic equilibrium. [28].  
 
5.6 VACUUM FOAM DRYING 
Vacuum foam drying is based on the principle of evaporation under vacuum at low 
temperatures. It is a suitable method to stabilize therapeutic biomolecules which are 
stable at moderate temperatures and pressures [126].  
Vacuum foam drying can be performed by using a freeze-dryer. A solution or 
suspension of a biopharmaceutical is supplemented with protective additives, in 
general sugars. The solution is transformed into foam by boiling under vacuum above 
the freezing point. Thereby foam is generated consisting of thin films of material of 
which water can be efficiently removed at an elevated temperature. The final solid 
product is amorphous and shows enhanced storage stabilities [27, 127]. 
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5.7 SUPERCRITICAL FLUID DRYING 
 
Supercritical fluid drying is, as spray drying and spray freeze-drying, a method 
capable to produce powders in the µm-range. Supercritical fluids are characterized 
by a temperature and a pressure above their critical points [128]. The fluid possesses 
unique thermo-physical properties, being able to penetrate substances like a gas and 
dissolve materials like a liquid. In pharmaceutical industry supercritical-CO2 is used 
as standard. In the concept of this technique, the supercritical fluid is used as an 
antisolvent for the biopharmaceutical and as a water extraction medium [129, 130].  
The process is divided into three parts. In the first step, water is extracted by the 
supercritical fluid out of the protein solution followed by an increase in concentration. 
In the second part, proteins and other constituents precipitate due to the increasing 
concentration and the dissolution of the supercritical fluid in the solution. In the last 
part supercritical fluid extracts the remaining solvent forming dry protein particles. 
Another method for supercritical fluid drying is by spraying the formulation in a 
supercritical fluid. The supercritical fluid is dissolved at high pressure in the solution 
containing the biopharmaceutical and other excipients and sprayed to atmospheric 
conditions. The supercritical fluid is used as propellant agent during the spray drying 
process at a low temperature. The atomization process is thereby enhanced and the 
duration of the drying process is shortened [129, 131]. Retention of the viral activity of 
a measles vaccine virus, live attenuated, formulated with trehalose was reported after 
supercritical fluid drying using a bubble-dryer process without the use of an organic 
solvent [108, 132].   
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6 DEVICES FOR INTRADERMAL VACCINATION 
The conventional use of needles and syringes commonly fail to target the 
immunocompetent cells in the epidermal layer of the skin, as due to the length of the 
needle and the applied standard technique only deeper subcutaneous or muscle 
tissue can be reached [133, 134]. The urgent need for devices to facilitate correct 
and accurate intradermal administration is attempted by the development of a variety 
of delivery systems [9]. Ballistic approaches were successfully proven in clinical trials 
in humans [89] and initiate the development of needle-free ballistic injection devices. 
A detailed review of delivery devices for intradermal vaccination [135] highlighting the 
pros and cons of the different systems was compiled within this thesis and can be 
found in the appendix. 
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7 OBJECTIVES OF THE THESIS 
 
The precise delivery of vaccine particles into the skin using a needle-free ballistic 
approach is crucial for vaccination efficiency. This depends firstly on particle 
characteristics and secondly on the performance of the ballistic device. The overall 
aim of this thesis was the preparation of dry powder vaccine formulations suitable for 
needle-free ballistic injections and the development of an appropriate delivery 
technology in cooperation with Dr. Lell (Pyroglobe GmbH, Hettenshausen, Germany). 
 
Appropriate particle characteristics of dry powder vaccine formulations for ballistic 
injection implicate a particle size in the range of 20-70 µm, a narrow particle size 
distribution and a highly dense and robust particle structure, as these preconditions 
are mandatory to achieve sufficient impact during ballistic injection and to breach the 
epidermal layers of the skin. Furthermore the incorporated vaccine has to exhibit 
stability throughout the shelf-life of the product.  
The aim was to achieve these goals by a two-step process of collapse freeze-drying 
and cryo-milling for the preparation of antigen loaded powder particles.  
It is known from previous work of our group that the application of an aggressive 
freeze-drying cycle leads to a controlled collapse and thereby a substantial reduction 
of the specific surface area of the sugar matrix, whilst protein stability can be 
preserved. It was anticipated that collapse freeze-drying leads to highly dense and 
robust particles. Thus, the first major objective was to investigate the effect of 
collapse freeze-drying and cryo-milling on particle morphology and stability of the 
model antigen ovalbumin and to benchmark the process with a conventional 
moderate freeze-drying cycle (chapter 3).  
A second major aim of this thesis was the systematic investigation and optimization 
of the cryo-milling process for the production of vaccine loaded powder particles, 
allowing a scale up of the milling process in a partially sterile environment appropriate 
for industrial standards. The influence of different adjustable milling parameters on 
particle morphology and protein stability as well as the applicability of the cryo-milling 
process on other model proteins will be outlined in chapter 4.  
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It was assumed in literature that higher molecular weight polymers would be essential 
to generate mechanical robust particles by spray-freeze-drying, though, the benefit of 
polymers as stabilizers in freeze-dried formulations is controversy discussed. 
A thorough formulation screening and storage stability for the model antigen 
ovalbumin after collapse freeze-drying and cryo-milling as well as an assessment of 
the effect of polymers on physico-chemical particle characteristics and antigen 
stability will be outlined in chapter 5.  
The interface between powder particles and the device surface plays an important 
role for the proper delivery of particles into the skin and thus has a decisive impact on 
the efficacy of the vaccination procedure. The adhesion of particles on membranes, 
representing the device surface, by the use of oily adjuvants as well as the stability of 
vaccine particles in combination with selected adjuvants will be explored in chapter 6. 
The effectiveness of ballistic particle injection depends decisively on the performance 
of the delivery device and the device-target interaction. The final pivotal aim of this 
thesis was to investigate a novel principle of particle acceleration to deliver vaccine 
loaded powder particles by a needle-free approach into the skin. The development of 
a method to measure the velocity of particles, a thorough investigation of the 
relationship of particle parameters like size and density as well as proof of concept of 
particle delivery in ex-vivo excised pig skin will be given in chapter 7. 
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CHAPTER 2  
 
MATERIALS AND METHODS 
 
1  MATERIALS 
1.1 OVALBUMIN 
Albumin from chicken egg white (ovalbumin, grade V) was obtained from Sigma-Aldrich 
Chemie GmbH, Steinheim, Germany. Ovalbumin, derived from chicken egg white, is a 
glycoprotein which comprises 386 amino acids. The sequence includes six cysteines 
with a single disulfide bond between Cys74 and Cys121. It has a molecular weight of 
44,287 Da (by calculation, data provided by the manufacturer Sigma-Aldrich) and 
features a net negative surface charge. Ovalbumin is a member of the serpin 
superfamily, however, without having any protease activity [1, 2]. It is commonly used 
as immunological model in in vivo and in vitro studies since specific monoclonal 
antibodies against different epitopes of OVA have been developed [3].  
 
1.2 RH-G-CSF 
Recombinant human granulocyte-colony stimulating factor (rh-G-CSF) was formulated 
in a 10 mM sodium acetate buffer at pH 4.0. The concentration of rh-G-CSF in the bulk 
drug substance was 4.04 mg/mL. The bulk solution contained 0.004 % polysorbate 20. 
The physiological role of rh-G-CSF is the stimulation of the proliferation and 
differentiation of neutrophilic immature cells to neutrophilic granulocytes. The rh-G-CSF 
molecule has two disulfide bonds between amino acids 36 and 42 and between amino 
acids 64 and 74, respectively. It belongs to the family of the four-helix bundle cytokines 
with four α-helices ranged in an up-up and down-down structure. Rh-G-CSF derives 
from E. coli and is not glycosylated [4, 5]. A high aggregation and self-association 
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tendency of the liquid formulation is a result of the fact that the major part of the rh-G-
CSF molecule consists of hydrophobic regions [6, 7]. The molecular weight of rh-G-CSF 
is about 18,816 Da [8].  
 
1.3 RH-INTERFERON-Α-2A 
Rh-IFN α-2a (rh-IFN α-2a) was provided at a concentration of 1.5 mg/mL and contained 
25 mM acetate buffer (pH 5.0) and 120 mM sodium chloride at pH 5. The protein 
consists of 166 amino acids and is not glycosylated with a molecular weight of 
19,241 Da. It has two disulfide bonds, one between amino acids 1 and 98, and the 
second between amino acids 29 and 138. The tertiary structure of the all-helical protein 
is arranged by five α-helices [9].  
1.4 OILY ADJUVANTS AND ADHESIVES 
Table 2.1: Excipients used for the preparation of oily adjuvants and for the use as 
adhesive 
Excipient Description Supplier 
Squalene ≥98% 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Squalane ≥99% 
VWR International GmbH 
(Darmstadt, Germany) 
Polysorbate 80 Ph.Eur. 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Span® 85 Ph.Eur. 
VWR International GmbH 
(Darmstadt, Germany) 
Paraffin oil Ph.Eur. 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Freund's incomplete adjuvant  
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Miglyol®812  
VWR International GmbH 
(Darmstadt, Germany) 
Silicon oil AP 100   
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Polyisobutylene  Mw~1,000,000 
Acino Pharma GmbH    
(Miesbach, Germany) 
Polyethylene glycol 400  
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Castor oil  Ph.Eur. 
VWR International GmbH 
(Darmstadt, Germany) 
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For the preparation of the mixture of the oily components of MF59 1500 µl squalene 
were vortexed with 150 µl polysorbate 80 and with 150 µl Span 85 in an Eppendorf tube 
for 10 seconds. 
 
1.5 FURTHER CHEMICALS, REAGENTS AND MATERIALS 
Table 2.2: Chemicals and reagents used for analytical purposes 
Excipient Description Supplier 
Acetic acid 100% 
VWR International GmbH 
(Darmstadt, Germany) 
Sodium acetate ≥99% 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
5α-Cholestane ≥97% 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Tert-butyl-methyl-ether 99.8% 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Sodium hydroxide 50% 
Merck KGaA                               
(Darmstadt, Germany) 
Sudan red Ph.Eur. 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Hydranal Methanol dry 
Riedel-de Haën, ≤0.01% 
water 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Hydranal Formamide dry 
Riedel-de Haën, ≤0.02% 
water 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Hydranal Water Standard 1.00 Riedel-de Haën, 0.1% water 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Hydranal Coulomat AG Riedel-de Haën 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
N-trimethylsilylimidazole p.A. 
Macherey Nagel (Düren, 
Germany) 
N-methyl-N-
trimethylsilyltrifluoroacetamide 
p.A. 
Macherey Nagel (Düren, 
Germany) 
Primary secondary amine 
(PSA) 
particle size 40 µm Varian (Harbor City, USA) 
Na2SO4   
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
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Table 2.3: Particles used for ballistic acceleration studies 
Particle Description Supplier 
Fluorescein isothiocyanate 
(FITC) labelled polystyrene 
particles 
Density 1.1 g/cm3; size 40 µm 
microparticles GmbH (Berlin, 
Germany) 
Blue dyed polystyrene 
particles 
Density 1.1 g/cm3; 20 µm; 
40 µm and 60 µm. 
microparticles GmbH (Berlin, 
Germany) 
Glass spheres 
Density 2.5 g/cm3; size 20-
40 µm; 40-63 µm; 63-70 µm; 
600 µm; 900 µm 
microparticles GmbH (Berlin, 
Germany) 
Hollow glass spheres Density 1.1 g/cm3; size 11 µm 
microparticles GmbH (Berlin, 
Germany) 
Hollow glass spheres Density 0.6 g/cm3; size 18 µm 
microparticles GmbH (Berlin, 
Germany) 
 
 
1.6 FREEZE-DRYING EXCIPIENTS 
 
Table 2.4: Excipients used for freeze-drying experiments 
Excipient Description Supplier 
D(+)-trehalose dihydrate Ph.Eur. 
VWR International GmbH 
(Darmstadt, Germany) 
Mannitol Ph.Eur. 
VWR International GmbH 
(Darmstadt, Germany) 
Dextran from Leuconostoc 
spp. (Mr~70,000) 
 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Dextran from Leuconostoc 
spp. (Mr~40,000) 
 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Dextran from Leuconostoc 
spp. (Mr~ 6,000) 
 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Phenylalanine ≥99% 
Sigma Aldrich Chemie GmbH 
(Steinheim, Germany) 
Hydroxyethylstarch 
(Mr~70,000) 
 
Serumwerk Bernburg 
(Bernburg, Germany) 
Sodium dihydrogen 
phosphate dihydrate 
p.A. 
VWR International GmbH 
(Darmstadt, Germany) 
di-Sodium hydrogen 
phosphate 
p.A. 
VWR International GmbH 
(Darmstadt, Germany) 
Sodium chloride p.A. 
VWR International GmbH 
(Darmstadt, Germany) 
CHAPTER 2 
 
27 
 
2 METHODS 
 
2.1 PREPARATION OF FORMULATIONS 
The formulations contained trehalose or a combination of trehalose and mannitol (at a 
weight ratio of 1:1), or a ternary combination of trehalose, mannitol and dextran (at a 
weight ratio of 3:3:4). The total solid content of the formulations varied from 15% to 35% 
(w/w) [10, 11].  
In terms of a large scale formulation screening, as described in chapter 5, a 
combination of trehalose, mannitol and hydroxyethylstarch (weight ratio 3:3:4) or a 
secondary combination of trehalose and phenylalanine (weight ratio 9.5:0.5) was used, 
if not stated otherwise.  
The excipients were dissolved in phosphate buffer (pH 7.0, 10 mM phosphate, 50 mM 
ionic strength adjusted with sodium chloride). Ovalbumin was adjusted to a final protein 
concentration of 2.5% (w/w) in each formulation. Phosphate buffer was chosen as it has 
been reported to stabilize ovalbumin [12, 13].  
Rh-G-CSF was formulated in a 20 mM sodium acetate buffer, pH 4.0, with 0.004% 
polysorbate and 15% (w/w) trehalose-mannitol (weight ratio 1:1) and a final protein 
concentration of 2.5% (w/w).   
Rh-IFN α-2a was formulated in a 25 mM sodium acetate buffer (pH 4.2), containing 
120 mM sodium chloride with 15% (w/w) trehalose-mannitol (weight ratio 1:1) and a 
final protein concentration of 2.5% (w/w).   
Prior to freeze-drying, all formulations were filtered through a 0.2 µm PVDF syringe filter 
unit (Pall GmbH, Dreieich, Germany). The filters were pre-flushed with 5 mL buffer prior 
to use. 
 
2.2 DIALYSIS 
Prior to usage the rh-G-CSF bulk solution was dialyzed against 20 mM acetate buffer at 
pH 4 or pH 3.7, respectively, in a volumetric ratio of 1:50 at room temperature. Dialysis 
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was carried out using a CelluSepT1® dialysis membrane with a molecular weight cut-off 
of 3,500 Da (Orange Scientific, Braine-l’Alleud, Belgium).  
The rh-IFN α-2a bulk solution was excessively dialyzed against 25 mM acetate buffer at 
pH 4.2 containing 120 mM sodium chloride. Dialysis was performed at room 
temperature in a volumetric ratio of 1:50 using a CelluSepT1® dialysis membrane with a 
molecular weight cut-off of 3,500 Da (Orange Scientific, Braine-l’Alleud, Belgium).  
 
2.3 VISCOSITY MEASUREMENTS 
A Physica MCR 100 rotational rheometer (Anton Paar, Graz, Austria) was used to 
measure the viscosity of the liquid formulations of 15 to 35% (w/w). One mL of each 
liquid was pipetted directly onto the plate of the rheometer and the temperature of the 
sample was adjusted to 25°C. The dimensions of the cone (CP50-1) were 50 mm 
diameter and a 1° angle. Thirty data points were collected over ten seconds at shear 
rates ranging from 1 to 100 s-1. 
 
2.4 FREEZE-DRYING  
One mL aliquots of the filtered solutions were filled into 2 R blow back vials glass type I 
from Schott (Schott, Mainz, Germany) resulting in a fill height of approximately 1.5 cm 
and partially stoppered with cross-linked high molecular weight polydimethylsiloxane-
coated rubber-lyophilization stoppers (B2-44, West, Eschweiler, Germany).  
Freeze-drying was performed using a Christ Epsilon 2-6D freeze dryer (Christ, Osterode 
am Harz, Germany). Two different freeze-drying protocols were applied, which were 
developed according to literature [14].  
 
2.4.1 MODERATE FREEZE-DRYING CYCLE 
The moderate freeze-drying cycle (moderate FD cycle) was conducted at -40 and -20°C 
during primary drying and followed by 20 and 35°C during secondary drying at a 
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chamber pressure of 0.03 mbar. A detailed freeze-drying protocol is given in table 2.6. 
The product temperature approached the shelf temperature and the final product 
temperature reached 32°C.  
 
Table 2.5: Conventional freeze-drying cycle 
Process Step Time [min] Temperature [°C] Pressure [mbar] 
Loading 0 20 1113 
Ramp 90 -50 1113 
Freezing  120 -50 113 
Vacuum ramp 1 -50 0.03 
Ramp 30 -40 0.03 
Primary drying 1800 -40 0.03 
Ramp 200 -20 0.03 
Secondary drying 600 20 0.03 
Ramp 80 35 0.03 
Secondary drying 300 35 0.03 
End 30 5 0.03 
 
2.4.2 COLLAPSE FREEZE-DRYING CYCLE 
An aggressive freeze drying cycle (collapse FD cycle) was applied in order to produce 
collapsed lyophilizates. Primary as well as secondary drying were performed at a shelf 
temperature of 45°C and at a chamber pressure of 1.98 and 0.03 mbar, respectively. A 
detailed freeze-drying protocol is given in table 2.6. The product temperature as well as 
the shelf temperature were monitored and the product temperature approached the 
shelf temperature after approximately ten hours, which indicates the endpoint of primary 
drying [15].  
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Table 2.6: Collapse freeze-drying cycle 
Process Step Time [min] Temperature [°C] Pressure [mbar] 
Loading 0 20 1113 
Ramp 90 -50 1113 
Freezing  120 -50 1113 
Preparing 30 -40 1113 
Ramp 1 -40 1.98 
Primary drying 20 -40 1.98 
Ramp 120 45 1,98 
Secondary drying 1440 45 1,98 
Ramp 1200 45 0.03 
Secondary drying 120 20 0.03 
End 15 5 0.03 
 
Regarding a conventional freeze-drying cycle, the degree of super-cooling influences 
the cake structure and thereby the sublimation rates as well as other product 
parameters like specific surface area and residual moisture [16, 17]. However, in the 
case of the aggressive freeze-drying cycle used in this study, the cake structure is re-
built during the drying process as the collapse temperature of the formulations is 
exceeded [18]. The rather long secondary drying time was chosen to assure low 
residual moisture of the product as the collapse leads to a very small specific surface 
area of the sugar matrix which makes it more difficult to remove the absorbed water. 
The process has the potential to be even further optimized; however, this was not the 
focus of this study. 
 
2.5 SAMPLE PROCESSING AFTER FREEZE-DRYING 
2.5.1 CRYO-MILLING SWING MILL RETSCH 
Milling was performed in a swing mill MM301 (Retsch Technology, Haan, Germany). 
Eight lyophilizate cakes, obtained from one-milliliter aliquots of the solutions for freeze-
drying, were filled in 5 mL high grade steel grinding beakers together with two stainless 
steel balls, dipped in liquid nitrogen for at least 2 minutes until a product temperature 
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below -130°C was reached and milled for 10 seconds or 30 seconds, at a frequency of 
30 s-1. 
 
2.5.2 CRYO-MILLING CRYO-MILL RETSCH 
Cryo-milling was performed semi-automatically using a cryo-mill (Retsch Technology, 
Haan, Germany). Three lyophilizate cakes, obtained from 6-mililiter aliquots of the 
solutions for freeze-drying, were filled in a 5 mL steel grinding beaker together with two 
stainless steel balls and mounted in the grinding station. Several parameters were 
adjusted using the semi-automatic program of the cryo-mill such as pre-cooling time, 
milling frequency, milling time and number and duration of the milling cycles. During the 
sequence pre-cooling, the stainless steel beaker was continuously flushed with liquid 
nitrogen, whilst the beaker was moving with a frequency of 5 s-1. After a pre-cooling 
time of 10 min, the product temperature was below -130°C. If not stated otherwise, 
milling was performed for 15 seconds at a frequency of 25 s-1. 
 
2.5.3 TEXTURE ANALYZER 
The rigidity of collapse freeze-dried cakes was examined using a Texture Analyzer 
XTPlus (Stable Mircosystems, UK). Therefore a cylindrical piston (4 mm in diameter) 
was moved with 1 mm/s into the sample. The maximally force (in N/s) to break the 
lyohilisate cake was recorded.  
 
2.6 ACCELERATED STABILITY TESTING AND STORAGE STABILITY 
2.6.1 STORAGE STABILITY OF THE FORMULATIONS 
Samples, comprised of lyophilizates or powder consisting of cryo-milled lyophilizates, 
were stored at 2-8°C for 12 months in 2R blow back vials type I from Schott (Mainz, 
Germany) stoppered with B2-44 lyophilization stoppers (West, Eschweiler, Germany). 
Vials as well as stoppers were washed and dried for at least 7 hours in a vacuum dryer 
VTS-2 (Memmert, Schwabach, Germany) at 0.1 mbar and 60°C.  
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After the 12 months storage interval, the samples were analyzed for protein aggregation 
and changes in particle morphology. 
 
2.6.2 STORAGE STABILITY OF SAMPLES WITH OILY ADJUVANTS AND ADHESIVES 
Samples were prepared by bedding approximately 50 mg of protein powder formulation 
on a 10 µl thin film comprised of the adhesive or composition of the oily adjuvant (list of 
adhesives and composition of the oily adjuvant see section 1.4.) on the surface of a 2R 
glass vial. The samples were stoppered with B2-44 lyophilization stoppers (West, 
Eschweiler, Germany) and were stored at 2-8°C, 25°C and 40°C for a time period of 12 
weeks. Vials as well as stoppers were washed and dried for at least 7 hours in a 
vacuum dryer VTS-2 (Memmert, Schwabach, Germany) at 0.1 mbar and 60°C.  
After a storage interval of 2, 4, 8 and 12 weeks the samples were analyzed for protein 
aggregation, changes in particle morphology and chemical stability of the oily adjuvants. 
 
2.7 CHARACTERIZATION OF PROTEIN STABILITY 
2.7.1 SIZE-EXCLUSION CHROMATOGRAPHY 
SE-HPLC for was performed on a summit HPLC system (Dionex GmbH, Idstein, 
Germany), equipped with an UVD 170 U detector (Dionex GmbH, Idstein, Germany) 
using a TSK gel G3000SWXL column (Tosoh Bioscience, Stuttgart, Germany). Samples 
were reconstituted in mobile phase and centrifuged at 10,000 rpm for 10 min (neo lab 
16/18, Hermle Labortechnik GmbH, Wehingen, Germany) prior to injection, in order to 
remove insoluble aggregates. The analytics were performed at a flow rate of 0.5 mL/min 
with UV-detection at 280 nm. Injection volume was 40 µl. At least two samples of each 
formulation was analyzed and injected twice. 
The running buffer for ovalbumin was composed of 0.05 M sodium phosphate and 
0.15 M sodium chloride, adjusted to pH 7.2 with sodium hydroxide. For rh-G-CSF a 0.1 
M sodium phosphate at pH 7.0 running buffer was used. The running buffer for rh-IFN 
α-2a consisted of 0.12 M disodium hydrogenphosphate dihydrate, 0.02 M sodium 
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dihydrogenphosphate and 4g/L sodium chloride, adjusted to pH 5.0 with hydrochloric 
acid.  
The peak areas of the chromatograms were integrated using the data acquisition 
program Chromeleon version 6.60 (Dionex GmbH, Idstein, Germany). Sample recovery 
was determined using a calibration curve of five known concentrations of the analyzed 
protein of the respective formulation. The content in % of soluble oligomers, dimers, 
monomer and fragments was calculated by dividing the partial area under the curve 
(AUC) of each species by the total AUC. Additionally, the amount of remaining 
monomer was evaluated from the area under the monomer peak compared with that of 
the respective liquid formulation prior to lyophilization.  
 
2.7.2 LIGHT OBSCURATION PARTICLE ANALYSIS 
Number and distribution of particles was analyzed by light obscuration using a SVSS-
C40 apparatus (PAMAS GmbH, Rutesheim, Germany). The system was flushed six 
times with 1.0 mL highly purified water with a fill and ejection rate of 10 mL/min, until 
less than 10 particles  1 µm/mL were detected. In order to decrease the viscosity of the 
samples to an appropriate level, 1 mL of the liquid formulation, which was prepared 
prior to freeze-drying, was diluted with 1 mL buffer. We have tested the effect of dilution 
on particle counting and found no effect within the precision of the method. 150 mg of 
the lyophilizate cake or powder samples were reconstituted in 2000 µl buffer, resulting 
in a protein concentration according to the liquid formulation. Prior to measurement, the 
system was flushed with 0.3 mL of sample followed by three injections at a volume of 
0.3 mL per injection. Particles larger than or equal to 1 µm are presented as cumulative 
counts per mL calculated from the mean value of three injections. 
 
2.7.3 TURBIDITY 
A NEPHLA turbidimeter (Dr. Lange, Düsseldorf, Germany) was used in order to 
determine the turbidity of protein formulations in formazine nephelometric units (FNU). 
Turbidity was measured by 90° light scattering at λ=860 nm according to the method 
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described in the European Pharmacopoeia (method 2.2.1). About 1 mL of the liquid 
formulation (pre-lyohilization solution) was diluted 1:1 with formulation buffer prior to 
measurement. Likewise, 150 mg of the lyophilizate cake or powder formulation, 
respectively, was dissolved in 2 mL formulation buffer prior measurement. Each value 
represents the average of at least two measurements. 
 
2.7.4 TRANSMISSION FOURIER TRANSFORM INFRARED (FTIR) SPECTROSCOPY 
The conformational stability of the proteins was analyzed by FTIR spectroscopy using a 
Tensor 27 FTIR spectrometer (Bruker Optics, Ettlingen, Germany) equipped with a 
calcium fluoride flow through cell (Aquaspec 1110 M, Bruker Optics, Ettlingen, 
Germany) with 6.5 µm path length and a nitrogen-cooled photovoltaic MCT detector. 
120 scans were performed per measurement at a resolution of 4 cm-1. Each sample 
was injected at least twice. Data analysis was performed by using Opus software 
Version 6.5. For relative comparison of the different samples, the obtained spectra of 
the amid I region was background subtracted, vector normalized and the second 
derivative was calculated. 
 
2.7.5 SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 
The aggregation and fragmentation of the protein formulations was determined by non-
reducing denaturating SDS-PAGE. The protein solutions were diluted in a pH 6.8 tris-
buffer, containing 2% SDS and 2% glycerine. Prior to loading 20 µl of the samples into 
the gel wells (NuPAGE© Pre-Cast 10% Bis-Tris gels 1 mm; Invitrogen, Groningen, The 
Netherlands), the samples were denaturated at 90°C for 30 min. A molecular weight 
standard (Mark 12 Unstained Standard, Invitrogen, Karlsruhe, Germany) was added to 
each gel in order to determine the molecular weight of the detected bands. 
Electrophoresis was performed using an XCell II Mini cell system (Novex, San Diego, 
CA, USA) in a constant current mode of 30 mA in a tris-glycerine/SDS running buffer 
(MES running buffer; Invitrogen, Groningen, The Netherlands) for approximately 40 min. 
The gels were stained with a silver staining kit (SilverXpress©, Invitrogen, Karlsruhe, 
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Germany) or by applying Coomassie staining (Imperial© protein stain solution, Thermo 
Fisher, Rockford, IL, USA). 
 
2.7.6 UV-SPECTROSCOPY 
UV-measurements for the determination of protein concentrations were carried out on 
an Agilent 8453 UV-VIS spectrophotometer (Agilent Technologies Deutschland GmbH, 
Böblingen, Germany) equipped with a Peltier temperature controller. 
OVA concentration was determined at λ = 280 nm using a UV extinction coefficient        
ε = 0.700 mL*mg-1*cm-1. Rh-G-CSF concentration was determined using a UV 
extinction coefficient ε = 0.815 mL*mg-1*cm-1 and rh-IFN α-2a using a UV extinction 
coefficient ε = 0.924 mL*mg-1*cm-1, respectively, at λ = 280 nm.  
 
2.8 CHARACTERIZATION OF LYOPHILIZATE AND POWDER CHARACTERISTICS 
2.8.1 X-RAY POWDER DIFFRACTION 
The morphology of the freeze-dried and ground products was analyzed using a X-ray 
diffractometer XRD 3000 TT (Seifert, Ahrenburg, Germany) equipped with a copper 
anode (= 154.17 pm, 40 kV, 30 mA). Samples were scanned between 5° and 40° 2-
Theta at steps of 0.05° 2-Theta and a duration of two seconds per step. 
 
2.8.2 KARL-FISCHER TITRATION 
Residual moisture content was determined by direct methanol extraction using a Karl 
Fischer coulometric titrator (652-KF Coulometer, Metrohm, Filderstadt, Germany). Ten 
to 20 mg of the samples was weighed accurately in a vial. The samples were weighed 
in a controlled low humidity environment using a glove box which was flushed with 
nitrogen until less than 10% RH was reached. The vial was sealed with a flange and 
1 mL dry methanol (Hydranal® Methanol dry, Fluka, Steinheim, Germany) was added 
by injection. To enhance the water extraction, the samples were placed into an 
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ultrasonic water bath for 10 min. 200 µl aliquots of the samples were injected into the 
reaction vessel of the titrator. The performance of the system was validated by the 
analysis of water standards (Hydranal® water standard 0.1, Riedel-de-Haën, Sigma 
Aldrich, Steinheim, Germany) at the beginning and the end of the measurement. Three 
blank measurements containing dry methanol were performed at the beginning and the 
end of the analysis. 
 
2.8.3 DIFFERENTIAL SCANNING CALORIMETRY 
Physicochemical characteristics of the samples were evaluated by differential scanning 
calorimetry using a DSC 204 Phoenix® (Netzsch, Selb, Germany). For the 
determination of the glass transition temperature of the maximally freeze-concentrated 
solution (Tg’) approximately 20 µl were weighed into aluminum crucibles. The aluminum 
crucibles containing the sample as well as an empty reference pan were cold-sealed. 
The samples were cooled to -70°C with a scan rate of 5 K/min and subsequently heated 
to +20°C with a scan rate of 10 K/min.  
Approximately 10 - 20 mg lyohilizate cakes as well as powdered formulations were 
weighed into aluminum crucibles and cold-sealed in a dry atmosphere. Therefore the 
preparation of the samples was conducted in a glove box which was flushed with dry 
nitrogen. Tg of the samples was determined in a first scan by cooling the samples to -
20°C and subsequently heating to +100°C with a scan rate of 10K/min, respectively. In 
a second scan, the samples were cooled to -20°C and subsequently heated to +200°C 
with a scan rate of 10K/min, respectively. The heat scans were analyzed for thermal 
events. 
 
2.8.4 SPECIFIC SURFACE AREA MEASUREMENT 
Specific surface area measurements were performed with krypton 4.8 using an 
Autosorb-1MP analyzer (Quantachrome, Odelzhausen, Germany). Samples were 
degassed under vacuum for at least three hours at 20°C before each measurement. 
Krypton adsorption at 77K was measured at eleven points over a relative pressure 
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range of 0.05 to 0.3. The Brunauer Emmett and Teller (BET) equation was used to fit 
the data and calculate the SSA. Therefore at least five measurement points were used. 
The correlation coefficient of the fit was at least 0.9975 and hence in line with the 
recommendation of the European Pharmacopoeia. 
 
2.8.5 DENSITY MEASUREMENT 
True density, defined as the density of the material excluding pores and interparticle 
spaces, was measured using an AccuPyc 1330 helium pycnometer (Micrometrics 
GmbH, Aachen, Germany) at a sample volume unit of 0.718507 cm³. Prior to analysis 
10 cleaning cycles were performed using analytical grade helium. Approximately 300-
350 mg of the sample was analyzed and the true density was calculated as an average 
of six measurements. 
Powder tap density was measured according to the method of the European 
Pharmacopoeia (7.0/2.9.34.) using a 10 mL volumetric flask.  
 
2.8.6 SCANNING ELECTRON MICROSCOPY 
The morphology of the freeze-dried cakes and ground powders was examined on a 
scanning electron microscope (Jeol JSM-6500F, Ebersberg, Germany). Samples were 
attached to a self-adhesive carbon tape (Bal-tec GmbH, Witten, Germany) before 
sputtering them under vacuum with a thin layer of carbon (MED 020, Bal-tec GmbH, 
Witten, Germany). 
 
2.8.7 MOISTURE SORPTION ANALYSIS 
Water sorption of the samples in dependence of relative humidity was analyzed using 
an IGASorp Moisture Sorption Analyzer (Hiden Analytical, Warrington, UK). 
Approximately 5-10 mg of sample was sequentially exposed to 0-90% relative humidity 
in 10% relative humidity steps. The temperature was held constant at 25°C during the 
measurement. Measurements were repeated three times for each formulation. 
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2.8.8 PARTICLE SIZE ANALYSIS BY STATIC LIGHT DIFFRACTION 
Particle size distribution of the ground powders was measured by laser light diffraction 
using a Horiba LA-950 (Retsch Technology, Haan, Germany). Samples were dispersed 
in isooctane at a concentration to achieve 90-70% transmittance of the LD laser and 90-
80 % transmittance of the LED laser. Background alignment was performed with pure 
isooctane before addition of the samples. Particle size distribution was calculated as an 
average of 6 measurements applying the Fraunhofer theory and characterized with 
median diameter and span of the volume distribution.  
Alternatively, particle size distribution was determined with a He-Ne laser beam 
equipped laser light diffraction using a Mastersizer X (Malvern, Herrenberg, Germany). 
Approximately 5 mg of the dried-powder was dispersed in 10 mL Miglyol 812 and 
pumped into the sample cell by using the small-volume-presentation-unit. Background 
alignment was performed with pure Miglyol 812 before the powder-dispersion was 
added. Particle size was evaluated by applying the Fraunhofer theory using a 
polydisperse mode.  
 
2.8.9 DIGITAL MICROSCOPY 
For the visualization of glass and polystyrene particles digital microscopy was 
performed using the Keyence VHX-500F (Keyence Corporation, Osaka, Japan). The 
employed magnification was 100 x 50 or 100 x 500. 
 
2.9 CHARACTERIZATION OF OILY ADJUVANTS 
2.9.1 ACCELERATED STABILITY TESTING OF OILY ADJUVANTS 
In order to investigate if the oily adjuvants were sensitive towards stress conditions 
during storage at elevated temperatures, the samples were subjected to different 
accelerated stress conditions. Chemical stress was applied by incubation of the 
samples with 1 mL 30% hydrogen peroxide or 1 N sodium hydroxide for a time period of 
24 hours. UV-light stress was applied in a SUNTEST CPS (Heraeus, Original Hanau, 
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Germany) at 54 W/m2 by a Xenon lamp for a time period of 7 days. As UV-light stress 
caused also heat and thus resulted in increased sample temperatures of 35°C, as a 
reference samples were additionally exposed to heat stress at 35°C whilst being 
protected from light by an aluminum cover, respectively. 
 
2.9.2  GAS CHROMATOGRAPHY AND MASS SPECTROMETRY 
Gas chromatography and mass spectrometry was accomplished in cooperation with Dr. 
Christoph Müller (Department Pharmaceutical Chemistry, Munich). 
Gas chromatography was performed using a Varian 3800 gas chromatograph 
connected with a Varian 1177 injector with split/splitless option (Darmstadt, Germany) 
and a Varian FactorFourTM VF- 5 ms capillary column (30 m x 0.25 mm inner diameter, 
0.25 µm film thickness), in order to quantify and detect changes in the quality of oily 
adjuvants. One µl of the pre-processed samples was injected with an inlet temperature 
of 250°C (split 1:25).  
Quantification of the oily adjuvant components squalane, squalene and the oily 
components of MF59 was performed using a Varian Iontrap 2200. After a solvent delay 
of 8 min the MS scanned from 8-14 min at 50-450 m/z. Data analysis and instrument 
control was performed with Varian Workstation 6.9 SP 1 software as described by 
Mueller et al. [19].  
Quantification of the oily substances paraffin and Freund’s incomplete adjuvant was 
performed by gas chromatography connected with a flame-ionization detector (GC–
FID). Analysis was accomplished in cooperation with Dr. Florian Plößl (ZInstSanBW, 
Munich). Gas chromatography was performed using an Agilent Hewlett Packard 6890 
gas chromatograph (Böblingen, Germany), equipped with a split/splitless injector, a 
flame-ionization detector (FID) and connected to an Agilent 19091J-413 HP-5 5% 
Phenyl-Methyl-Siloxane capillary column (30 m x 0.32 mm inner diameter, 0.25 µm film 
thickness). One µl of the pre-processed samples was injected with an inlet temperature 
of 250°C (split 1:15). Data analysis and instrument control was performed with Agilent 
ChemStation software.  
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The method for recovery of the oily substances was validated using a calibration curve 
of the solutions at 5 different concentrations ranging from 40 – 70 µg/mL. Three 
individual samples of each concentration were injected 6 times each. 
Samples contained approximately 10 mg of the oily substance and 50 mg of OVA 
loaded powder particles (a trehalose/mannitol formulation with 25 µg/mg OVA). For the 
extraction of the oily substance 1 mL purified water was added to the sample in order to 
reconstitute the protein-sugar matrix. One mL of tert-butyl-methyl ether (MTBE) 
containing an internal standard (10 mg/mL 5α-cholestan) was added and the mixture 
was vortexed for 10 seconds. For the separation of the organic upper layer, the sample 
was centrifuged at 10,000 rpm for 10 min. After a second solvent extraction step with 
1 mL MTBE an aliquot of 1500 µl of the two combined organic upper layers was 
transferred to another Eppendorf cap containing 40 mg of a mixture of PSA/Na2SO4 
(1:7). After another mixing and centrifugation step an aliquot of the organic phase was 
diluted (1:100) with MTBE  
Samples containing the oily adjuvant substance as single component (without a protein-
sugar matrix) were mixed directly with 1 mL MTBE containing 10 mg/mL 5α-cholestan 
and 1 mL MTBE. The mixture was diluted 1:100 with MTBE.  
 
2.9.3 REPROCESSING OF SAMPLES WITH OILY ADJUVANTS FOR FURTHER ANALYSIS OF 
PROTEIN SUGAR MATRIX 
Prior to the analysis of the protein formulation for protein stability, the oily substances 
had to be separated from the protein sugar matrix as the oily adjuvants were shown to 
interfere with the established analytical methods. Therefore, 1 mL of MTBE was 
pipetted into the vial containing the sample, vortexed for 10 seconds and transferred 
subsequently into an Eppendorf cap. The suspension was then centrifuged for 10 
seconds at 10000 rpm. The powder pellet was retained for two further washing steps 
with MTBE, whereas the supernatant was discarded. The powder pellet was dried in a 
vacuum chamber at 25 mbar for at least four hours at 25°C prior to analysis.  
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2.10 TESTING OF THE ADHESIVE STRENGTH AT THE INTERFACE BETWEEN PARTICLES AND 
DEVICE SURFACE 
2.10.1 PREPARATION OF THE SAMPLES 
Membranes, consisting of metal or plastic material, were covered with a thin film 
(approximately 10 µL/cm2) of adhesive and dipped in a bed of particles. The excess of 
particles was tapped off. The adhesion force of the particles onto the adhesives covered 
membranes was scrutinized using either a jolting volumeter or a custom made drop 
apparatus. 
 
2.10.2 JOLTING VOLUMETER 
Membranes, prepared as described above, were fixed on the inner surface of a petri 
dish and were attached headfirst to a jolting volumeter. The particle covered side was 
turned downwards. The border of the petri-dish served as a spacer to the surface of the 
jolting volumeter. The mass of remaining particles and adhesive on the membranes 
after 10, 20, 50, 100 and 500 beats performed by the jolting volumeter was determined 
gravimetrically.  
 
2.10.3 CUSTOM MADE DROP APPARATUS 
A piece of membrane coated with adhesive and particles as described before was fixed 
in a metal clam and dropped from one meter height using a custom made drop 
apparatus, charged with 382 g weight, as described by Stabenau et al.[20]. By the 
impact onto two distance pieces at the bottom of the drop apparatus, the metal clam 
was stopped abruptly from free-falling by a beat. The experiment was repeated 10 times 
with three replicates. The remained particles and adhesive mass on the membrane was 
determined gravimetrically.  
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2.11 BALLISTIC ACCELERATION OF PARTICLES 
2.11.1 LELL’S FOUCAULT ACCELERATOR 
The Lell’s Foucault accelerator is a custom made surrogate accelerator for ballistic 
acceleration of particles. The repulsive force to accelerate particles is generated by a 
magnetic field in an electromagnetical coil. Thus a turbulent electrical current is induced 
in a carrier membrane. Dependent on the pre-selected voltage of the capacitor bank, 
different particle velocities can be generated. Further approaches for the ballistic 
acceleration of particles using different actuator mechanisms is described in detail in 
chapter 7. 
 
2.11.2 VELOCITY MEASUREMENT USING HIGH SPEED CAMERAS 
The velocity of particles accelerated by ballistic approaches was measured using two 
synchronized Flash Cam PCO cameras. The distance of the flight of the particle cloud 
or single particles was calibrated using a scale. The velocity of the particles was 
calculated as a quotient of the flight distance and the time frame between the two 
synchronized cameras. 
 
2.11.3 CONFOCAL LASER SCANNING MICROSCOPY (CLSM) 
For the analysis of the penetration depth of fluorescein isothiocyanate (FITC) labelled 
polystyrene particles in pig skin after ballistic injection a confocal scanning laser 
microscope (Zeiss LSM 510 Meta Invert Laser Scan Microscope, Carl Zeiss Microscope 
Systems, Jena, Germany) equipped with an Argon and a HeNe1 laser for excitation was 
used. 3D images of the samples were obtained using a Z-stacking mode of Zeiss LSM 
Image Browser software as described by Deng et al.[21]. 
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CHAPTER 3  
 
TOWARD INTRADERMAL VACCINATION: PREPARATION OF 
POWDER FORMULATIONS BY COLLAPSE FREEZE-DRYING 
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1  INTRODUCTION 
Vaccination is an effective tool to control and eliminate infectious diseases, preventing 
two to three million deaths each year [1]. However, the administration of liquid vaccines 
using conventional needles and syringes holds the risk of needle-stick injuries and 
thereby the transmission of blood-borne diseases. In addition, the administration 
requires well trained health care personnel [2]. Emerging needle-free injection 
technologies such as the intradermal powder injection, which is the main focus of our 
study and is one very specific approach in the area of upcoming needle-free 
technologies, offer the potential to overcome these issues and furthermore allow the 
effective targeting of immunocompetent cells in the epidermal or dermal layers of the 
skin [3, 4]. The use of dried particles for powder injection provides enhanced stability for 
vaccines and may offer a superior long term stability of the vaccine in comparison to 
liquid formulations [4]. Particularly with regard to mass vaccination programs in 
developing countries, the use of dried vaccine particles may permit independency of a 
cold chain, thereby facilitating the distribution of vaccines. 
In order to be suitable for the intradermal delivery, the dried vaccine particles have to 
fulfill several requirements. Particle characteristics like size, density, shape and 
morphology have a great influence on the penetration depth of the particles. Particularly 
a high rigidity of the particles, which is attributed to the particle surface structure and to 
particle porosity, prevents fragmentation of the particles during acceleration and 
penetration [5]. 
Different processes can be used to generate dry vaccine particles for intradermal 
injection like spray drying, spray freeze-drying, freeze-drying, spray coating or simply 
desiccation [6-11]. Applying freeze-drying or desiccation requires a subsequent milling 
step in order to generate particles in the desired size ranges [6, 12]. The use of sugars 
as excipients to stabilize the vaccine during the preparation process implicates a rather 
low density of the particles (~700-1200 kg/m³) [13, 14]. Therefore, an appropriate size of 
the particles of 20 to 70 µm is needed to achieve appropriate physical characteristics for 
the intradermal injection process [7, 12]. Several approaches have been reported in 
literature to increase the tap density of the particles. The group of Costantino et al. 
showed that a high solid content of the liquid formulation is necessary to obtain particles 
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of high density, when particles are produced by spray-freeze-drying [15]. The group of 
Maa et al. stated that the formulation composition as well as the solid content of the 
formulation have an influence on the resulting particle morphology and tap density of 
the particles [6]. Similar results were obtained by the group of Schiffter et al. [11]. They 
were able to increase the density of sugar particles prepared by spray-freeze-drying by 
increasing the solid content of the spraying solution and by the formulation composition. 
The addition of the polymer dextran in a ternary mixture with mannitol and trehalose and 
35% (w/w) led to shrinkage of the particles. The tap density of the powder was 
maximized to 0.72 g/cm³ using this approach. However, high molecular weight polymers 
like dextran might lead to phase-separation and have a poor protein stabilizing effect 
[10]. Also the increase of the total solid content of the formulation was limited to 35% 
(w/w) due to the high viscosity of the formulation which also complicates several 
manufacturing steps [6, 16]. 
Besides the physical characteristics, the particles also have to maintain physical and 
chemical integrity of the incorporated vaccine in addition to a high loading capacity of 
the vaccine antigen [17], as only a limited amount of powder can be injected into the 
skin. Particles based on sugar matrices also bear the potential for the incorporation of 
substructures like nanoparticulate carriers, which are preferentially internalized by the 
Langerhans cells [18]. 
In this study we investigated the development of protein loaded powder particles that 
fulfill the requirements for intradermal injection. Two different formulations, based on 
trehalose and a ternary combination of trehalose, mannitol and dextran with total solid 
contents ranging from 15% to 35% (w/w) were investigated. The ternary mixture of 
trehalose, mannitol and dextran was chosen as it was found in literature to be 
appropriate to generate high density spray-freeze-dried particles with appropriate 
characteristics for intradermal injection [10].  
Ovalbumin was chosen as model antigen. Powder particles for intradermal powder 
injection were prepared by freeze-drying and subsequent cryo-milling. An aggressive 
freeze drying cycle was applied similar to the method published by Schersch et al., 
leading to a controlled collapse of the sugar matrix [19, 20]. Most importantly, using an 
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aggressive freeze-drying-cycle a much more dense structure of the freeze dried cake 
can be obtained.  
We investigated the effect of collapse freeze-drying on particle morphology and protein 
quality in comparison to a conventional moderate freeze-drying cycle. We scrutinized 
the effect of formulation composition as well as the total solid content of the formulation. 
Samples were analyzed after the cryo-milling process for particle size, density, specific 
surface area and residual moisture as well as protein stability. Long term storage 
stability at 2-8°C and 50°C was also investigated.  
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2 FORMULATION PREPARATION AND LYOPHILIZATION PROCESS 
In this study we explored the possibility to combine the approach of collapse freeze-
drying with a subsequent cryo-milling-step of the lyophilizates. A controlled collapse of a 
sugar matrix, induced by an aggressive freeze-drying cycle, offers the potential to 
generate collapsed lyophilizates with a dense matrix structure and reduced surface 
porosity without having negative effects on protein stability [20].  
Regarding a conventional freeze-drying cycle, the degree of super-cooling influences 
the cake structure and thereby the sublimation rates as well as other product 
parameters like specific surface area and residual moisture [21, 22]. However, in the 
case of the aggressive freeze-drying cycle used in this study, the cake structure is re-
built during the drying process as the collapse temperature of the formulations is 
exceeded [19]. 
The subsequent cryo-milling of the lyophilizates generates particles in the desired size 
range with high density and appropriate properties for intradermal injection. A second 
objective was to investigate the role of formulation composition and the total solid 
content of the formulation on particle density, and on particle morphology by applying 
the collapse freeze-drying cycle. Two different formulations based on trehalose and a 
ternary combination of trehalose, mannitol and dextran were prepared with 15%, 25% 
and 35% (w/w) total solids content. 
 
Table 3.1: Viscosity of the liquid formulations obtained at a shear rate of 100 (1/s). 
formulation composition 
viscosity [mPa*s] at shear rate 100 
[1/s] 
trehalose 15% (w/w) solid content 1.95 ± 0.25 
trehalose 25% (w/w) solid content 2.24 ± 0.29 
trehalose 35% (w/w) solid content 3.19 ± 0.51 
trehalose/mannitol/dextran 15% (w/w) solid content 4.10 ± 0.62 
trehalose/mannitol/dextran 25% (w/w) solid content 11.15 ± 0.13 
trehalose/mannitol/dextran 35% (w/w) solid content 35.50 ± 2.63 
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The preparation of the liquid formulation was complicated with increasing solid contents 
of the formulation by the viscosity of the formulations. Table 3.1 shows that the viscosity 
of the formulations, which all show Newtonian behavior, increased drastically with 
increasing solid content. The trehalose/mannitol/dextran formulation at 15% (w/w) 
showed a higher viscosity (4.10 ± 0.62 mPa*s) than the trehalose formulation with 35% 
(w/w) (3.19 ± 0.51 mPa*s). The viscosity of the trehalose/mannitol/dextran formulation 
increased up to 35.50 ± 2.63 mPa*s at 35% (w/w), leading to difficulties during the 
filtration of the liquid formulation as it required high pressure forces. Freeze-drying was 
performed using a conventional, moderate freeze-drying cycle and an aggressive 
freeze-drying cycle.  
The macroscopic appearance of the freeze-dried cakes was investigated by visual 
inspection. Collapse-drying of the formulations resulted in completely collapsed cakes, 
exhibiting a foam-like structure, whereas formulations freeze-dried after the moderate 
freeze-drying protocol resulted in elegant, porous, non-collapsed cakes (figure 3.1).  
 
 
Figure 3.1: Macroscopic appearance of lyophilizates after moderate and collapse freeze-
drying: (1) moderate freeze-dried trehalose lyophilizate, (2) moderate freeze-dried 
trehalose/mannitol/dextran lyophilizate, (3) collapse freeze-dried trehalose lyophilizate 
and (4) collapse freeze-dried trehalose/mannitol/dextran lyophilizate. 
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Figure 3.2: Scanning electron micrographs of lyophilizate cakes after moderate and 
collapse freeze-drying. Magnification 450x. (A) Moderate freeze-dried trehalose 
lyophilizate, (B) moderate freeze-dried trehalose/mannitol/dextran lyophilizate, (C) 
collapse freeze-dried trehalose lyophilizate and (D) collapse freeze-dried 
trehalose/mannitol/dextran lyophilizate. 
However, trehalose based lyophilizates underwent slightly partially collapse in form of 
slight cake shrinkage even after application of the moderate freeze-drying protocol. 
Scanning electron micrographs showed a very smooth and dense matrix structure of the 
collapse freeze-dried trehalose lyophilizates, whilst moderate freeze-dried trehalose 
lyophilizates revealed a more porous cake structure, as commonly described in 
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literature (figure 3.2). Morphological differences between collapse-dried and moderate 
freeze-dried lyophilizates were less pronounced in trehalose/mannitol/dextran 
formulations. 
The impact of formulation composition and the freeze-drying process on the morphology 
of the lyophilizates was also analyzed by X-ray powder diffraction.  
 
Figure 3.3: Exemplary XRD patterns of cryo-milled lyophilizates after collapse freeze-
drying. The morphological pattern did not change also after 12 months of storage at 2-
 8°C. Peaks at 9.7°2-Theta (emphasized with a frame) in combination with the absence of 
peaks at 17.9°2-Theta (indicated by arrows) are characteristic for the δ-modification of 
mannitol. 
 
Formulations based on trehalose formed an amorphous sugar matrix during freeze-
drying, whilst the ternary formulation of trehalose, mannitol and dextran showed a partly 
crystalline structure due to the bulking agent mannitol. Mannitol crystallized into the δ-
modification during freeze-drying as confirmed by the characteristic XRD-patterns. The 
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δ-modification of mannitol is characterized by peaks at 9.7 °2-Theta, whilst no peaks are 
apparent at 17.9 °2-Theta (figure 3.3). 
Despite the reduced drying time, the residual moisture content of the collapse freeze-
dried lyophilizates was comparable to the residual moisture content of moderate freeze-
dried lyophilizates (figure 3.4).  
Figure 3.4: Residual moisture levels of moderate and collapse freeze-dried lyophilizates 
before and after cryo-milling and after 12 months storage at 2-8°C. (A) Trehalose 
formulations with 15% (w/w) at the beginning of the study (black bars) and after 12 
months storage at 2-8°C (grey bars). (B) Trehalose/mannitol/dextran formulations with 
15% (w/w) at the beginning of the study (black bars) and after 12 months storage at 2-8°C 
(grey bars). 
 
The residual moisture level of moderate freeze-dried trehalose lyophilizates was 
approximately 2.9%, whereas the residual moisture level of collapse freeze-dried 
trehalose lyophilizates was 3.3%. Moderate freeze-dried trehalose/mannitol/dextran 
formulations had residual moisture levels of 2.5%, whilst collapse freeze-drying of this 
composition resulted in 1.8% residual moisture. In general, formulations containing a 
mixture of trehalose, mannitol and dextran had lower residual moisture levels in 
comparison to trehalose formulations. This can be attributed to the content of the 
crystalline bulking agent mannitol in the formulation. 
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3 INFLUENCE OF THE CRYO-MILLING PROCESS ON PARTICLE MORPHOLOGY 
In order to generate particles suitable for intradermal injection, the lyophilizates had to 
be further processed by milling. In general, milling applies mechanical stress to the 
product, which is turned into heat and surface energy and is associated with newly 
created particle surfaces [23]. Cryo-milling involves a cooling step of the lyophilizates by 
the use of liquid nitrogen and thereby decreases the product temperature to -130°C 
prior to the milling process. This step makes the lyophilizates brittle and in addition 
absorbs most of the heat that is created during the milling process. Cryo-milling was 
performed using a swing mill MM301 (Retsch Technology, Haan, Germany) as 
described in Chapter 2. 
In our study, cryo-milling of the lyophilizates resulted in irregularly shaped particles as 
observed by scanning electron microscopy (figure 3.5). Particles based on trehalose 
showed a very smooth surface, whereas trehalose/mannitol/dextran particles were 
square edgily shaped.  
The median volume diameter of the cryo-milled particles varied between 23.2 ± 2.2 µm 
and 25.8  ± 1.9 µm for the moderate freeze-dried trehalose formulations and between 
25.7 ± 0.9 µm and 31.4 ± 4.2 µm for the collapse freeze-dried trehalose formulations 
(table 3.2). The span of the volume distribution indicates a narrow particle size 
distribution. 
Lyophilizates consisting of the ternary combination of trehalose/mannitol and dextran 
resulted in slightly larger particles, what might be due to a higher rigidity of the cakes. 
As the rigidity of collapse freeze dried trehalose/mannitol/dextran lyophilizates with 
35% (w/w) exceeded the rigidity of the other formulations, it was necessary to adjust the 
cryo-milling protocol in order to result in comparable particle sizes. For these 
formulations the total milling time was set to 30 seconds instead of 10 seconds. A 
comparable particle size of the different formulations was in the main focus of the 
project as this allows us to compare the specific surface area of the particles among 
each other.  The specific surface area of the particles served as a parameter for the 
extent of collapse and is related to highly dense, robust and most likely stable particles. 
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Subsequent experiments showed that the prolongation of the milling time to 30 seconds 
did not decrease further the particle size of trehalose lyophilizates (data not shown). 
 
 
 
 
Figure 3.5: Scanning electron micrographs of cryo-milled particles after moderate and 
collapse freeze-drying. Magnification 450x. (A) Moderate freeze-dried trehalose particles, 
(B) moderate freeze-dried trehalose/mannitol/dextran particles, (C) collapse freeze-dried 
trehalose particles and (D) collapse freeze-dried trehalose/mannitol/dextran particles. 
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Table 3.2: Particle size distribution of cryo-milled powders calculated as an average of 6 
measurements and characterized with median diameter and span of the volume 
distribution.  
 
* Collapse freeze-dried trehalose/mannitol/dextran lyophilizates with 35% (w/w) were milled for 30 seconds, 
whereas all other lyophilizates were milled for 10 seconds. 
 
XRD-analysis of the particles showed, that cryo-milling did not change the crystallinity of 
the formulations. Formulations based on trehalose remained amorphous and also the 
crystalline structure of trehalose/mannitol/dextran formulations was not altered 
(figure 3.3). 
Cryo-milling did only slightly increase the residual moisture levels of the lyophilizates 
(figure 3.4). However, a distinct increase in the residual moisture levels of cryo-milled 
moderate freeze-dried trehalose particles was observed after storage at 2-8°C for 12 
months. This will be discussed more in detail in section 5. 
In summary, cryo-milling was found to be appropriate to generate particles in the 
desired size range without altering particle morphology or strongly increasing the 
residual moisture level of the particles. The influence of the cryo-milling process on 
protein stability will be discussed in section 5. 
 
  
 median particle size [µm] 
cryo-milled powders 
collapse 
freeze-dried 
span 
moderate 
freeze-dried span 
trehalose 15% (w/w) solid content 27.0 ± 4.3 3.0 ± 2.1 23.2 ± 2.2 6.7 ± 3.0 
trehalose 25% (w/w) solid content 25.7 ± 0.9 1.6 ± 0.1 24.8 ± 2.7 2.8 ± 1.1 
trehalose 35% (w/w) solid content 31.4 ± 4.2 3.1 ± 0.6 25.8 ± 1.9 3.0 ± 1.4 
trehalose/mannitol/dextran 15% (w/w) solid content 42.9 ± 8.0 3.8 ± 1.6 33.2 ± 0.6 3.1 ± 1.4 
trehalose/mannitol/dextran 25% (w/w) solid content 39.0 ± 2.5 3.0 ± 0.3 37.0 ± 1.9 2.4 ± 0.1 
trehalose/mannitol/dextran 35% (w/w) solid content    23.5 ± 1.2 * 4.5 ± 0.0 47.2 ± 4.9 3.6 ± 0.4 
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4 INFLUENCE OF THE COLLAPSED MATRIX STRUCTURE ON PARTICLE 
MORPHOLOGY 
The moisture sorption properties of pharmaceutical formulations have an impact on their 
storage stability [24]. We expected a reduction of the moisture uptake of particles due to 
the reduction of their specific surface area when prepared by the collapse-freeze-drying 
process. However, collapse freeze-dried particles showed only small differences in their 
vapor-adsorption curves in comparison to moderately freeze-dried particles (figure 3.6).  
 
 
Figure 3.6: Moisture sorption properties of moderate and collapse freeze-dried cryo-
milled lyophilizates after exposure to 0-90% relative humidity. The temperature was 
constantly held at 25°C during the measurement. (A) Collapse freeze-dried trehalose 
particles (filled circle) and moderate freeze-dried trehalose (open circle). (C) Collapse 
freeze-dried trehalose/mannitol/dextran particles (filled circle) and moderate freeze-dried 
trehalose/mannitol/dextran particles (open circle).  
Trehalose particles showed less water vapor uptake above 50% relative humidity than 
trehalose/mannitol/dextran formulations. This may be attributed to the hygroscopic 
characteristic of the polymer dextran, as it is capable to sorb 10-20% moisture at 50% 
relative humidity [25]. 
It is reported in literature that a high density of the particles is required, with a tap 
density ≥ 0.5 g/cm³ for effective skin penetration [6]. In our study, we achieved high 
powder tap densities by applying the collapse freeze-drying cycle. Trehalose 
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formulations reached a tap density of 0.739 g/cm³ and trehalose/mannitol/dextran 
formulations 0.771 g/cm³ (table 3.3), respectively. The tap density of collapse dried 
powder particles was increased in comparison to moderate freeze dried particles (table 
3.3). With rising solid content of the formulation, a further increase in tap density up to 
0.903 g/cm³ was observed.  
 
Table 3.3: True and tap density values for collapse and moderate freeze-dried 
lyophilizates after cryo-milling. Hausner factor was calculated from the quotient of tap 
and bulk density. 
formulation composition true density [g/cm³] tap density [g/cm³] 
  
collapse
freeze-dried 
moderate
freeze-dried 
collapse 
freeze-dried 
moderate
freeze-dried 
trehalose 15% (w/w) solid content 1.532 ± 0.002 1.528 ± 0.001 0.739 ± 0.023 0.671 ± 0.031
trehalose 25% (w/w) solid content 1.521 ± 0.002 1.528 ± 0.001 0.806 ± 0.024 0.671 ± 0.020
trehalose 35% (w/w) solid content 1.517 ± 0.001 1.532 ± 0.001 0.878 ± 0.007 0.705 ± 0.028
trehalose/mannitol/dextran 15% (w/w) solid content 1.492 ± 0.002 1.511 ± 0.002 0.771 ± 0.005 0.654 ± 0.002
trehalose/mannitol/dextran 25% (w/w) solid content 1.489 ± 0.003 1.509 ± 0.002 0.869 ± 0.002 0.716 ± 0.026
trehalose/mannitol/dextran 35% (w/w) solid content 1.494 ± 0.002 1.507 ± 0.001 0.903 ± 0.030 0.739 ± 0.033
 
The true density of the formulations is not much influenced by the kind of freeze-drying 
cycle or the solid content of the formulation, but by the composition of the formulation. 
Formulations based on trehalose have a slightly higher true density (1.517 – 
1.532 g/cm³) as formulations based on the ternary composition of trehalose, mannitol 
and dextran (1.489 – 1.511 g/cm³) (table 3.3).  
 
The specific surface area (SSA) is an important parameter to characterize the structure 
of dried matrices. Compared to the true density of the formulations, it allows a more 
accurate differentiation of the densification of the sugar matrix due to the kind of the 
applied freeze-drying cycle. The collapse of the sugar matrix led to a strong reduction of 
the specific surface area of the lyophilizates. 
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Figure 3.7: Specific surface area (SSA) of (A) trehalose (black bars) and 
trehalose/mannitol/dextran formulations (grey bars) generated by moderate and collapse 
freeze-drying as determined by BET gas adsorption. (B) SSA of the cryo-milled powder 
particles. Trehalose formulations are indicated with black bars and 
trehalose/mannitol/dextran formulations are indicated with grey bars. 
 
Collapse freeze-dried trehalose lyophilizates (15% (w/w)) showed a SSA of 0.028 ± 
0.025 m²/g, moderate freeze-dried lyophilizates of 0.757 ± 0.062 m²/g (figure 3.7 A). 
The SSA of trehalose/mannitol/dextran lyophilizates was reduced from 0.836 ± 0.048 
m²/g to 0.279 ± 0.012 m²/g. Hence, the collapse of the sugar matrix resulted in a 
reduction of the SSA of trehalose lyophilizates down to 3.7 % and in 
trehalose/mannitol/dextran formulations down to 33%. Abdul Fattah and colleagues 
obtained comparable results in an amorphous sugar matrix applying foam drying [26]. 
Furthermore, Abdul Fattah et al. were able to show that the reduced surface area of the 
lyophilizates, which was obtained by foam drying, increased the stability of the 
incorporated vaccine. Similar stabilization trends were also obtained investigating spray-
freeze-dried BSA particles stabilized with trehalose or mannitol. Costantino et al. 
correlated the specific surface area of the particles with the monomer loss of BSA and 
thereby demonstrated a stabilizing effect on the protein by reduction of the SSA [15]. 
Expectedly, cryo-milling resulted in an increase of the SSA in all formulations (figure 
3.7 B) due to the formation of small particles in the range of 23.24 to 65.60 µm size. The 
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relatively smaller SSA of the particles after collapse drying of the sugar matrix was 
maintained also after the cryo-milling process compared to moderate dried particles. 
The SSA of moderate freeze-dried cryo-milled powders was also lower for formulations 
with higher solid content [6]. Notably, this effect was less pronounced in collapse freeze-
dried cryo-milled powders. 
Besides the economic advantages of the collapse freeze-drying process, we were able 
to obtain powder particles with a small surface area. A small surface area is related to 
highly dense, robust and most likely stable particles. During intradermal injection, 
particles are accelerated to high velocities, even above the sonic barrier. Therefore 
particles have to be robust and require a highly dense structure, so that they are able to 
breach the outermost barrier of the skin, the stratum corneum. 
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5 PROTEIN STABILITY AFTER CRYO-MILLING AND STORAGE 
The protein stability of ovalbumin was assessed by size exclusion chromatography and 
light obscuration. Regarding the results obtained by size exclusion chromatography, the 
freeze-drying process and also the cryo-milling process had no influence on the stability 
of ovalbumin (table 3.4).  
Table 3.4: Recovery of soluble monomer [%] of ovalbumin of moderate and collapse 
freeze-dried samples with 15% (w/w) as determined by size-exclusion chromatography. 
  
after 
lyophilisation 
after cryo-
milling 
after 12 months 
storage 
trehalose collapse freeze-dried 100.15 ± 0.02 100.55 ± 0.14 100.61 ± 0.42 
trehalose moderate freeze-dried 100.10 ± 0.01 100.02 ± 0.14 101.24 ± 0.05 
trehalose/mannitol/dextran collapse freeze-dried 99.99 ± 0.08 99.81 ± 0.19 100.22 ± 0.22 
trehalose/mannitol/dextran moderate freeze-dried 100.01 ± 0.01 100.05 ± 0.07 100.52 ± 0.10 
 
There was no change in the recovery of soluble monomer of ovalbumin, neither after 
the moderate nor after the collapse freeze-drying cycle (table 3.4). These results 
confirm the findings of Schersch et al., that an aggressive freeze-drying cycle, leading to 
a collapse of the sugar matrix, does not result in a detrimental effect on protein stability 
[20]. Also the cryo-milling process did not influence monomer recovery. All powder 
formulations remained stable during storage at 2-8°C for 12 months. 
However, an additional stability study at elevated temperature (50°C) over a time period 
of 12 weeks showed a negative influence of formulations containing dextran on the 
stability of ovalbumin. Though none of the glass transition temperatures of the 
formulations was lower than the storage temperature, a slight increase of higher 
molecular weight aggregate species was observed after 12 weeks of storage at 50°C in 
trehalose/mannitol/dextran (70 kDa) formulations. No change in the recovery for soluble 
aggregates was found in trehalose formulations (figure 3.8). 
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Figure 3.8: Recovery of ovalbumin protein species [%] in trehalose/mannitol/dextran 
formulations (A) and trehalose formulations (B) as determined by size-exclusion 
chromatography after 0, 8 and 12 weeks of storage at 50°C. Higher molecular weight 
aggregates (black bars), dimers (grey bars), fragments (dark grey bars). Recovery of 
soluble monomer [%] (filled circle), total protein recovery [%] (open circle). The increase 
of higher molecular weight aggregates after 8 and 12 weeks of storage at 50°C are 
indicated with black arrows. 
 
Formulations containing the polymer dextran seem to be detrimental for protein integrity 
during storage at elevated temperatures. These results are also supported by light 
obscuration and turbidity measurements (data not shown). A destabilizing effect of 
higher molecular weight polymers on bovine liver catalase during spray freeze-drying 
was also observed by Rochelle et al. [10]. Whilst the addition of polymers into spray-
freeze-dried formulations is necessary to obtain appropriate particle morphology and 
density for intradermal injection, this need can also be fulfilled by applying collapse 
freeze-drying and subsequent cryo-milling. 
The formation of insoluble aggregates in the liquid formulations as well as in the 
reconstituted lyophilizates and cryo-milled powders was assessed by light obscuration. 
The increase in particle count can be attributed to the formation of protein aggregates; 
no increase in particle counts was determined in cryo-milled placebo lyophilizates, 
excluding that abrasion had created particulate matter (data not shown). The cumulative 
particle counts > 1 µm of the samples increased after freeze-drying in comparison to the 
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particle counts in the liquid formulation before drying. This was observed in both 
moderate and collapse freeze-dried formulations. However, collapse freeze-dried 
trehalose formulations showed only a small increase in particle counts > 1 µm in 
comparison to the moderate freeze-drying cycle (figure 3.9 A). 
Trehalose/mannitol/dextran formulations showed already in the liquid formulation higher 
particle counts than trehalose formulations. An increase in particles > 10 µm was 
observed in moderate freeze-dried samples, whereas no increase in the particle count > 
10 µm was visible in collapse freeze-dried lyophilizates (figure 3.9 B).  
 
  
Figure 3.9: Cumulative particle counts (A) > 1 µm per ml and (B) > 10 µm per ml in 
trehalose (black bars) and trehalose/mannitol/dextran formulations (grey bars) with 
15% (w/w) as measured by light obscuration. 
 
After cryo-milling, the cumulative particle count > 1 µm increased in both formulations 
independent of the kind of freeze-drying process (figure 3.9 A). Though regarding the 
cumulative particle counts > 10, cryo-milling resulted in higher particle counts in 
moderate freeze-dried lyophilizates (figure 3.9 B) in comparison to collapse freeze-dried 
lyophilizates. Collapse freeze-drying shows herein a superior protein stabilizing effect in 
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comparison to moderate freeze-drying. Trehalose/mannitol/dextran formulations 
showed after each processing step a generally higher particle count than trehalose 
formulations. The particle count did not further increase after storage at 2-8°C for 
12 months. Neither the secondary structure, nor the tertiary structure, nor the activity of 
ovalbumin were assessed in this study. Therefore, we cannot predict if the collapse 
might induce any changes or inactivation even without the formation of aggregates. 
 
After 12 months storage at 2-8°C the residual moisture content increased in cryo-milled 
moderate freeze-dried trehalose particles (figure 3.4). This was not the case for cryo-
milled collapse freeze-dried trehalose particles. Also an increase in the residual 
moisture level of collapse freeze-dried trehalose lyophilizates was observed. All other 
lyophilizates and milled powder particles showed just a slight increase in their residual 
moisture levels after storage. It was reported in literature that moisture transfer from 
stoppers or the vapors permeability of stoppers have to be taken into count as possible 
causes for moisture increase of lyophilizates during storage [27-30]. Generally, an 
increase in moisture levels during storage is related to an adverse effect on protein 
stability [31-33]; however, this could not be confirmed in this study for ovalbumin in 
trehalose formulations during storage at 2-8°C for 12 months. 
XRD-analysis showed that storage over 12 months at 2-8°C did not influence the 
amorphous structure and crystallinity of the trehalose or trehalose/mannitol/dextran 
formulations (figure 3.3). 
We were able to show that collapse freeze-drying and subsequent cryo-milling of the 
lyophilizates generated dense particles with a low specific surface area, independent of 
the formulation composition or the total solid content of the formulation. Furthermore 
protein stability of the model antigen ovalbumin could be preserved in trehalose based 
formulations over a storage period of 12 months at 2-8°C and 50°C (figure 3.8). Further 
investigations in order to see if this process is also applicable to other model proteins 
will be discussed in chapter 4. 
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6 SUMMARY AND CONCLUSION 
We established a process to generate particles suitable for intradermal injection by 
combining the collapse-freeze-drying process with subsequent cryo-milling of the 
lyophilizates. Collapse freeze-drying provides lyophilizates with a very dense matrix 
structure and low specific surface area. Subsequent cryo-milling of the cakes was found 
to be an appropriate method to generate particles in the desired size range and with a 
narrow size distribution without having a negative influence on the stability of ovalbumin. 
Particles of high density were generated by applying this approach, independent of the 
formulations composition or the solid content of the formulation. The collapse freeze-
drying process is, in comparison to a standard lyophilization process, a rather fast 
drying-process, reducing costs by saving drying time and can be easily combined with a 
subsequent cryo-milling step. 
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CHAPTER 4  
 
EVALUATION OF A CRYO-MILLING PROCESS FOR PARTICLE 
PROCESSING 
 
Within this chapter, the work related to section 2.2 - 2.4 includes results from the 
“Advanced Practical Course A” with the title “Scale-up and optimization of the 
manufacturing process of collapse freeze-dried and cryo-milled particles” by Josefine F. 
Pott, LMU Munich, 2011. The results within section 2.2 – 2.4 are expressed in figures 
4.1 – 4.7, which were reproduced in a modified form. The “Advanced Practical 
Course A” has been planned, structured and carried out under my direct supervision. 
The results obtained and the conclusions drawn have been discussed under my 
supervision. 
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1  INTRODUCTION 
 
The main challenge for the preparation of dry powder vaccine formulations for needle-
free ballistic injection is firstly the production of the powders with reproducible particle 
size and distribution as well as the ability of the formulation to stabilize the incorporated 
vaccine. Secondly, an appropriate delivery technology is crucial for the application of 
the powdered formulation at the target site, the superficial layers of the skin, in order to 
elicit an adequate immune response. 
As discussed in Chapter 3, the preparation of powdered formulations by collapse-freeze 
drying and subsequent cryo-milling generated particles with a narrow particle size 
distribution of 25-50 µm, comprising a dense matrix structure and low specific surface 
area of the particles. A size range of 20-70 µm of the particles is mandatory to achieve 
sufficient impact during ballistic injection to breach the epidermal layers of the skin [1-4], 
as sugar particles have to compensate their generally low density by their size. 
By applying the above described process it was possible to preserve protein stability of 
the model protein ovalbumin. However, cryo-milling was performed using a swing mill, 
whereat the milling beakers were dipped manually into liquid nitrogen prior to the milling 
process. Thus the process is limited to a laboratory scale.  
The aim of the following work was to systematically investigate and optimize a cryo-
milling process for the production of vaccine loaded powder particles for intradermal 
ballistic delivery by using a semi-automated approach of a cryo-mill, allowing the 
development of a sterile production process, one crucial requirement to scale-up the 
process to industrial standards. Within this system the milling beakers are flushed 
continuously with liquid nitrogen prior to the automated milling-process. Further insight 
in different adjustable parameters like milling frequency, milling time and time of pre-
cooling with liquid nitrogen was taken. The influence of the different milling parameters 
on particle size, microscopic appearance and residual moisture of the powders as well 
as on the stability of the model vaccine ovalbumin was assessed. Furthermore, the 
applicability of the cryo-milling process on other model protein was investigated. 
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2 DEVELOPMENT OF A CRYO-MILLING PROCESS 
2.1 SELECTION OF DIFFERENT FORMULATIONS FOR THE EVALUATION OF THE CRYO-MILLING 
PROCESS 
Three different formulations were selected for the evaluation of the cyro-milling process: 
a formulation based on trehalose (T), a combination of trehalose and the amino acid 
phenylalanine (TP) at a weight ratio of (9.5:0.5) and a ternary mixture of trehalose, 
mannitol and dextran (TMD) at a weight ratio of (3:3:4), respectively. Dextran had an 
average molecular weight of 70 kDA. All formulations contained 2.5% (w/w) ovalbumin 
and had a total solid content of 15% (w/w). The formulations were freeze-dried applying 
a collapse freeze-drying cycle according to the protocol described in chapter 2 [5]. This 
approach allowed for a collapse of the sugar matrix and the generation a high density 
structure of the freeze dried cake.  
The ternary mixture of trehalose, mannitol and dextran was selected as it is known from 
literature to be appropriate to generate high density particles with appropriate 
characteristics for ballistic injection [6-9]. As already described in chapter 3, 
trehalose/mannitol/dextran formulation preserved, despite of the collapse-freeze drying 
cycle, a macroscopically elegant cake structure. 
The formulation based on trehalose was chosen, as it showed superior morphological 
characteristics for ballistic injection and as it was able to preserve protein stability of 
ovalbumin for a time period of 12 months at 2-8°C and 50°C [10].  
Generally, collapse freeze-drying of formulations based on trehalose results in 
macroscopic collapse of the matrix structure. By contrast, the addition of amino acids in 
lyophilizate formulations prevents the macroscopic collapse of amorphous 
lyoprotectants. Phenylalanine does not only act as cryoprotactant by exerting 
preferential exclusion from the protein/water interface [11], but also forms a network 
structure, on which amorphous trehalose can attach during lyophilization [12, 13].  
The impact of these different cake structures on the rigidity of the lyophilizates and 
hence the impact of the formulation on the resulting particle size and distribution of the 
powders after cryo-milling was investigated.  
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2.2 MACROSCOPIC APPEARANCE AND RIGIDITY OF THE LYOPHILIZATES 
Figure 4.1 depicts the macroscopic appearance of the lyophilizates after collapse-freeze 
drying. Formulations containing a ternary mixture of trehalose/mannitol/dextran were 
slightly shrunken, however, maintained an elegant cake structure. 
Trehalose/phenylalanine formulations showed a partially collapsed structure to a higher 
extent as trehalose/mannitol/dextran formulations. Formulations based on trehalose 
were foam-like shaped. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Macroscopic appearance of the lyophilizates after collapse freeze drying. (A) 
trehalose/mannitol/dextran (B) trehalose/phenylalanine (C) trehalose. 
 
The rigidity of collapse freeze-dried cakes provides an indication on the resistance of 
the formulation during milling and was examined using a texture analyzer. Therefore a 
cylindrical piston was moved with 1 mm/s into the sample as described in chapter 2.  
The required force to deform or break through the lyophilizate cake was monitored. A 
high rigidity (breaking force 30.4 N ± 2.8) of the freeze-dried cake was observed in 
formulations containing a combination of trehalose, mannitol and dextran (figure 4.2).  
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Figure 4.2: Rigidity of the lyophilizates determined by indentation using a texture 
analyzer.  
Lower rigidity (4.9 N ± 2.9) of the freeze-dried cake was observed in formulations 
containing trehalose or a combination of trehalose and phenylalanine (7.8 N ± 3.8). 
Thus, as the rigidity of the freeze-dried cakes were comparable, formulations containing 
trehalose were chosen representatively for trehalose and trehalose/phenylalanine 
formulations for the subsequent investigation of the milling parameters. 
 
2.3 INFLUENCE OF THE MILLING PARAMETERS PRE-COOLING TIME AND MILLING FREQUENCY 
ON THE POWDERED PRODUCT 
First, the influence of pre-cooling time and milling frequency on the resulting particle 
size after cryo-milling was analyzed. Stainless-steel milling beakers, containing the 
milling load of 1.0 g and a milling ball of 1 cm diameter, were flushed during the pre-
cooling phase continuously with liquid nitrogen. A pre-cooling time of 5 and 10 min was 
explored and compared to milling without pre-cooling. A subsequent milling step was 
performed for 30 seconds at 25 Hz using a milling load of 1.0 g. The temperature of the 
milling load was measured directly after milling. These experiments were performed 
exemplarily with trehalose-formulations. The resulting particle size distribution of the 
powders was measured by laser light diffraction as described in chapter 2. Particle size 
distribution was calculated as an average of 6 measurements applying the Fraunhofer 
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theory and characterized with median diameter and span of the volume distribution. 
Each sample was measured at least in triplicates. 
 
 
Figure 4.3: (A) Median particle size of trehalose powders after 0, 5 and 10 minutes of pre-
cooling of the grinding beaker and (B) at 15, 20 and 25 Hz milling frequency. 
The pre-cooling time prior milling affected particle size and distribution of the powder as 
well as the homogeneity of the milled product. Milling without pre-cooling of the sample 
at room temperature (20°C) resulted in a mean particle size of 76.45 µm ± 36.9 µm and 
a span of 3.59 ± 1.17 (figure 4.3). The friction forces, which were caused by the milling 
process, created heat which in turn induced a melt together of the particles as pointed 
out in the scanning electron micrographs (figure 4.4). 
Generally, heat caused by friction forces during milling might not only induces a local 
melting of the particles but also exceed the glass transition temperature of the 
formulation [14] and hence potentially destabilize the incorporated protein [15]. 
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Figure 4.4: Scanning electron micrographs of trehalose powder particles after milling 
without pre-cooling of the sample for 30 seconds at 25 Hz and a milling load of 1.0 g. 
Magnification 450x. 
This observation was also confirmed in experiments performed by Garmise et al. Milling 
of an influenza vaccine formulation based on lactose or trehalose intended for nasal 
delivery at room temperature using a micro-ball mill required milling times larger than 
15 min up to 2 hours in order to result in the required particle size of 45-125 µm [16, 17]. 
The milling load of the freeze-dried cakes was 200 mg. Higher velocity during milling 
resulted in larger flakes, suggesting melting and recrystallization of the formulation 
components [17], supporting our observations. Similar observations were made by Maa 
et al. after compressing, manually grounding and sieving of a lyophilizate containing a 
Hepatitis-B vaccine and a ternary formulation of trehalose, mannitol and dextran 
(~ 10 kDa). The potency recovery of the Hepatitis-B vaccine was quite low with 20-30%, 
indicating a destabilizing effect of the process steps. Furthermore, manually grinding 
and sieving of the powder resulted in a broad particle size distribution and a low yield of 
particles in the desired size range of 25-30 µm [8]. 
After a pre-cooling time of 5 minutes the temperature of the powdered product 
decreased to -52°C. However, this did not influence the mean particle size or 
distribution of the powder, which remained 75.70 µm ± 32.38 µm in size with a span of 
2.91 ± 0.29.  A pre-cooling time of 10 minutes resulted in a maximal low product 
temperature of -136°C. Thus, the low product temperature created brittle cakes and 
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uniform powder particle size of 39.47 µm ± 6.45 µm and a narrow size distribution (span 
3.20 ± 1.43). Applying this approach, cryo-milling generally resulted in non-spherical 
solid particles.  
The choice of a maximal milling frequency of 25 Hz reduced the required milling time 
(figure 4.3B). By controlling the temperature of the milling load, the potential to reduce 
vaccine potency can be minimized whereas milling speed (frequency) and milling time 
can be optimized.  
These conditions, 10 min pre-cooling and 25 Hz milling frequency, maximized the 
production of appropriately sized particles and were chosen for the following production 
conditions. 
 
2.4 INFLUENCE OF MILLING TIME ON THE MEDIAN PARTICLE SIZE OF THE POWDERS 
For trehalose formulations a milling time of 15 seconds at 25 Hz was sufficient to obtain 
particles in the desired size range of 41.95 µm ± 8.73 µm (span 3.07 ± 0.58). Longer 
milling times lead to particle agglomeration (figure 4.5).  
 
Figure 4.5: Median particle sizes of trehalose powders (black bars) and trehalose/ 
mannitol/dextran powders (grey bars) after 15, 30 and 60 seconds of milling. 
Formulations containing a ternary formulation of trehalose/mannitol and dextran 
required longer milling times. 30 seconds of milling at a frequency of 25 Hz were 
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appropriate to generate particles in the desired size range of 40.57 µm ± 8.32 µm (span 
3.03 ± 0.77).  
Figure 4.6A depicts exemplarily particle sizing results of a trehalose/mannitol/dextran 
formulation after 10 min of pre-cooling using a milling load of 1 g and a milling time of 30 
seconds at 25 Hz. Figure 4.6B depicts particle sizing results of a trehalose formulation 
cryo-milled using the same conditions though after a milling time of 15 seconds.  
 
 
Figure 4.6: Median particle sizes of trehalose powder (A) after a pre-cooling time of 10 
minutes and 15 seconds of milling at 25 Hz. Median particle size trehalose: 43.22 µm; 
span 2.42; D (v, 0.1) 10.49 µm; D (v, 0.9) 115.02 µm. (B) Trehalose/mannitol/dextran 
powder after a pre-cooling time of 10 minutes and 30 seconds of milling at 25 Hz. Median 
particle size trehalose/mannitol/dextran: 48.66 µm; span 2.11; D (v, 0.1) 10.17 µm; D (v, 
0.9) 112.85 µm. 
Particle size distribution of the powders could be confirmed by scanning electron 
microscopy (figure 4.7.). Cryo-milling of trehalose/mannitol/dextran formulations 
resulted in irregularly square-edged shaped particles, whereas cryo-milled trehalose 
particles exhibited a smooth surface structure. In contrast, common methods for protein 
powder preparation as spray drying or spray freeze-drying generally result in spherical 
particles with very smooth surfaces and a porous inner particle structure [4, 18, 19]. 
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Figure 4.7: (A) Scanning electron micrographs of trehalose/mannitol/dextran powders 
and (B) trehalose powders after cryo-milling after 30 seconds and 15 seconds of milling, 
respectively. Magnification 450x. 
 
However, a porous inner particle structure indicates a low mechanical stability of 
powders [20] as well as a low density. As these properties are unfavourable for ballistic 
injection of the powders, cryo-milling of freeze-dried lyophilizates provide an important 
option for this purpose. 
 
2.5 INFLUENCE OF CRYO-MILLING ON RESIDUAL MOISTURE LEVELS AND PROTEIN STABILITY 
Residual moisture content of the formulations was determined directly after 
lyophilization and subsequently after cryo-milling. Initial residual moisture levels of 
trehalose/mannitol/dextran lyophilizate cakes were 1.51% ± 0.07%, whereas trehalose 
lyophilizate cakes showed higher residual moister levels with 4.34% ± 0.16%. The 
presence of phenylalanine in trehalose/phenylalanine lyophilizates reduced the initial 
residual moisture level of the lyophilizate cake to 2.34% ± 0.24%. Cryo-milling using the 
semi-automated cryo-mill did only slightly increase the residual moisture levels of the 
lyophilizate cakes (figure 4.8). This confirms also the findings using a non-automated 
cryo-milling set-up as described in chapter 3. 
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Figure 4.8: (A) Residual moisture content of trehalose (T), trehalose/phenylalanine (TP) 
and trehalose/mannitol/dextran (TMD) lyophilizates prior to the milling process and after 
cryo-milling. (B) Recovery of soluble monomer [%] of ovalbumin after cryo-milling, as 
compared to the amount of monomer present in the solution prior to freeze-drying as 
determined by size-exclusion chromatography. 
The influence of the cryo-milling process on protein stability was investigated by size 
exclusion chromatography. No significant changes in the recovery of the soluble 
monomer of ovalbumin were observed (figure 4.8) directly after the cryo-milling process, 
thus confirming the results using a non-automated cryo-milling set-up [10]. The 
performance of cryo-milled powders during storage at elevated temperatures is 
discussed in chapter 5. 
 
2.6 DEVELOPMENT OF A STERILE PRODUCTION PROCESS FOR CRYO-MILLED POWDERS 
A sterile production process was developed to produce low endotoxin cryo-milled 
powders. All primary packaging materials, vials, stoppers as well as additional 
equipment like spatulas, beaker glasses and grinding beakers were sterilized either by 
heat sterilization at 160°C for two hours or by steam pressure sterilization at 120°C for 
15 min.  
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Figure 4.9: Process flow chart of the sterile production process for cryo-milled powders. 
 
All excipients were dissolved in buffer and filtered under the laminar air flow using 
0.2 µm PVDF filters into sterile 50 ml tubes. The liquid formulation was filled into 
lyophilization vials and stoppered completely before taking them out of the laminar air 
flow. The stoppered vials were transferred under appropriate conditions into the clean 
room class A of the sterile facility. The vials were opened and partially stoppered again 
before loading them into the freeze-dryer. After freeze-drying the vials were stoppered 
completely and transferred out of the sterile facility into the laminar air flow. The freeze-
dried cakes were filled into the grinding beaker of the cryo-mill and closed properly. 
Cryo-milling was conducted under non-sterile conditions. After the milling process the 
grinding was transferred into the laminar air flow and the powder was filled into sterile 
glass beakers. 
Sterility tests of the powders were performed according to the European 
Pharmacopoeia [21] using the membrane filter test. All powders were sterile according 
to pharmacopoeia, confirming the possibility to use the semi-automated cryo-mill 
process for the production of powders suitable for parenteral administration. 
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3  APPLICABILITY OF THE CRYO-MILLING PROCESS TO THE MODEL PROTEINS 
RH-GCSF AND RH-IFN Α-2A 
 
Formulations containing ovalbumin were shown to be stable after cryo-milling. Rh-G-
CSF and rh-IFN-α-2a were chosen as model proteins to investigate the applicability of 
the cryo-milling process to different proteins in addition to the already thoroughly 
scrutinized model antigen ovalbumin. Both proteins are known to be prone towards 
aggregation, particularly if the proteins are subjected to heat [22], an extensive air-water 
interface or agitation [23-25]. However, little is known about the effect of milling or cryo-
milling of the lyophilizates on protein aggregation. 
 
Rh-G-CSF was dialyzed using a 0.02 M acetate buffer pH 4.0, and formulated with 
0.004% polysorbate and 15% (w/w) trehalose/mannitol in a weight ratio of 1:1. Rh-IFN-
α-2a was formulated in a 0.025 M acetate buffer pH 5.0, containing 0.12 M sodium 
chloride and 15% (w/w) trehalose/mannitol in a weight ratio of 1:1. Ovalbumin was 
dissolved in phosphate buffer (pH 7.0, 10 mM phosphate, 50 mM ionic strength 
adjusted with sodium chloride) and formulated with 15% (w/w) trehalose/mannitol in a 
weight ratio of 1:1. The final protein content of all formulations was 2.5% (w/w).  
Lyophilization was performed applying the collapse cycle as described in chapter 2. 
Cryo-milling was carried out after a pre-cooling time of 10 min at 25 Hz for 15 seconds. 
A trehalose/mannitol formulation containing ovalbumin (15% solid content, 2.5% protein 
content) served as a reference.  
 
Size exclusion chromatography showed a significant decrease of 6 to 7% of the total 
protein recovery of rh-IFN-α-2a after freeze-drying, indicating an increase of insoluble 
aggregates (table 4.1). No changes in the recovery of the monomer species were 
observed. This is also in line with the results obtained by Sharma et al., showing the 
formation of insoluble aggregates of vacuum dried rh-IFN-α-2a formulations along with 
the absence of soluble aggregates [26]. Interestingly, the total protein content of rh-IFN-
α-2a formulations did not change after the cryo-milling process in comparison to the 
total protein content after collapse freeze-drying.  
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Rh-G-CSF formulations showed a slight increase in dimer species of 1.67% after 
collapse freeze-drying accompanied by an equal decrease in monomer species. The 
formation of dimers in rh-G-CSF formulations was already observed after collapse 
freeze-drying and did not change after cryo-milling. This reflects the sensitivity of rh-G-
CSF towards surface-induced stress at air-water interfaces, which was also a stress 
vector during cryo-milling [23, 24]. 
Formulations containing ovalbumin showed no significant differences in protein recovery 
or the pattern of protein species after collapse freeze-drying or after cryo-milling. Only a 
slight increase in the content of higher molecular weight species could be observed, 
however the changes were not significant. 
 
Table 4.1: Protein recovery and pattern of the protein  species as determined by size-
exclusion chromatography. 
  higher 
molecular 
weight 
aggregate 
[%] 
dimer [%] 
monomer 
[%] 
fragments 
[%] 
relative 
recovery* 
[%] 
Rh-IFN-
α-2a 
liquid formulation   100.00 ± 0.00  99.45 ± 1.76 
lyophilizate   100.00 ± 0.00  93.00 ± 2.90 
cryo-milled powder   100.00 ± 0.00  93.90 ± 0.86 
G-CSF 
liquid formulation   100.00 ± 0.00  99.28 ± 1.30 
lyophilizate  1.67 ± 0.14 98.33 ± 0.14  100.64 ± 0.36 
cryo-milled powder  1.57 ± 0.69 98.43 ± 0.69  99.71 ± 0.97 
OVA 
liquid formulation 1.86 ± 0.61 7.59 ± 0.13 89.90 ± 0.60 0.65 ± 0.08 101.84 ± 0.78 
lyophilizate 1.63 ± 0.24 7.82 ± 0.01 89.90 ± 0.28 0.66 ± 0.03 99.76 ± 0.33 
cryo-milled powder 2.17 ± 0.28 7.96 ± 0.04 89.13 ± 0.37 0.74 ± 0.05 98.86 ± 0.38 
*Relative recovery of the total protein content = area under the curve after cryo-milling/area under the 
curve at t0 (liquid formulation) x 100. 
 
Rh-IFN-α-2a lyophilizates showed a strong increase in turbidity after lyophilization up to 
turbidity levels of 5.7 ± 0.07 NFU (figure 4.10 A). This was in accordance with the 
results obtained by size exclusion chromatography.  
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Figure 4.10: Turbidity of rh-IFN-α-2a-formulations (A), rh-G-CSF-formulations (B), and 
ovalbumin-formulations (C). The liquid formulation is abbreviated as “form”, lyophilizate 
is abbreviated as “lyo” and cryo-milled powders are abbreviated as “cryo”. Residual 
moisture levels after lyophilization and cryo-milling of rh-IFN-α-2a-formulations (D) rh-G-
CSF-formulations (E) and OVA formulations (F). Formulations containing protein (black 
bars) and placebo formulations (grey bars). 
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The turbidity of rh-IFN-α-2a further increased after the cryo-milling process up to 7.96 ± 
0.14 NFU indicating a destabilization of the protein.  
A slight increase in turbidity of rh-G-CSF formulations was observed after collapse 
freeze-drying and cryo-milling in comparison to placebo samples (containing only 
excipients) (figure 4.9 B).  
Rh-G- CSF lyophilizates exhibited a turbidity level of 0.73 ± 0.02 FNU whereas the 
corresponding placebo lyophilizates showed a turbidity level of 0.50 ± 0.07 FNU. After 
cryo-milling rh-G-CSF powders had a turbidity level of 1.13 ± 0.10 FNU in comparison to 
the corresponding placebo powders with 0.84 ± 0.05 FNU. 
Similarly, the turbidity of ovalbumin formulations increased after the cryo-milling 
process, however to an extent comparable to the increase of placebo formulations 
(containing only excipients) after the milling process (figure 4.10C). This indicates that 
insoluble particles were formed in the course of the cryo-milling process due to the 
formation of particles built up of excipients (as observed in the placebo samples as 
control samples) rather that due to the formation of protein aggregates.  
 
The residual moisture levels of all formulation increased just slightly after cryo-milling 
with 0.05% in rh-IFN-α-2a formulations, 0.17% in rh-G-CSF formulations and 0.73% in 
ovalbumin formulations (figure 4.10 D-F). All cryo-milled protein powders showed 
acceptable residual moisture levels with less than 1.6%. Placebo formulations showed 
already after collapse freeze-drying a slightly higher residual moisture level compared to 
formulations containing protein.  
 
Figure 4.11 A-C shows the cumulative particle counts of rh-G-CSF formulations 
measured by light obscuration. The cryo-milling process caused particles larger than 1, 
10 and 25 µm per mL in rh-G-CSF formulations as well as in the corresponding placebo 
formulations. Only the cumulative particle count larger than 10 µm per mL was 
significantly higher than in the placebo formulations. However, particle counts > 10 μm 
were below 400 counts per containment, which is well in line with the specified limits of 
the European Pharmacopoeia (Ph. Eur.), requiring less than 6000 particles per 
containment in this size range. 
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Figure 4.11: (A-C) Cumulative particle counts > 1, 10 and 25 µm of rh-G-CSF formulations 
as determined by light obscuration. (D) Second derivative amid I FTIR-spectra of rh-G-
CSF formulations. Formulations containing protein (black bars) and placebo 
formulations (grey bars). 
 
In order to assess the conformational stability of rh-G-CSF after lyophilization and cryo-
milling, FTIR spectra of the liquid formulation, the lyophilizate and the cryo-milled 
powder were obtained. The lyophilizate as well as the cryo-milled powder had to be 
reconstituted in purified water prior to analysis. Since particle-free solutions are required 
for the recording of the spectra in the IR-transmission cell, the samples were centrifuged 
and only the remaining supernatant was analyzed. The FTIR spectra of the amid I 
bands of the rh-G-CSF formulations depicted in figure 4.11B were background 
corrected against the respective placebo formulation and vector-normalized. The α-
helical band at 1656 cm-1 showed no changes in its intensity after lyophilization and 
cryo-milling indicating the preservation of the native secondary structure of rh-G-CSF 
A B 
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after both process steps. Baseline slopes and shifts in the intensity of the spectra in the 
region of 1600 – 1630 cm-1 and 1670 – 1720 cm-1 were observed after lyophilization and 
cryo-milling, however, the formation of new bands, which might be attributed to 
intermolecular ß-sheet formations, could not be observed [27-29]. It is known from 
literature that FTIR spectra of freeze-dried proteins often show band broadening and 
shifts in the band positions and intensities of amide I spectra due to the removal of 
water and hence environmental changes [30, 31], but are not consequently based on 
disturbances in the secondary structure of the protein.  
Minor perturbations in the conformational stability of rh-G-CSF occurred after collapse 
freeze-drying; however, no relevant changes in the spectra were observed after the 
cryo-milling process in comparison to the spectra obtained after collapse freeze-drying.  
 
Figure 4.12 A-C depicts the cumulative particle counts of rh-IFN-α-2a-formulations 
formulations measured by light obscuration. Cumulative particle counts larger than 1 
and 10 µm per mL increased significantly after lyophilization and were further 
reduplicated after the cryo-milling process (figure 4.12 A and B). These results are in 
accordance with the findings of size exclusion chromatography and turbidity analysis. 
Only a small increase in particles larger than 25 µm per mL was observed. 
The FTIR spectra of the amid I bands of reconstituted rh-IFN-α-2a formulations depicted 
in figure 4.12 D were background corrected against the respective placebo formulation 
and vector-normalized. The intense peak in the rh-IFN-α-2a formulations at 1654 cm-1, 
the typical feature of an α-helix band [29], did show only a marginal shift to 1658 cm-1 
indicating, that the secondary structure of the protein could be preserved.  
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Figure 4.12: (A-C) Cumulative particle counts > 1, 10 and 25 µm of rh-IFN-α-2a-
formulations as determined by light obscuration. (D) Second derivative amid I FTIR-
spectra of rh-IFN-α-2a-formulations. Formulations containing protein (black bars) and 
placebo formulations (grey bars). 
 
Similarly to the observations in rh-G-CSF formulations, baseline slopes and shifts in the 
intensity of the spectra in the region of 1600 – 1630 cm-1 and 1665 – 1720 cm-1 were 
observed after lyophilization and cryo-milling of rh-IFN-α-2a formulations. However, only 
slight differences in the spectra of rh-IFN-α-2a lyophilizates or cryo-milled powders 
could be detected. In addition to the results obtained by size exclusion chromatography, 
turbidity and light obscuration, it can be concluded, that aggregation of rh-IFN-α-2a does 
not take place via an intermediate formation of soluble aggregates but directly by the 
formation of larger, insoluble aggregates. This is clearly in contrast to the findings of 
Sharma et al. demonstrating the stabilization of rh-IFN-α-2a in a trehalose-mannitol 
formulation after vacuum drying [26].  
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Also ovalbumin formulations showed an increase in cumulative particle counts > 1, 10 
and 25 µm (figure 4.13A-C). This is clearly in contradiction to the results obtained by 
turbidity measurements (figure 4.10C) and size exclusion chromatography (table 4.1).  
 
 
 
 
 
 
 
 
 
 
Figure 4.13: (A-C) Cumulative particle counts > 1, 10 and 25 µm of OVA-formulations as 
determined by light obscuration. (D) Second derivative amid I FTIR-spectra OVA-
formulations. Formulations containing protein (black bars) and placebo formulations 
(grey bars). 
 
 
FTIR spectra of ovalbumin formulations showed a decrease in the α-helical region after 
freeze-drying (figure 4.13D), thus pointing out changes in the secondary structure of the 
protein. However, these structural changes remained comparable after the cryo-milling 
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process. Long-term storage stability of ovalbumin in collapse freeze-dried and cryo-
milled trehalose/mannitol formulations will be scrutinized in chapter 5 of this thesis.  
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4 SUMMARY AND CONCLUSION 
A systematic investigation of different milling parameters using a semi-automated cryo-
mill was explored as well as the development of a sterile production process for cryo-
milled powders. The sterile production process opens up the possibility to upscale cryo-
milling to industrial standards. 
Optimal parameters regarding the cryo-milling process were evaluated for formulations 
with discriminant differences regarding the rigidity of the lyophilizates. Pre-cooling of the 
product loaded milling beakers was determined to be necessary to prevent local melting 
of the particles during milling. Thus, the optimized parameters allowed a fast, efficient 
and gentle milling process resulting in the target size range of the particles. The majority 
of the particles were in the size range of 20 to 70 µm. Only a small amount of the 
particles were larger than 100 µm. However, regarding the ballistic intradermal injection 
process, it might be necessary to separate particles > 100 µm from the powders, as it is 
known from literature, that large particles can harm the skin and provoke pain and 
bleeding at the injection site [32]. Depending on the delivery device used, it might also 
be necessary to separate the fine particle fraction < 20 µm as the fine particle fraction 
might not be able to penetrate into the epidermal layers of the skin. Residual moisture 
levels of the powders were only marginal affected by the cryo-milling process. 
Furthermore a sterile production process was set up, where the cryo-milling step could 
be performed outside the sterile facility.  
The applicability of the cryo-milling process for another two model proteins, rh-G-CSF 
and rh-IFN - α-2a in a trehalose/mannitol formulation was investigated and compared to 
ovalbumin formulations as a reference. Collapse freeze-drying of rh-G-CSF formulations 
resulted only in a slight increase of soluble dimer species and moreover, the recovery of 
soluble dimer species did not change after cryo-milling in comparison to the 
lyophilizates. Turbidity levels, light obscuration as well as the FTIR-spectra of cryo-
milled rh-G-CSF formulations showed only slight perturbations of the protein.  
Rh-IFN-α-2a formulations were not stable after collapse freeze-drying, what was 
reflected in the formation of insoluble aggregates. Aggregation of rh-IFN-α-2a was also 
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observed after cryo-milling. This is in accordance with the results obtained by Sharma et 
al., observing aggregation of rh-IFN-α-2a formulations after vacuum drying [26]. 
Similarly, Mohl et al. showed that trehalose was not effective to stabilize rh-IFN-α-2a in 
a freeze-dried formulation, which was subsequently incorporated in a lipid carrier 
system. In contrast to that, the addition of hydroxypropyl-β-cyclodextrin as stabilizing 
excipient during freeze-drying, was successful to retain up to 95% of the native form of 
rh-IFN-α-2a after freeze-drying and release of the protein of the lipid carrier system. 
Ovalbumin formulations showed no significant differences in protein recovery or the 
pattern of protein species after the collapse freeze-drying cycle or after the cryo-milling 
process as determined by size exclusion chromatography. This was also confirmed by 
turbidity measurements. However, light obscuration and FTIR analysis indicated 
perturbations in protein stability. Stability of cryo-milled ovalbumin powders at elevated 
temperatures will be evaluated and discussed in chapter 5.  
In summary the applicability of the cryo-milling process to other proteins was shown for 
rh-GSCF, however, not for rh-IFN-α-2a. As the stabilizing excipient plays a key role in 
the preservation of the protein integrity rather than the cryo-milling process itself, 
stability after cryo-milling has to be evaluated for each protein or antigen individually. 
The effect of formulation composition on ovalbumin in cryo-milled powders during 
storage will be scrutinized in chapter 5 of this thesis. 
Comprehensively, cryo-milling was shown to be a rapid and adjustable process, 
enabling sterile manufacturing of powder particles. However, the described 
manufacturing process for powder particles comprises at least two steps: (1) collapse 
freeze-drying, (2) cryo-milling and optionally a third one, (3) sieving. Based on the 
overall growing interest on intradermal vaccination the competitiveness of this two or 
three step process to other manufacturing processes, like spray-drying or spray-freeze-
drying, as well as the up-scaleability to industrial standards have still to be proven. 
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CHAPTER 5 
 
FORMULATION SCREENING AND STORAGE STABILITY OF 
OVALBUMIN AT ELEVATED TEMPERATURES 
 
1 INTRODUCTION  
 
Vaccines are generally sensitive to environmental stress, especially to elevated 
temperatures and require a thorough formulation strategy to ensure stability of the 
vaccine during processing to a final drug as well as long term storage and distribution 
[1, 2]. In chapter 3 and 4 of this thesis it was shown that collapse freeze-drying and 
cryo-milling of the collapsed lyophilizates is a suitable method to generate highly dense 
and robust particles being appropriate for intradermal injection. Thereby, the formulation 
has not only to fulfill several criteria with regard to its suitability for intradermal injection, 
it has also to cope with the task to stabilize a vaccine antigen throughout the stress 
applied during processing and, moreover, during subsequent storage at different 
temperature conditions.  
During collapse freeze-drying, cryo-milling and storage of the final drug several stress 
vectors are affecting the native conformation of the antigen. Denaturation of the antigen 
can occur e.g. during freezing due to cold denaturation [3-5], surface induced 
denaturation at the solid-liquid interface (ice and water) [6, 7] phase separation of the 
stabilizing amorphous excipient [8-10] or due to an increasing concentration of the 
solute [11, 12], which is often accompanied by pH-shifts [13-15]. Furthermore 
dehydration and denaturation of the antigen can take place during the drying step [16]. 
Subsequently the lyophilizate cakes are exposed to mechanical stress during cryo-
milling in form of friction and shear forces [17], possibly leading to recrystallization of the 
excipients or aggregation of the antigen [18, 19]. Further chemical or physical 
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degradation of the antigen can also occur during storage and shipment, dependent on 
the ability of the formulation to preserve antigen quality, which also determines the 
shelf-life of the product [20].  
It is well described in literature that cryoprotectants (sugars, polyols and polymers) can 
stabilize the antigen during freezing by preferential exclusion, an indirect interaction 
between the excipient and protein, allowing a thermodynamic favored, hydrated state of 
the protein [21, 22]. Lyoprotectants can build an amorphous glass in the freeze-dried 
cake and are responsible for the stabilization of the antigen against dehydration induced 
stress during freeze-drying and subsequent storage by a mechanism also known as 
“vitrification” [23-26].  
Hence, a careful selection and combination of cryo- and lyoprotectants is needed with 
regard to the type of antigen which should be stabilized, the shelf life of the drug as well 
as to the route of drug administration.  
The different formulation compositions of the following formulation screening and 
storage stability for the model antigen ovalbumin include the lyo- and cryo- protectants 
trehalose and mannitol, which showed a very good stabilizing effect on ovalbumin 
during collapse freeze-drying and cryo-milling, overcoming the aforementioned stress 
vectors and fulfilled satisfactory morphological characteristics [27]. In addition, polymers 
like dextran and hydroxyethylstarch were scrutinized regarding their behavior during 
storage at elevated temperatures as further components. It was stated in literature that 
these polymers would be essential to generate mechanical robust particles by spray-
freeze-drying [28-30]. Again, for the intradermal route of administration using a ballistic 
device, mechanical robustness of the particles is crucial. However, the role of polymers 
in collapse freeze-dried and cryo-milled particles during storage is yet not well 
characterized and need further investigation. In addition, the amino acid phenylalanine 
was scrutinized as excipient in the formulation composition as it was shown in previous 
work of Bosch et al. that phenylalanine possess superior physico-chemical powder 
characteristics in aggressively freeze-dried formulations [31], which offers also 
promising properties for intradermal injection. 
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Though, the benefit of higher molecular weight polymers as stabilizers in freeze-dried 
formulations is controversy discussed. As described in chapter 3, formulations 
containing dextran with a molecular weight of 70 kDa showed a poor stabilizing effect 
on ovalbumin during storage at elevated temperatures [27]. This was also confirmed by 
Rochelle et al., indicating a destabilizing effect of higher molecular weight polymers like 
dextran and hydroxyethylstarch on catalase in a spray freeze-dried formulation [32]. 
Similar results were obtained by Pikal et al. They could show that dextran 40 kDA in an 
amorphous conformation failed to stabilize human growth hormone [33]. 
However, the group of Maa et al. demonstrated superior stabilizing effect of a subunit 
influenza vaccine in a ternary formulation composition comprising trehalose, mannitol 
and dextran (10 kDa) [28]. This indicates that next to the type of protein also the length 
of the molecular chain of the polymer impact protein or antigen stability. Similar 
observations were made for freeze-dried ɣ-globulin, insulin, HBsAg, LDH and ß-
galactosidase [28, 34, 35]. Moreover it was stated that the addition of these polymers in 
formulations (based on trehalose and mannitol) together with a high solid content of the 
liquid formulation were crucial to generate highly dense and mechanically robust 
particles by spray drying resulting in particles with appropriate properties for intradermal 
injection [28, 32, 36]. We could show in chapter 3 and chapter 4 that, next to the above 
mentioned formulation strategy, mechanically robust particles with a dense matrix 
structure and reduced surface area could be generated by a novel combination of firstly 
collapse-freeze drying of the liquid formulation and secondly cryo-milling of the freeze-
dried cakes. However, a systematic screening of different formulation excipients and 
mixtures thereof as well as their ability to stabilize the model antigen ovalbumin 
throughout storage is still required. A more thorough understanding of the role of 
polymers and their molecular weight on antigen stability in collapse freeze-dried and 
cryo-milled powders during storage at elevated temperatures will be given in the 
following work. Furthermore, physico-chemical and morphological characteristics of the 
particles with focus on a dense matrix structure intended for intradermal injection will be 
investigated. Beyond this, a view is given on the possibility to increase the antigen load 
per powder dose and its impact on antigen stability and particle morphology. 
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2 INFLUENCE OF FORMULATION COMPOSITION ON ANTIGEN STABILITY 
As already outlined in the introduction, formulation strategy for intradermal powders 
emphasizes ternary mixtures of polymers with mannitol and trehalose as they show 
superior physico-chemical characteristics in terms of powder density and mechanical 
robustness [28-30]. In order to gain a more detailed insight into the impact of different 
formulation compositions on the stability of the well characterized model antigen 
ovalbumin in collapse freeze-dried and cryo-milled formulations, ternary mixtures of 
trehalose, mannitol and polymers, including dextran with different molecular weight (6, 
40 or 70 kDA) and hydroxyethylstarch (70 kDa), were investigated. Furthermore 
polymer-free formulations containing a binary combination of trehalose and mannitol or 
a binary combination of trehalose and the amino acid phenylalanine or solely the 
disaccharide trehalose were evaluated. Table 5.1 lists the different formulation 
compositions and abbreviations of the formulations which will be used in the following. 
 
Table 5.1: Summary of all formulations used in the study 
formulation composition abbreviation weight ratio 
   
trehalose, mannitol, dextran (70 kDA) TMD_70 (3:3:4) 
trehalose, mannitol, dextran (40 kDA) TMD_40 (3:3:4) 
trehalose, mannitol, dextran (6 kDA) TMD_6 (3:3:4) 
trehalose, mannitol, hydroxyethylstarch (70 kDA) TMHES_70 (3:3:4) 
trehalose T - 
trehalose, mannitol TM (1:1) 
trehalose, phenylalanine TP (10:0.5) 
   
 
All formulations contained 2.5% (w/w) ovalbumin, comprised a total solid content of 
15% (w/w) and were collapse-freeze dried and subsequently cryo-milled as described in 
chapter 2. The cryo-milled powders were stored for a period of twelve weeks at 2-8°C, 
25°C and 50°C. Stability of the model antigen ovalbumin was assed using different 
analytical methods. Primary protein structure was analyzed by HP-SEC, the standard 
analytical tool for the detection of soluble protein aggregates. The formation of insoluble 
protein aggregates and subvisible particles was analyzed by light obscuration and 
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turbidimetry measurement. The influence of the formulation composition on particle 
morphology and physico-chemical characteristics was scrutinized by the specific 
surface area of the particles, particle size distribution, residual moisture and X-ray 
powder diffraction measurement of the cryo-milled powders. With the intention to 
ascertain that the formulation process (collapse freeze-drying and subsequent cryo-
milling of the lyophilizate cakes) did not harm the integrity of ovalbumin, the recovery of 
the different protein species of ovalbumin was analyzed by HP-SEC for both, the liquid 
formulations prior to collapse freeze-drying and directly after cryo-milling of the freeze-
dried cakes (figure 5.1.).  
 
Figure 5.1: Recovery of ovalbumin protein species (%) of the liquid formulations prior to 
freeze-drying (A) and after collapse freeze-drying and subsequent cryo-milling (B) as 
determined by size exclusion chromatography. Black bars represent higher molecular 
weight aggregates, light grey bars represent dimers, dark grey bars represent monomers 
and white bars represents fragments. Filled circles represent the total protein recovery 
(average +/- SD, n=3). 
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The formulations had before and after collapse freeze-drying and cryo-milling same 
monomer, dimer, higher molecular weight aggregate and fragment pattern for all 
formulation compositions (figure 5.1.A). Collapse freeze-drying and subsequent cryo-
milling had no impact on the formation of soluble for none of the formulations, as 
determined by the recovery of the protein species. Total protein recovery ranged from 
minimum 97.2% ± 1.9 (trehalose/mannitol/hydroxyethylstarch (70 kDa)) and maximum 
98.9% ± 2.0 (trehalose/mannitol/dextran (6 kDa)) (figure 5.1.B), thus, indicating 
indirectly the absence of insoluble aggregates. This reaffirms the results described in 
chapter 3 and 4, and, in addition, shows that the process steps (collapse drying and 
cryo-milling) had no negative effect on antigen quality using formulation compositions 
including dextrans with different molecular weight chains, hydroxyethylstarch or 
phenylalanine. 
 
In a next step storage stability of the cryo-milled powders was evaluated at 2-8°C, 25°C 
and 50°C for a time period of twelve weeks. 
Figure 5.2 illustrates the results of size exclusion chromatography of 
trehalose/mannitol/dextran formulations containing 6, 40 and 70 kDa dextran prior to 
storage and after eight and twelve weeks of storage at 2-8°C or 50°C (samples stored 
at 25°C can be found in figure 9.1 and 9.2 in the appendix). Trehalose/mannitol/dextran 
70 kDa formulations showed clearly an increase in higher molecular weight aggregates 
from 1.0% to 2.8% after eight and, respectively, twelve weeks of storage at 50°C. The 
increase of soluble higher molecular weight aggregates was accompanied by a 
decrease of the dimer species from 7.3% to 6.9%. This suggests that protein-protein 
interactions due to weak forces like van der Waals interactions, hydrogen bonding or 
hydrophobic and electrostatic interactions built up protein agglomerates of several dimer 
and monomer species of ovalbumin. These results further confirm the outcome of long 
term storage stability of trehalose/mannitol/dextran (70 kDa) formulations for twelve 
months at 50°C as outlined in chapter 3, showing a destabilizing effect of dextran (70 
kDa) on ovalbumin.  
Similar results were observed in trehalose/mannitol/dextran (40 kDa) formulations after 
eight and twelve weeks of storage at 50°C (figure 5.2. D).  
CHAPTER 5 
 
101 
 
 
  
  
Figure 5.2: Recovery of ovalbumin protein species (%) as determined by size exclusion 
chromatography in cryo-milled powders after 0, 8 and 12 weeks of storage at 2-8°C (A, C, 
E) and 50°C (B, D, F). Trehalose/mannitol/dextran 70 kDa formulations are depicted in A 
and B. Trehalose/mannitol/dextran 40 kDa formulations are depicted in C and D. 
Trehalose/mannitol/dextran 6 kDa formulations are depicted in E and F. Black bars 
represent higher molecular weight aggregates, light grey bars represent dimers, dark 
grey bars represent fragments. Open circles represent the total protein recovery, filled 
circles represent monomer recovery (average +/- SD, n=3). 
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Next to the increase of higher molecular weight aggregates from 0.9% to 3.9%, an 
increase in soluble dimer from 7.3% to 10.9% was observed. At the same time a 
decrease in soluble monomer from 100.0% to 94.4% was detected.  
However, both formulations (TMD_70 and TMD_40) did not fail to stabilize ovalbumin at 
lower temperature conditions of 2-8°C (figure 5.2 A, C) and 25°C (samples stored at 
25°C can be found in figure 9.1 in the appendix) for a time period of twelve weeks.  
In trehalose/mannitol/dextran (6 kDa) formulations no protein aggregation could be 
observed after twelve weeks of storage neither at 2-8°C (figure 5.2 E), 25°C (samples 
stored at 25°C can be found in figure 9.2 in the appendix) nor at 50°C (figure 5.2 F). No 
changes in the pattern of different protein species were observed. Recovery of soluble 
monomer and total protein recovery was constantly > 99% for the monitored time 
period. 
Summing up the findings regarding the polymer dextran, a destabilizing effect on the 
native structure of ovalbumin could be observed in collapse freeze-dried and cryo-milled 
formulations containing dextran 40 kDA and dextran 70 kDA after eight and twelve 
weeks of storage at 50°C. Only formulations containing dextran 6 kDa exhibited a long 
term stabilizing effect on ovalbumin at elevated temperatures. Similar results were 
obtained, for instance, by Maa et al. [28]. They could show that low molecular weight 
dextran (10 kDa) was able to stabilize a subunit influenza vaccine in a spray freeze-
dried ternary formulation composition comprising trehalose and mannitol. Pikal et al. 
observed a poor stabilizing effect of dextran 40 kDa on human growth hormone (hGh) in 
a freeze-dried formulation, leading to aggregation during storage at 40°C [33], thus 
pointing out that with rising molecular weight of dextran a destabilizing effect on proteins 
can be observed. Izutsu et al. [37] discussed as one possible option for the destabilizing 
effect on proteins of higher molecular weight dextran the hindrance of accessible 
hydroxyl groups to stabilize the protein by water-substitution mechanism. Interestingly, 
they observed perturbance of the secondary structure of the model protein BSA in 
freeze-dried formulations with low molecular weight dextrans (1.6 to 10.2 kDa) without 
exposing the formulations to elevated storage temperature. It was also anticipated that 
next to steric hindrance also phase separation in the freeze-concentrate could possibly 
CHAPTER 5 
 
103 
 
preclude higher molecular weight dextran or other large saccharide molecules to 
preserve the native conformation of the protein. More similar findings are reported in 
literature, supporting this theory that higher molecular weight polymers fail to inhibit 
conformational changes in proteins due to an increased steric hindrance of the 
molecules with rising molecular weight and hence a decreased H-bonding ability 
compared with smaller molecules [32, 38, 39].  
Allison et al. could show that dextran with a molecular weight of 192 kDa was not able 
to stabilize actin during drying, however a combination of disaccharides and dextran 
showed superior storage stability of freeze-dried actin [40].  
Contrary to this Yoshioka et al. showed that protein stability of freeze-dried ɣ-globulin 
formulations benefit from the excipient dextran with increasing molecular weight 
(10 kDa, 40 kDa, 70 kDa and 510 kDa). They explained that the stabilizing effect 
increases with increasing molecular chain of the polymer and is dependent on the 
molecular mobility of the formulation [34]. Supporting this theory, Tonnis et al. 
demonstrated that a number of proteins (insulin, HBsAG, LDH and β-galactosidase) 
were more stable at the presence of dextran 70 kDa than in the presence of dextrans 
with a lower molecular weight chain. Noteworthy, a substantially higher stabilizing effect 
was found in formulations containing dextran and trehalose in a 1:1 mixture in 
comparison to formulations containing dextran alone [35]. 
Based on the results of the formulation screening and the controversy discussed benefit 
of dextran with different molecular weight as stabilizing amorphous polymer in freeze-
dried formulations, it can be concluded, that formulation composition (most notably the 
addition of disaccharides), the type of protein to be stabilized as well as the 
manufacturing process have to be considered in formulation development strategy. In 
this study only low molecular weight dextran (6 kDa) showed appropriate long term 
stabilizing effect on ovalbumin at elevated temperature in collapse freeze-dried and 
cryo-milled formulations.  
Figure 5.3 A and B illustrates the results of size exclusion chromatography of 
trehalose/mannitol/hydroxyethylstarch 70 kDa after eight and twelve weeks storage at 
2-8°C and 50°C (samples stored at 25°C can be found in figure 9.2 in the appendix). No 
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relevant changes in the protein species pattern of ovalbumin were visible in this 
formulation composition.  
It is known that polymers like hydroxyethylstarch (and dextran) alone, without the 
addition of other excipients, mostly fail to stabilize a protein during freeze-drying [41]. 
However, in combination with a disaccharide like trehalose or mannitol they can 
increase the glass transition temperature of the final product and hence provide 
improved storage stability [42].  
 
   
  
Figure 5.3: Recovery of ovalbumin protein species (%) as determined by size exclusion 
chromatography in cryo-milled powders after 0, 8 and 12 weeks of storage at 2-8°C (A, C) 
and 50°C (B, D). Trehalose/mannitol/hydroxyethylstarch formulations are depicted in A 
and B. Trehalose/phenylalanine formulations are depicted in C and D. Black bars 
represent higher molecular weight aggregates, light grey bars represent dimers, dark 
grey bars represent fragments. Open circles represent monomer recovery, filled circles 
represent the total protein recovery (average +/- SD, n=3). 
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Contrary to our findings, Rochelle et al. showed that hydroxyethylstarch 200 kDa in a 
ternary mixture with trehalose and mannitol had a detrimental effect on the remaining 
activity of catalase in a spray freeze-dried formulation [32].  
However, Garzon-Rodriguez observed optimized storage stability of lyophilized 
recombinant human interleukin 11 using a formulation based on trehalose and 
hydroxyethylstarch with a mean molecular weight of hydroxyethylstarch of 200 kDa [43], 
hence supporting our findings. This emphasizes again, that apart from the formulation 
composition, the type of protein which has to be stabilized and also the manufacturing 
process have to be considered for each formulation individually in order to achieve 
optimal results regarding vaccine stability. 
Similar results as for formulations containing hydroxyethylstrach were obtained for 
trehalose/phenylalanine formulations (figure 5.3 C and D). Monomer recovery as well as 
total protein recovery remained > 99 % after twelve weeks storage at 2-8°C, 25°C 
(samples stored at 25°C can be found in figure 9.3 in the appendix) and 50°C. This is 
also in line with the results obtained by Bosch et al., who explored low amounts of 
phenylalanine as bulking agent in aggressively freeze-dried lyophilizates based on 
trehalose (ratio trehalose to phenylalanine (10:0.5)). The freeze-drying protocol used in 
the referred study was comparable to the collapse freeze-drying protocol used within 
this thesis. Excellent stabilization of an IgG1 monoclonal antibody (mab_T1) could be 
achieved after six months of storage at 50°C [31]. This points out that trehalose based 
formulations that contain low amounts of phenylalanine as bulking agent are well suited 
for the stabilization of sensitive proteins by applying aggressive freeze-drying protocols 
and are also able to preserve protein quality during cryo-milling and subsequent storage 
at elevated temperatures.  
The binary combination of trehalose/mannitol and trehalose based formulations (figure 
5.4) showed excellent stabilization of ovalbumin throughout storage at 2-8°C, 25°C 
(samples stored at 25°C can be found in figure 9.3 and 9.4 in the appendix) as well as 
at 50°C after twelve weeks. No significant changes in the pattern of the different protein 
species were observed. Recovery of soluble monomer and total protein recovery was 
constantly > 99% for the monitored time period. 
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Figure 5.4: Storage stability of the cryo-milled powders after 8 and 12 weeks storage at 2-
8°C and 50°C. Recovery of ovalbumin protein species (%) as determined by size 
exclusion chromatography in cryo-milled powders after 0, 8 and 12 weeks of storage at 2-
8°C (A, C) and 50°C (B, D). Trehalose/mannitol formulations are depicted in A and B. 
Trehalose formulations are depicted in C and D. Black bars represent higher molecular 
weight aggregates, light grey bars represent dimers, dark grey bars represent fragments. 
Open circles represent monomer recovery, filled circles represent the total protein 
recovery (average +/- SD, n=3). 
 
In order to assure the results given by size exclusion chromatography turbidity 
measurement and light obscuration analysis were used as orthogonal methods to 
assess the formation of large insoluble aggregates or subvisible particles.  
Both methods provide valuable information about the product, however are not suitable 
to directly crosscheck the accuracy of size exclusion chromatography [44]. 
A 
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Figure 5.5: Turbidity of the cryo-milled powders after 0 (black bars) and 12 weeks (grey 
bars) of storage at 2-8°C (A) and 50°C (B).  
 
According to the European Pharmacopoeia samples are regarded as clear if the 
turbidity level of the sample is below the degree of opalescence of the reference 
solution “I” [45]. The corresponding turbidity of this solution, determined using a 
NEPHLA turbidimeter (Dr. Lange, Düsseldorf, Germany), as described in chapter 2 was 
3.2 FNU [45-47]. Turbidity measurements of the cryo-milled powders showed that 
formulations containing higher molecular weight polymers like dextran 70 or 40 kDa or 
hydroxyethylstarch 70 kDa exhibited higher turbidity levels than binary combinations of 
trehalose/mannitol, trehalose/phenylalanine or formulations based on 
trehalose/mannitol/dextran (6 kDa) or on trehalose alone (figure 5.5). However, the 
turbidity levels remained below 3.2 FNU, and are therefore, consistent with the 
European Pharmacopoeia, regarded as clear. Furthermore, turbidity levels did not 
change significantly after storage of the powders for twelve weeks either at 2-8°C or at 
50°C. Yet, only a trend towards a destabilizing effect on ovalbumin of higher molecular 
weight polymers can be observed. 
 
Figure 5.6 depicts the cumulative particle counts > 1 µm, > 10 µm and > 25 µm of the 
powders after cryo-milling and storage at 2-8°C and 50°C for twelve weeks.  
Formulations containing dextran (70 kDa) showed after twelve weeks of storage at 2-
8°C an increase in particle counts > 1 µm from 8304 ± 775 to 16963 ± 1339 (figure 5.6 
A). Similarly an increase in particles > 1 µm to 16886 ± 23 could be observed after 
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FORMULATION SCREENING AND STORAGE STABILITY OF OVALBUMIN AT ELEVATED 
TEMPERATURES 
 
108 
 
twelve weeks of storage at 50°C. Formulations containing dextran (40 kDa) showed 
already initially particle counts > 1 µm in the range of 22783 ± 163. However, the 
number of particles did not further increase during storage at 2-8°C or 50°C. 
Formulations based on trehalose/mannitol/dextran (6 kDA) showed an increase in 
particle counts > 1µm after twelve weeks of storage at 2-8°C, though this was not the 
case at 50°C. The particle counts > 1 µm did not change significantly in 
trehalose/mannitol/hydroxyethylstarch (70 kDa), trehalose/mannitol or trehalose 
formulations after twelve weeks of storage at 2-8°C, but, interestingly, decreased after 
storage at 50°C. Trehalose/phenylalanine formulations showed an increase in particle 
counts > 1 µm after twelve weeks of storage at 2-8°C. However, this was not observed 
in samples stored at 50°C. Generally the numbers of particles > 1 µm were below 
25000 counts for all formulations during the monitored time period, and can therefore 
only depict trends. The obtained results support the observations obtained by size 
exclusion chromatography, showing a trend towards a destabilizing effect of higher 
molecular weight dextran on ovalbumin. 
The impact of the population of particles in the range of 1 µm to 10 µm in protein 
pharmaceutics, also known as subvisible particles, on drug safety is extensively 
discussed in literature [48-50]. Just recently an informational USP chapter, “Subvisible 
Particulate Matter in Therapeutic Protein Injections <1787>” [51, 52] was published, 
providing guidance on subvisible particles in the 2-µm to 10-µm range. The chapter 
does not provide count limits but highlights the determination of this inherent protein 
population and its character as an aid for the scientific development process for 
therapeutic protein products. Hence, the above-mentioned results in the subvisible 
particle range, obtained for formulations containing higher molecular weight polymers, 
should be assessed critically and in the overall context of stability assessment. 
 
Formulations with higher molecular weight dextrans (70 and 40 kDa) and 
hydryoxyethylstarch (70 kDa) showed already initially higher total particle counts 
> 10 µm than the binary combinations of trehalose/mannitol, trehalose/phenylalanine 
formulations or trehalose formulations (figure 5.6. C, D). Trehalose/mannitol/dextran (70 
kDa) formulations showed an increase in particles > 10 µm after storage at 2-8°C from 
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257 ± 9 to 312 ± 6 as well as after twelve weeks at 50°C to 377 ± 10. A decrease in 
particle counts > 10 µm after storage at 2-8°C and 50°C was observed in 
trehalose/mannitol/dextran (40 kDa) and trehalose/mannitol/hydroxyethylstarch (70 
kDa) formulations. Trehalose/mannitol/dextran (6 kDa), trehalose/mannitol, 
trehalose/phenylalanine and trehalose formulations showed no relevant changes in 
particle counts > 10 µm after twelve weeks of storage at 2-8°C or 50°C. 
In all samples particle counts > 10 μm were below 400 counts per containment, which is 
well in line with the specified limits of the European Pharmacopoeia (Ph. Eur.), requiring 
less than 6000 particles per containment in this size range. 
 
Regarding particle counts > 25 µm, trehalose/mannitol/dextran (70 and 6 kDa) and 
trehalose/mannitol/hydroxyehtylstarch (70 kDa) showed higher levels in comparison to 
the other formulations (figure 5.6. E, F). However, particle counts decreased after 
storage at 2-8°C and 50°C. In all samples particle counts > 25 μm were below 
35 counts per containment, which is well in line with the specified limits of the European 
Pharmacopoeia (Ph. Eur.), requiring less than 600 particles per containment in this size 
range.  
 
It has to be emphasized that the results of light obscuration measurement were well 
within the limits of the European Pharmacopeia for all samples during storage at 2-8°C 
and 50°C for at least twelve weeks. The specified limits of the European Pharmacopeia 
are set for particulates in parenteral injectables in order to prevent clogging of blood 
vessels. Regarding subvisible particles in the 1 µm to 10 µm range, only little is known 
about the relevance of these inherent protein aggregates, and particularly in the above 
mentioned magnitude for other application routes, such as subcutaneous or intradermal 
injection. Though, in terms of early formulation development valuable information about 
the stability of the incorporated protein and trends towards protein aggregation can be 
obtained. 
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Figure 5.6: Cumulative particle counts > 1, 10 and 25 µm of cryo-milled powders as 
determined by light obscuration (average +/- SD, n=3) after 0 (black bars) and 12 weeks 
(grey bars) of storage at 2-8°C (A, C, E) and 50°C (B, D, F).  
 
In summary, formulations with higher molecular weight polymers showed higher particle 
counts, which confirm the results obtained by turbidity measurements and size 
exclusion chromatography.   
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3 INFLUENCE OF FORMULATION COMPOSITION ON PHYSICO-CHEMICAL 
CHARACTERISTICS OF PARTICLES 
Particle morphology of the cryo-milled powders was characterized by particle size 
measurement and determination of the specific surface area of the particles. Both 
characteristics are crucial for an intradermal ballistic application route as only dense and 
robust sugar particles with particle sizes between 20 µm and 70 µm can be accelerated 
to a certain velocity having a sufficient momentum to breach the outermost layers of the 
skin [28, 30, 53].  
The cryo-milling process was selected according to the rigidity of the formulation 
composition and the established protocol as described in chapter 2 and 4. Thus, 
formulation compositions with higher molecular weight polymers were milled for 30 
seconds at 25 Hz after a pre-cooling time of 10 min using a cryo-mill. All other 
formulations were milled for 15 seconds at 25 Hz after a pre-cooling time of 10 min, 
respectively. Consequently, a uniform particle size distribution in the targeted size range 
for intradermal injection could be achieved. The resulting particle size distribution of the 
powders was measured by laser light diffraction as described in chapter 2. Particle size 
distribution was calculated as an average of 6 measurements applying the Fraunhofer 
theory and was characterized with median diameter and span of the volume distribution. 
Each sample was measured at least in triplicates. 
The median volume diameter of the cryo-milled particles varied between 21.3 ± 1.5 µm 
and 37.2 ± 0.5 µm (figure 5.7) for all formulations and the span of the volume 
distribution indicates a narrow particle size distribution with 3.3 to 5.5. 
Table 5.2 illustrates the amount of particles > 100 µm and < 10 µm within the particle 
size distribution of each formulation. The separation of particle fractions > 100 µm and 
< 10 µm by sieving might be necessary, as particles > 100 µm can cause injuries on the 
skin surface [53-55]. Depending on the injection device used, particles < 10 µm fail to 
penetrate into the skin, as a low particle size in combination with a generally low true 
density of sugar particles result in a decreased impact momentum of the particles [28, 
56-58]. Further relevant issues related to ballistic particle acceleration will be discussed 
in chapter 7. 
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Figure 5.7: Particle size distribution of cryo-milled powders calculated as an average of 
three measurements and characterized with median diameter (black bars) and span (grey 
bars) of the volume distribution (average +/- SD, n=3). 
 
 
 
formulation 
composition 
particles 
> 100 µm [%] ± SD 
particles 
< 10 µm [%] ± SD 
TMD_70 12.0 ± 0.6 24.4 ± 0.3 
TMD_40 13.4 ± 1.0 21.3 ± 0.7 
TMD_6 12.0 ± 0.8 24.5 ± 0.6 
TMHES_70 15.2 ± 1.2 17.8 ± 0.2 
TM 10.9 ± 0.4 24.1 ± 0.3 
T 11.9 ± 2.3 31.8 ± 1.5 
TP 17.1 ± 0.9 30.1 ± 0.5 
 
Formulations containing polymers or phenylalanine showed the highest proportion of 
particles > 100 µm. Trehalose and trehalose/phenylalanine formulations had the highest 
Table 5.2: Particle size distributions after cryo-milling µm of the different cryo-milled 
powders and particle fractions > 100 µm and < 10 within each distribution.  
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amount of particles < 1µm. Trehalose/mannitol/hydroxyethylstarch (70 kDa), 
trehalose/mannitol/dextran (40 kDa) and trehalose/mannitol formulations had the 
highest proportion of particles in the desired size range with a yield of 65 to 67%. 
 
As already discussed in chapter 3, not only collapse freeze-drying led to a strong 
reduction of the specific surface area of the sugar matrix and thereby to a dense matrix 
structure, but also the formulation composition itself has an impact on the specific 
surface area of the cryo-milled powder particles.  
The specific surface area of the particles was determined by BET krypton gas 
adsorption as described in chapter 2. Figure 5.8 shows, that particles of formulations 
containing higher molecular weight polymers exhibited a lower specific surface (0.6 -
0.9 m2/g) as particles of formulations containing lower molecular weight dextran, a 
binary combination of trehalose/mannitol, trehalose/phenylalanine or formulations based 
on trehalose (1.2 – 1.4 m²/g).  
  
Figure 5.8: Specific surface are of the cryo-milled powders as determined by BET krypton 
gas adsorption (average +/- SD, n=3).  
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Generally, the two-stage process of collapse freeze-drying and cryo-milling resulted in a 
smaller specific surface area of the particles than known from other drying processes 
like spray-drying or spray-freeze-drying. For example, spray freeze-drying and spray 
freezing into liquid of the model protein lysozyme in a formulation based on trehalose 
resulted in a specific surface area of the particles in the range of 26.9 to 86.4 m²/g [59]. 
Webb et al. obtained a specific surface area of 12-14 m²/g for rh-IFNɣ in a spray freeze-
dried formulation based on trehalose [60]. Commonly, spray freeze-dried particles 
exhibit low density, have a high internal porosity and hence, a high specific surface area 
[36]. A small surface area of the particles is related to low porosity and highly dense and 
robust particles. Therefore, a positive impact on the mechanical strength of the particles 
during ballistic acceleration and injection is expected [56].  
Furthermore, it was reported by Abdul-Fattah et al. that a low specific surface area of 
the product enhanced storage stability of the incorporated protein in foam dried 
formulations such as trehalose/phenylalanine and trehalose/mannitol formulations [61].  
 
Figure 5.9: Residual moisture of the cryo-milled formulations after 0 (black bars) and 12 
weeks (grey bars) of storage at 2-8°C (A) and 50°C (B), determined using the Karl-Fischer 
direct methanol extraction method.  
 
Another characteristic of the powder formulation, which influences storage stability of 
the product, is the residual moisture of the powders. 
Figure 5.9 shows the residual moisture of powders directly after cryo-milling and after 
twelve weeks of storage at 2-8°C and 50°C. Trehalose powders showed already at the 
beginning of the stability study the highest residual moisture levels with 4.9% ± 0.4 in 
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comparison to formulations based on the bulking agents mannitol (1.2% ± 0.3 to 
2.6% ± 0.6) or phenylalanine (2.7% ± 0.8). This is in agreement with the common 
knowledge that the addition of bulking agents improves the drying behavior of 
lyophilizates [62]. No increase in residual moisture levels could be observed dependent 
on storage temperature. A slight decrease in residual moisture levels upon twelve 
weeks of storage was observed, which was caused most probably by water vapor 
permeability of the rubber stoppers. 
Figure 5.10: X-ray powder diffraction patterns of the cryo-milled powders after 12 weeks 
of storage at 50°C. 
 
X-ray powder diffraction of the cryo-milled powders showed that trehalose and 
trehalose/phenylalanine powders were fully amorphous after freeze-drying and cryo-
milling (figure 5.10). This is in good agreement with the characterization of aggressively 
freeze-dried trehalose-phenylalanine (ratio 10:0.5) formulations as demonstrated by 
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Bosch et al. [31]. This is particularly advantageous as it is known that amorphous 
components can act as water substitute in the dried state and hence provide an 
increased stability for the protein [63-65]. Trehalose/mannitol formulations and 
formulations containing polymers showed crystalline patterns. Mannitol crystallized into 
the δ-modification during freeze-drying, which is characterized by peaks at 9.7 °2-Theta, 
whilst no peaks were apparent at 17.9 °2-Theta. It is known that bulking agents like 
mannitol in the crystalline modification not only give mechanical strength to the 
lyophilized cake but also take influence on the drying behavior of the formulation and 
thus having impact on the residual moisture level of the freeze-dried cake. By doing so, 
mannitol in the crystalline modification acts indirectly as protein stabilizer as only 
mannitol in the amorphous state can prevent protein aggregation by molecular 
interactions [17, 66]. The different storage conditions did not influence the XRD-patterns 
after twelve weeks of storage at 50°C. 
 
Table 5.3: Glass transition temperatures after collapse freeze-drying, cryo-milling and 
storage at 2-8°C, 25°C and 50°C as determined by DSC (average ± SD, n=3). 
formulation 
composition 
storage 
temperature [°C] 
storage time 
[weeks]  Tg [°C] ± SD ∆cp [J/gK] ± SD 
     
T  -  0 69.83 ± 0.42 0.51 ± 0.02 
 2-8°C 12 72.20 ± 4.12 0.41 ± 0.26 
 25°C 12 51.20 ± 18.56 0.56 ± 0.06 
 50°C 12 73.90 ± 0.90 0.54 ± 0.04 
TP  -  0 87.30 ± 0.85 0.56 ± 0.15 
 2-8°C 12 78.80 ± 16.83 0.53 ± 0.07 
 25°C 12 48.00 ± 32.08 0.60 ± 0.05 
 50°C 12 86.10 0.53 
TM  -  0 73.75 ± 2.76 0.27 ± 0.05 
 2-8°C 12 74.65 ± 0.35 0.27 ± 0.09 
 25°C 12 70.17 ± 0.96 0.27 ± 0.02 
  50°C 12 41.80 ± 15.32 0.33 ± 0.02 
 
Physicochemical properties of the formulations like glass transitions and melting events 
were characterized by differential scanning calorimetry (DSC). Glass transition 
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temperatures could be determined in trehalose, trehalose/mannitol and 
trehalose/phenylalanine formulations by differential scanning calorimetry (table 5.3). As 
no melting peaks were detectable in trehalose and trehalose/phenylalanine formulations 
it can be concluded that both formulations were amorphous after collapse freeze-drying 
and cryo-milling as well as after twelve weeks storage at 2-8°C, 25°C and 50°C. 
This is in good agreement with the results observed earlier by X-ray powder diffraction 
measurements. Trehalose/mannitol formulations showed a partly amorphous and partly 
crystalline structure, as glass transition events were detected next to melting peaks 
(figure 5.11). Tg was determined in trehalose/mannitol formulations in the range of 42 to 
75°C and can be assigned to trehalose with regard to its residual moisture content [67, 
68]. The glass transition temperature can be lowered by 10K for each percent of 
moisture in the product, as water acts as plasticizer [69]. The melting peak at 132-
137°C with a shoulder at 139-151°C can be assigned to the melting point of mannitol. 
This is in good agreement with literature, as it was observed that δ-mannitol can be 
transformed at 130°C to ß-mannitol, showing a subsequent melting peak at 150 to 
158 °C [70-72]. Furthermore, it has to be considered that all formulations are composed 
of mixtures and therefore the melting points can be shifted to lower temperatures as for 
pure materials.  
No glass transition events could be determined in formulations containing either the 
polymer dextran or hydroxyethylstarch (figure 5.11). However, endothermic peaks were 
visible at 130°C - 138°C with a shoulder in the range of 140°C - 150°C, indicating the 
melting point of the crystalline components. Though, these formulations consist either of 
fully crystalline material, or, the glass transition temperature of these formulations is 
overlapped by the melting peak of the crystalline components. Contrary to our findings 
Rochelle et al. observed that spray-freeze-dried powders of catalase in a 
trehalose/mannitol formulation containing dextran or hydroxyethylstarch remained fully 
amorphous according to X-ray diffraction [32]. Hence, the different results can be 
attributed to the different manufacture processes. 
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Figure 5.11: DSC heating scans (2nd scan) of collapse freeze-dried and cryo-milled 
formulations comprising the polymers dextran with different molecular weight or 
hydroxyethylstarch, showing melting endotherms of the crystalline components. 
 
The glass transition of trehalose/mannitol formulations decreased during storage at 
50°C, whereas it remained comparable prior to storage in trehalose and 
trehalose/phenylalanine formulations (table 5.3). High glass transition temperatures of 
the trehalose, trehalose/mannitol and trehalose/phenylalanine formulations (>70 °C) 
indicate superior storage stability.  
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4 SUMMARY AND CONCLUSION 
To sum up the findings of the formulation screening and storage stability study, 
aggregate formation was observed in formulations containing higher molecular dextran 
(40 and 70 kDa) during storage at 50°C as determined by size exclusion 
chromatography. A destabilizing effect of higher molecular weight polymers on antigen 
conformation was further confirmed by turbidity and light obscuration measurements. 
No aggregate formation was detected in trehalose/mannitol/hydroxyethylstarch 
formulations, trehalose/mannitol formulations, trehalose/phenylalanine formulations and 
trehalose/mannitol/dextran 6 kDa and trehalose formulations after collapse freeze-
drying and cryo-milling as well as during storage at accelerated temperatures. 
Trehalose/mannitol formulations show superior properties in terms of both, protein 
stability and particle morphology.  
The median particle size of all formulations was within a narrow range between 21.3 ± 
1.5 µm and 37.2 ± 0.5 µm and targeted hence our scope, however, trehalose/mannitol 
formulations, trehalose/hydroxyethylstarch and trehalose/mannitol/dextran 6 kDa 
formulations showed additionally the highest yield of particles in the range of 10 to 
100 µm. Formulations containing higher molecular weight polymers exhibited the 
smallest specific surface area of particles within the formulation screening, which is 
associated with a high mechanical strength of the particles - a vital property for ballistic 
injection of the particles [56]. Notably, all formulations showed a low specific surface 
area of the particles in comparison to particles produced by other drying processes than 
collapse freeze-drying like spray-drying or spray-freeze-drying. The amorphous matrix 
structure of trehalose formulations, trehalose/phenylalanine formulations and the partly 
amorphous structure of trehalose/mannitol formulations together with the high glass 
transition temperatures of these formulations are associated with a superior protein 
stabilizing effect during storage. Among the last mentioned formulations, 
trehalose/mannitol formulations showed additionally low residual moisture levels 
throughout the time of storage. 
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In conclusion, trehalose/mannitol formulations exhibited excellent protein stability 
throughout storage at elevated temperatures and showed moreover superior physico-
chemical and morphological characteristics. 
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5 EXCURSUS: HIGHLY CONCENTRATED OVALBUMIN FORMULATIONS 
 
The skin, to be more precise, the epidermis, is an attractive target for needle-free 
vaccine injection as it possesses a network of immunocompetent cells. Intradermal 
vaccination can elicit mucosal immune responses as well as an enhanced cellular 
immunity in comparison to conventional vaccination via intramuscular injections [73]. 
Furthermore, the epidermis generally lacks blood vessels and sensory nerve endings, 
thus, a nearly pain free application comes into reach and hence, an increased 
acceptance among patients might be expected. However, due to the low thickness of 
this tissue layer of about 50 – 100 µm [74] it is not only challenging to reach this target 
in terms of accuracy. In addition, the epidermis has also only a limited capacity to take 
in a powdered vaccine dose [75]. Similarly, current devices for ballistic injection are 
restricted to retain a certain amount of powder. Dependent on the type of device the 
maximal payload of powder is limited to 1 to 2 mg [30] or 0.5 to 5 mg [76]. Although the 
effectiveness of low doses of intradermal vaccines is comparable to full doses of 
conventional intramuscular vaccines [77-85], so far, often more than one skin site had to 
be injected in order to apply an adequate vaccine dose [29]. 
A high load capacity of the powder with antigen is desirable and hence another 
objective in early formulation development. 
Particularly for ballistic powder injections, an adequate ratio between the amount of 
excipients and the amount of antigen is crucial. The type and character of the excipient 
mixture as well as the manufacturing process influence the physical characteristic of the 
particles [28, 36]. A highly dense and mechanically robust structure of the particles is, 
as already mentioned previously, vital to breach the outermost layers of the skin by 
impacting at the skin surface [30, 56].  
In this excursus, selected formulation compositions of the prior formulation screening 
were subjected to a study, investigating the influence of a higher antigen load of the 
powder particles on antigen stability and on physico-chemical characteristics of the 
powder particles. Challenges in the formulation strategy of highly concentrated protein 
formulations are analytical challenges, as for the most of the established analytical 
techniques dilution of the samples is required [86, 87]. Furthermore, the viscosity of 
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formulation composition, which is dependent on the excipient protein ratio, can be 
challenging for the sample preparation prior to analysis, too [87]. 
Even though the lyophilization step itself can be used to concentrate a liquid protein 
formulation, which can be reconstituted after lyophilization with a lower, desired solvent 
volume [87], little is known about the stability of high protein concentrations in solids.  
Lyophilization with appropriate cryo- and lyoprotectants can act as stabilizing step also 
for high protein concentration solutions during formulation as the molecular mobility of 
the proteins is reduced in a rigid, amorphous matrix. It is postulated that the molar ratio 
of the lyoprotectant to the protein should be 360:1 or even greater to provide effective 
protection against protein aggregation [88]. Furthermore, it was shown in the previous 
section, that bulking agents like mannitol or phenylalanine, as well as polymers have a 
favorable influence on powder particles with regard to their residual moisture as well as 
on other physico-chemical characteristics like the specific surface area or particle size 
after cryo-milling.  
An antigen load of powder particles with 25 µg of the model antigen ovalbumin per mg 
powder was well characterized previously. In this section the antigen load was 
increased from 25 µg/mg ovalbumin to 200 µg/mg. Four representative formulations 
(trehalose/mannitol/dextran 70 kDa, trehalose/mannitol/hydroxyethylstarch 70 kDa, 
trehalose/mannitol and trehalose/phenylalanine) were collapse freeze-dried and cryo-
milled as described previously (see chapter 2). The influence of the higher antigen load 
of the formulation was scrutinized with regard to protein quality in terms of formation of 
aggregates and physico-chemical characteristics of the lyophilizates and powders. 
 
5.1 INFLUENCE OF HIGH ANTIGEN LOAD ON PROTEIN STABILITY 
The gold standard to analyze soluble protein aggregates is size exclusion 
chromatography. However, sample preparation required dilution of the samples to low 
concentrations. Therefore, it cannot be excluded, that the protein aggregates underwent 
self-dissociation [87]. 
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Figure 5.12 shows the recovery of different ovalbumin protein species in 
trehalose/mannitol/dextran70 kDA and trehalose/mannitol/hydroxyethylstarch 70 kDa as 
determined by size exclusion chromatography.  
 
 
 
 
Figure 5.12: Recovery of ovalbumin protein species (%) as determined by size exclusion 
chromatography of highly concentrated ovalbumin formulations containing 200 µg/mg 
ovalbumin (A, C) in comparison to ovalbumin formulations containing 25 µg/mg 
ovalbumin (B, D). Trehalose/mannitol/dextran 70 kDa are depicted in A and B, 
trehalose/mannitol/hydroxyethylstarch formulations are depicted in C and D. Black bars 
represent higher molecular weight aggregates, light grey bars represent dimers, dark 
grey bars represent fragments. Open circles represent monomer recovery, filled circles 
represent the total protein recovery (average +/- SD, n=3). 
 
Neither formulations with an antigen load of 25 µg/mg ovalbumin (figure 5.12 B, D) nor 
with an antigen load of 200 µg/mg (figure 5.12 A,C) showed additional formation of 
aggregates in comparison to the liquid formulation after freeze-drying or cryo-milling.  
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Figure 5.13: Recovery of ovalbumin protein species (%) as determined by size exclusion 
chromatography of highly concentrated ovalbumin formulations containing 200 µg/mg 
ovalbumin (A, C) in comparison to ovalbumin formulations containing 25 µg/mg 
ovalbumin (B, D). Trehalose/mannitol formulations are depicted in A and B, 
trehalose/phenylalanine formulations are depicted in C and D. Black bars represent 
higher molecular weight aggregates, light grey bars represent dimers, dark grey bars 
represent fragments. Open circles represent monomer recovery, filled circles represent 
the total protein recovery (average +/- SD, n=3). 
 
It has to be mentioned, that the ovalbumin bulk used in this study showed a different 
protein species pattern as previously in the 3 months stability study, with higher 
molecular weight aggregate levels (HMWA) between 6.5 and 8% , dimer levels of 8.2 to 
8.7% and monomer levels of 80% in the bulk solution. However, the amount of 
aggregates and the recovery of the soluble monomer did not change after freeze-drying 
and cryo-milling. Monomer recovery as well as total protein recovery of both polymer-
A B
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containing formulations was constantly > 98% and > 95%, respectively, independently 
of the antigen load. 
Similarly, no relevant changes in the pattern of the different ovalbumin protein species 
pointing out the formation of soluble aggregates were detected in trehalose/mannitol 
formulations (figure 5.13 A, B) or trehalose/phenylalanine formulations (figure 5.13 C, D) 
due to the antigen load.  
 
 
 
Figure 5.14: Turbidity of the cryo-milled powders as determined by nephelometric 
turbidity analysis (A). Cumulative particle counts > 1 µm (B), 10 µm (C) and 25 µm (D) of 
cryo-milled powders as determined by light obscuration (average +/- SD, n=3). Black 
bars: formulations containing 25 µg/mg ovalbumin. Grey bars: formulations containing 
200 µg/mg ovalbumin. 
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Possible formation of insoluble aggregates or precipitated material due to the increase 
of protein concentration in the formulations was scrutinized by turbidity measurements 
and light obscuration. As the highly concentrated ovalbumin formulations exceeded the 
detection limit of these analytical methods, dilution of the samples prior to the 
measurement was necessary in order to compare equal protein concentrations to the 
low concentrated ovalbumin formulations. Further dilution of the samples and analysis 
was performed as described in chapter 2. 
The different formulation compositions showed comparable turbidity levels in the range 
of 0.8 ± 0.1 to 1.8 ± 0.7 NFU, independently of the antigen load and in good agreement 
with the results obtained from the previous stability study (figure 5.14 A). Interestingly, 
light obscuration measurement showed that the number of particles > 1 µm was higher 
in trehalose/mannitol/dextran 70 kDa, trehalose/mannitol/hydroxyethystarch 70kDa and 
trehalose/mannitol formulations containing 25 µg/mg ovalbumin as in formulations with 
200 µg/mg ovalbumin. Trehalose/phenylalanine formulations showed comparable 
particle counts independently of the antigen load (figure 5.14 B). Similarly, particle 
counts > 10 µm were higher in trehalose/mannitol/dextran 70 kDa, 
trehalose/mannitol/hydroxyethystarch 70kDa and trehalose/mannitol formulations 
containing 25 µg/mg ovalbumin as in formulations with 200 µg/mg ovalbumin. Particle 
counts > 25 µm were comparable in trehalose/mannitol/dextran 70 kDa formulations 
regarding both protein concentrations 25 µg/mg and 200 µg/mg. 
Trehalose/mannitol/hydroxyethylstarch 70kDa, trehalose/mannitol and 
trehalose/phenylalanine formulations with 200 µg/ml ovalbumin showed generally low 
particle counts > 25 µm with 2.2 ± 0.8, 3.9 ± 0.9 and 3.9 ± 1.2 particles. Again, the lower 
protein concentration (25 µg/mg) in trehalose/mannitol/hydroxyethylstarch 70k Da and 
trehalose/mannitol exhibited higher particle counts than formulations with an antigen 
load of 200 µg/mg. 
It is known from literature that the protein concentration of a formulation itself can be an 
inducing factor for aggregation due to bimolecular interaction of molecules [89, 90]. 
However, this was not confirmed for ovalbumin formulations with an antigen load 
200 µg/mg in various trehalose based formulations. Though it cannot be excluded, as 
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dilution of the formulations was necessary prior to analysis, that reversible association 
and dissociation of protein aggregates occurred. 
 
5.2 INFLUENCE OF HIGH ANTIGEN LOAD ON PHYSICO-CHEMICAL CHARACTERISTICS OF THE 
LYOPHILIZATES AND POWDERS 
The influence of an increase of the protein concentration on physico-chemical 
characteristics of the formulations was investigated by residual moisture measurement, 
particle size measurement and determination of the specific surface area of the cryo-
milled powders. 
Except in the case of trehalose/mannitol/dextran 70 kDa formulations, a slight decrease 
in the residual moisture of the formulations was observed due to the increase in the 
antigen load (figure 5.15).  
 
Figure 5.15: Residual moisture of the cryo-milled formulations determined using the Karl-
Fischer direct methanol extraction method. Black bars: formulations containing 25 µg/mg 
ovalbumin. Grey bars: formulations containing 200 µg/mg ovalbumin. 
 
Formulations with 25 µg/mg antigen load showed residual moisture levels in the range 
of 2.0% to 2.7% with a large standard deviation (SD 0.2 to 1.3), whereas formulations 
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with an antigen load of 200 µg/mg were in the range of 1.5% to 2.6% (SD 0.2 to 0.6). 
This can be attributed to the ability of proteins to act as bulking agents in freeze-dried 
formulations [91]. 
 
  
Figure 5.16: (A) Particle size distribution of cryo-milled powders containing 200 µg/mg 
ovalbumin calculated as an average of three measurements and characterized with 
median diameter (grey bars) and span (filled circles) of the volume distribution. (B) 
Specific surface are of the cryo-milled powders as determined by BET krypton gas 
adsorption (average +/- SD, n=3). Black bars: formulations containing 25 µg/mg 
ovalbumin. Grey bars: formulations containing 200 µg/mg ovalbumin. 
 
The median particle size of cryo-milled formulations containing 200 µg/mg ovalbumin 
was 23 µm for formulations based on trehalose/mannitol and ranged between 30 to 
35 µm for trehalose/mannitol/dextran 70 kDa, trehalose/mannitol/hydroxyethylstrach 
70 kDa and trehalose/phenylalanine formulations (figure 5.16 A). As these results are 
comparable to the median particle size of cryo-milled formulations with the same 
excipient mixture containing 25 µg/mg ovalbumin, it can be concluded that the increase 
of the protein content of the formulation did not influence the particle size of the milled 
product. 
The specific surface area (SSA) of the cryo-milled particles of highly concentrated 
ovalbumin formulations containing 200 µg/mg was also comparable to formulations with 
an antigen load of 25 µg/mg (figure 5.16 B). Abdul-Fattah et al. determined the SSA of 
foam-dried carbohydrate formulations to range between 0.04 m2/g and 0.17 m2/g [61]. It 
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was pointed out that the SSA of the formulations increased with increasing mass ratio of 
protein to stabilizer. Though, in the referred example the protein ratio exceeded the 
stabilizer ratio. The increase of the concentration of ovalbumin from 25 µg/mg to 
200 µg/mg did not affect the SSA of the particles as the stabilizer ratio still dominated 
particle characteristics. 
 
5.3 SUMMARY AND CONCLUSION 
The antigen load of four representative formulations using the model antigen ovalbumin 
was successfully increased from 25 µg to 200 µg per mg powder.  
Complication during manufacturing associated with high protein concentrations, or 
perturbations of protein quality, were not observed. According to size exclusion 
chromatography comparable results were obtained for formulations containing 
200 µg/mg ovalbumin as for formulations containing 25 µg/mg. Turbidity and light 
obscuration measurements showed even a superior performance of formulations 
containing 200 µg/mg ovalbumin. 
Due to the route of application in form of dry powder particles, challenges like 
reconstitution, molar tonicity etc. were omitted. The physico-chemical attributes of the 
particles are met the requirements for ballistic injection. Particle size ranged with 23 µm 
to 35 µm in the desired scope [28, 29]. Also the SSA of the particles showed that a 
comparable dense matrix structure of the powder particles was achieved as for particles 
with an antigen load of 25 µg/mg. 
In conclusion, it was possible to increase the ovalbumin load to 200 µg per mg powder 
in several formulation compositions without affecting protein quality and preserving the 
physico-chemical characteristics of the powder needed for ballistic injection. 
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CHAPTER 6 
 
THE INTERFACE BETWEEN PARTICLES AND DEVICE SURFACE 
AND ITS CHALLENGES 
 
1  INTRODUCTION 
Chapter 3 and 4 summarized a) the implementation of a novel freeze-drying technology, 
collapse freeze-drying, for the generation of lyophilizates exhibiting a small specific 
surface area of the sugar matrix and b) the optimization of a subsequent cryo-milling 
step for the generation of powdered vaccine particles for ballistic intradermal 
application. Formulation screening and storage stability of powder particles containing 
ovalbumin, summarized in chapter 5, revealed a secondary mixture of trehalose and 
mannitol as a promising formulation with excellent protein stabilizing properties. In 
addition to the protein stabilizing properties, the particles showed satisfying 
morphological characteristics, especially in size and density, which are essential for 
intradermal application of the powdered particles. 
This chapter addresses the interface between powder particles and the device surface, 
which plays an important role for the accurate delivery of the particles into the skin and 
thus has a decisive impact on the efficacy of the vaccination procedure. 
As the adhesion of particles on the device surface is essential for the successful 
delivery of the particles into the skin, this interface has to fulfill several requirements. 
First, the adhesion of the particles on the device surface has to allow safe and stable 
storage as it has to retain the vaccine dose at the surface of the device part. The 
adhesion of the particles has to resist certain mechanical stress conditions such as 
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transport, storage and handling. However, at the same time, it has to allow the release 
of the solid vaccine dose from the device surface to a full or at least fully sufficient 
extent when actuated for injection into the skin. Second, a homogenous distribution of 
the particles on the device surface, ideally structured in a monolayer, is necessary to 
guarantee the later homogenous acceleration of the particles using the ballistic device 
and herein also a homogenous distribution of the particles in the targeted skin. 
The following chapter first describes a method of attaching particles to a membrane 
surface by the use of oily substances, simulating the adhesion of the vaccine particles 
on the device surface. The oily substances selected for this approach should comprise 
all above listed properties. The assorted oily substances include also oily adjuvants or 
single components of oily adjuvants. The choice of oily adjuvants as adhesives was 
driven by the idea to combine the adhesive effect with a second function, i.e. the 
enhancement of the immunogenicity of the delivered vaccine. Many different adjuvants 
are known not only to activate the immune system sufficiently to induce long-lasting and 
protective immune responses but also to allow the use of lower antigen doses [1, 2]. It is 
also described in literature, that, especially using the approach of transcutaneous 
immunization, a robust immune response to antigens is dependent on the co-delivery of 
an adjuvant [3, 4]. Therefore, the suitability of different oily substances to adhere 
particles onto different membrane materials is challenged in different experimental set-
ups in chapter 6.2.  
In a second part the stability of the antigen loaded particles in combination with selected 
adjuvants was investigated in a short term stability study at elevated temperatures 
(chapter 6.3). 
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2  MECHANICAL ADHESION OF PARTICLES ON DIFFERENT SURFACES 
The ability of oily substances and oily components of adjuvants to act as an adhesive 
between particles and different membrane surfaces for the use in a ballistic powder 
injection device was explored in different experimental setups.  
 
2.1  EXPLORATION OF DIFFERENT SURFACE MATERIALS AND OILY SUBSTANCES FOR THE 
ADHESION OF PARTICLES ONTO THE DEVICE SURFACE 
The oily components of MF59 (mixture of squalene, polysorbate 80 and Span® 85, as 
described in chapter 2), silicon oil and paraffin oil were explored as adhesives at the 
interface between aluminum membranes and glass particles. Glass particles were 
chosen as model particles for vaccine particles because of their well characterized and 
reproducible physical properties, allowing a high reproducibility of the conducted 
experiments. For the preparation of the oily components of the adjuvant MF59 
squalene, polysorbate 80 and Span® 85 were mixed as described in chapter 2. The oily 
substances silicon oil and paraffin oil did not need any further preparation steps. 
Aluminum membranes, having a surface area of 6.28 cm², were covered with 10 µl 
adhesive (as described in chapter 2) and dipped subsequently in a bed of glass 
particles, so that the particles were fixed onto the membrane surface. The size of the 
glass particles ranged from 20 µm to 40 µm and particle density was 2.5 g/cm³. The 
excess particles were tapped off. The mass of adhesive and particles was determined 
gravimetrically. Only a thin film of adhesive was needed to attach the particles, as the 
ratio between the mass of adhesive and the mass of particles was approximately 1:10. 
The appearance of the membrane’s surface covered with the adhesive and the particles 
is depicted in figure 6.1.  
The mechanical force acting on the device during shipping, storage and handling was 
simulated using a jolting volumeter (figure 6.2). Therefore, the membranes were fixed 
on the inner surface of a petri dish and were attached headfirst to the jolting volumeter 
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with the particle covered side turned downwards. The border of the petri-dish served as 
a spacer to the surface of the jolting volumeter.  
 
 
Figure 6.1: Aluminum membranes (d = 0.5 mm) covered with the oily components of 
MF59 and glass particles (size range 20-40 µm). (A): Magnification 100 x 50. (B): 
Magnification 100 x 500. The pictures were obtained using a Keyence VHX-500 F 
microscope. 
 
 
Figure 6.2: Schematic illustration of the experimental set-up using a jolting volumeter, 
simulating the mechanical force acting on the device during shipping, storage and 
handling. 
 
The mass of particles and adhesive remaining on the membranes after 10, 20, 50, 100 
and 500 beats performed by the jolting volumeter was determined gravimetrically.  
After 500 beats 99.2% of the mass of glass particles remained adhered on the 
membrane using the oily components of MF59 and silicon oil as adhesive, and 98.6% of 
A B
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the mass of glass particles remained adhered on the membrane using paraffin oil (figure 
6.3). Thus the suitability of all three adhesives to attach the particles onto the surface of 
aluminum membranes was confirmed. 
 
Figure 6.3: Remaining mass of particles (glass particles, 20 - 40 µm, particle density 2.5 
g/cm³) and adhesive on aluminum membranes using the oily components of MF59, 
silicon oil and paraffin oil as adhesives after 10, 20, 50, 100 and 500 beats of the jolting 
volumeter. Number of replicates n=3. 
 
In order to increase the stress simulated by the jolting volumeter a custom made drop 
apparatus was used (figure 6.4). A piece of membrane coated with adhesive and 
particles as described before was fixed in a metal clam and dropped from one meter 
height, using this experimental set-up. By the impact onto two distance pieces at the 
bottom of the drop apparatus, the metal clam was stopped abruptly from free-falling by 
a beat. The experiment was repeated 10 times with three replicates each. Thereby 
particles with a weak adherence were detached from the membrane surface. The mass 
of the particles and adhesive, which were not detached form the membrane, was 
determined gravimetrically.  
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Figure 6.4: Schematic illustration of the custom made drop apparatus. 
 
Using the principle of the custom made drop apparatus, different plastic materials 
suitable for the use as membrane surfaces in a ballistic powder injection device were 
explored. The membranes were covered with the mixture of the oily components of 
MF59 and coated with glass particles as described before. 
 
Figure 6.5: Adherence strength of glass particles on different membrane materials using 
the oily components of MF59 as adhesive. Polypropylene (PP), polyethylene (PE) 
polyoxymethylene (POM), polyether ether keton (PEEK), aluminum (AL). Number of 
replicates n=3. 
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After 10 drops from one meter height, 97.9% ± 1.2% of the mass of particles and 
adhesive were recovered using aluminum as membrane surface (figure 6.5). Also the 
use of other plastic materials like polypropylene (PP), polyethylene (PE) 
polyoxymethylene (POM), polyether ether keton (PEEK) confirmed the suitability of the 
oily components of MF59 as adhesive. 
Once several membrane materials were found to be suitable to cover the device 
surface, further substances were explored to be used as adhesive. Therefore, the oily 
components of MF59, paraffin oil, silicon oil, miglyol, castor oil, squalene, polyethylene 
glycol 400, polyisobutylene and Freund’s incomplete adjuvant, which is composed of 
85% paraffin oil and 15% mannide monooleate, were investigated. Two different 
membrane surface materials, aluminum and polyethylene membranes, were covered 
with adhesive and glass particles, as described before. The mechanical force acting on 
the device during shipping, storage and handling was simulated by using the custom 
made drop apparatus, as described before. 
After 10 drops from one meter height more than 78% of the mass of particles and 
adhesive remained on the surface of the aluminum membranes using the oily 
components of MF59, paraffin oil, silicon oil, castor oil, polyethylene glycol 400, 
polyisobutylene or Freund’s incompletes adjuvant as adhesive (figure 6.6). Less 
adhesive strength could be observed by the use of miglyol with 46% ± 11% remaining 
mass of particles and adhesive. By the use of squalene 56% ± 12% remaining mass of 
particles and adhesive could be found. The adherence to PE surfaces was comparable 
to the adherence on aluminum surfaces, in some cases slightly higher or lower 
compared to aluminum surfaces. 
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Figure 6.6: Adherence strength of glass particles on aluminum membranes (black bars) 
and PE-membranes (grey bars) using different adhesives. The custom made drop 
apparatus was used to investigate the adhesive force between the membrane surface 
and the particles. Number of replicates n=3. 
 
Once several membrane materials and oily substances were investigated for their 
suitability to act as surface material and as adhesive at the interface between the device 
surface and particles, the role of the surface structure of the membrane material was 
explored. The adherence strength between glass particles and membranes is not only 
dependent on the type of adhesive and the membrane material itself, but also on the 
roughness of the surface membrane material. The adherence strength of glass particles 
on smooth surfaces was compared with the adherence strength on structured 
membrane surfaces (figure 6.7). The mixture of the oily components of MF59 was used 
exemplarily as adhesive in this experimental set-up. Aluminum and polyethylene 
membranes were prepared as described before and the adherence strength of the 
particles was challenged by dropping the membrane ten times from one meter height 
using the custom made drop apparatus. 
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Figure 6.7: Adherence strength of glass particles on perfectly smooth foils (grey bars) or 
structured surfaces (black bars) using the oily components of MF59 as adhesive. Number 
of replicates n=3. 
 
Regarding the adherence strength of the particles on aluminum and polyethylene 
membranes 98% and 88% of the glass particles, respectively, were retained on 
membranes having a structured surface. 93% and 81% of the particles were retained on 
perfectly smooth aluminum and PE foils. Thus, as expected, the surface structure of the 
membrane material has an influence on the adherence strength of the particles. 
An additional option to adhere particles onto the surface of the membranes, the 
adherence by electrostatic interactions, was taken into consideration. Three different 
membrane materials (Teflon, aluminum and polyethylene) were dipped in a bed of glass 
particles having a particle size as described before in order to fix the glass particles onto 
the membrane surface without the use of an adhesive but only by electrostatic 
interactions. The mass of glass particles adherent on the membrane surface was 
determined gravimetrically. Likewise, the three different membrane materials were 
covered by the oily components of MF59. The amount of adhesive was determined 
gravimetrically. The membranes covered with adhesive were dipped in a bed of glass 
particles. The excess glass particles were tapped off. The mass of glass particles was 
determined gravimetrically.  
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Without the application of an adhesive only 5.73 mg glass particles were attached to 
Teflon membranes, 0.27 mg to aluminum membranes and 2.17 mg to polyethylene 
membranes due to electrostatic interactions. However, 18.23 mg, 12.53 mg and 
15.00 mg glass particles were attached to Teflon membranes, aluminum membranes 
and polyethylene membranes, respectively, using the oily components of MF59 (table 
6.1).  
Table 6.1: Adhesion of glass particles on the surface of polyethylene membranes by the 
use of adhesives or electrostatic interactions 
type of membrane 
particle mass  
without the use of adhesive [mg] 
particle mass  
using the oily components of MF59 
as adhesive [mg] 
Teflon 5.73 ± 1.42 18.23 ± 2.64 
Aluminum 0.27 ± 0.06 12.53 ± 3.16 
Polyethylene 2.17 ± 0.81 15.00 ± 6.10 
 
This proves the ability of the oily components of MF59 to attach a substantial mass of 
glass particles on different membranes and demonstrate herein the rational for the use 
of adhesives. 
 
2.2  RESISTANCE OF THE ADHERENT STRENGTH AT THE INTERFACE BETWEEN PARTICLES 
AND DEVICE SURFACE UNDER DIFFERENT TEMPERATURE CONDITIONS 
The oily components of MF59 and Freund’s incomplete adjuvant were investigated at 
different ambient temperature conditions for the use as adhesive agent between glass 
particles and membranes. Two different membrane surface materials, aluminum and PE 
membranes, were covered with adhesive as described before. The mechanical force 
acting on the device during shipping, storage and handling was simulated by dropping 
the membrane ten times from one meter height using the custom made drop apparatus, 
as described before. The samples as well as the custom made drop apparatus were 
tempered for two hours prior to the experiment to 2-8°C, 25°C or 40°C, respectively.  
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Figure 6.8: Adherence strength of glass particles on aluminum and polyethylene (PE) 
membranes using the oily components of MF59 or Freund’s incomplete adjuvant as 
adhesive at 2-8°C (black bars), 25°C (grey bars) and 40°C (dark grey bars). 
 
After ten drops from one meter height more than 82.5% of the mass of particles and 
adhesive remained on the surface of aluminum and polyethylene membranes using the 
oily components of MF59 as adhesive, independent of the present ambient temperature 
(figure 6.8). Optimal adherence was found at 25°C for samples using Freund’s 
incomplete adjuvant as adhesive on both, aluminum and polyethylene membranes. 
Less adherence strength was observed at 2-8°C and 40°C with 49% to 60% remaining 
mass of particles and adhesive after ten drops from one meter height using the custom 
made drop apparatus. 
The resistance of the adherence strength between the particles and the membranes 
after 12 weeks of storage at 2-8°C, 25°C and 40°C was investigated with regard to the 
storage stability of the composition. 
The oily components of MF59 and Freund’s incomplete adjuvant were used as adhesive 
agent between glass particles and PE and aluminum membranes. The samples were 
stored for 12 weeks at 2-8°C, 25°C and 40°C. After this storage period, the mechanical 
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strength of the adhesion was investigated using again the custom made drop apparatus 
as described before. The samples were re-tempered to room temperature prior to the 
experiment. 
 
Figure 6.9: Adherence strength of glass particles on aluminum and polyethylene (PE) 
membranes using the oily components of MF59 or Freund’s incomplete adjuvant as 
adhesive after 12 weeks of storage at 2-8°C (black bars), 25°C (grey bars) and 40°C (dark 
grey bars). 
 
By using the oily components of MF59 as adhesive more than 60% of particles and 
adhesive were recovered after ten drops form one meter height after 12 weeks of 
storage at 25°C and 40°C using both membrane types (figure 6.9). Good adherence 
strength after 12 weeks of storage at 25°C and 40°C was shown for the use of PE 
membranes covered with Freund’s incomplete adjuvant. Less adherence strength was 
found for aluminum membranes covered with Freund’s incomplete adjuvant over the 
investigated period independently on the ambient temperature. The storage 
temperature of 2-8°C had also a negative influence on the adherence strength of the 
adhesives after 12 weeks of storage, except for the combination of PE membranes 
covered with the oily components of MF59.  
Generally, the viscosity of the adhesives rises with decreasing temperature, hence 
having less capability to coat the particles. Therefore, the adherence strength seems to 
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decrease with a decreased contact area between adhesive and particles. In addition, 
the ability of the adhesive to spread on the membrane surface has also an impact on 
the mechanical strength of the adhesion. However, this interrelationship has to be 
evaluated for each adhesive and each surface material individually. 
 
2.3 PROOF OF CONCEPT – RELEASE OF THE PARTICLES UPON ACTUATION OF THE DEVICE 
The ability of the adhesive to assure the adherence of particles on the membrane 
surface during transport and storage is similar important as the ability to release the 
particles upon acceleration using a ballistic device. 
A ballistic accelerator was used to simulate the ballistic injection process. The basic 
working principle of the ballistic accelerator is the generation of a repulsive force by a 
magnetic field which induces a turbulent electrical current in a metal carrier, e.g. an 
aluminum membrane, which is thereby accelerated to high velocities. The aluminum 
membrane acts as carrier surface for the particles and is stopped by a stopper plate, 
while the particles attached on the membrane are further accelerated (figure 6.10). 
 
Figure 6.10 Schematic set-up of the ballistic accelerator (created by Dr. Lell, Pyroglobe 
GmbH). 
Aluminum membranes were prepared as described before. Aluminum membranes were 
covered with the oily components of MF59 and glass particles of a size fraction of 
20 µm to 40 µm were attached.  
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Figure 6.11: (A) Photograph taken by a Flash Cam PCO high speed camera (PCO, 
Kehlheim am Ufer, Germany), depicting two clouds of glass particles detached from the 
aluminum membrane and accelerated to high velocities. (B) Light micrograph of the 
surface of the aluminum membrane after the experiment, showing that the glass particles 
were completely detached from the membrane surface. The picture was obtained using a 
Keyence VHX-500 F microscope. 
 
Upon acceleration using the ballistic accelerator glass particles attached with the oily 
components of MF59 were completely detached from the aluminum membranes gaining 
high velocity above 100 m/s (figure 6.11 A and B). This proves that the mechanical 
strength at the interface between glass particles and aluminum membranes using the 
oily components of MF59 as adhesive is on the one hand side strong enough to avoid 
powder loss during storage and shipping; but on the other hand side the particles can 
even so be detached upon acceleration using a ballistic accelerator.  
The release of glass particles attached on aluminum membranes using the oily 
components of MF59 using a ballistic acceleration was compared to the use of 
polyisobutylene and superglue as adhesives. Glass particles attached with the oily 
components of MF59 on aluminum membranes were completely detached upon 
acceleration using the ballistic accelerator (figure 6.12 A). Particles attached with 
polyisobutylene on aluminum membranes were not detached upon acceleration and 
remained almost completely on the membrane surface (figure 6.12 B). Particles 
attached with superglue were partially detached in form of solid pieces which consisted 
of aggregates of glue and particles (figure 6.12 C). 
BA 
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Figure 6.12: Photographs taken by a Flash Cam PCO high speed camera (PCO, Kehlheim 
am Ufer, Germany), depicting clouds of glass particles detached from the aluminum 
membrane attached with different adhesives. 
 
A homogenous distribution of the particles and a disintegration of agglomerates into 
single particles are crucial for the penetration of the particles into the targeted layers of 
the skin. It is conceivable that large agglomerates will not be able to breach the 
outermost layer of the skin, the stratum corneum, and also might cause severe injuries 
on the skin when accelerated using a ballistic device. Hence, the texture of the adhesive 
plays an important role for its use at the interface between particles and the device 
surface of a ballistic injector. Conventional adhesives, as polyisobutylene or superglue, 
do not comprise these requirements, and furthermore, are not skin-compatible. 
A further requirement on the adhesive is, besides the attachment of the particles during 
storage and handling and the release of the particles upon actuation of the injection 
device, that it can be entrained together with the particles during detachment from the 
membrane. An adjuvant effect of the adhesive can only be achieved, if a substantial 
amount of adjuvant is entrained together with the particles and herein injected into the 
skin. 
In order to visualize if the adhesive is entrained together with the particles upon 
detachment from the interface to the device surface, a mixture of the oily components of 
MF59 was mixed with 1% Sudan red. Glass particles of a size fraction of 20 µm to 
40 µm were attached onto aluminum membranes using the Sudan red dyed mixture of 
the oily components of MF59 as described before. Particles were detached upon 
Oily components of MF59 Polyisobutylene Superglue 
A  B  C
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acceleration using the ballistic accelerator and caught on the surface of a second 
membrane. Figure 6.13 shows A) a light-micrograph of particles detached from the 
membrane surface upon acceleration and B) subsequently caught on a second 
membrane.  
 
 
Figure 6.13: Light-micrographs of particles covered with adhesive (A) and without 
adhesive (B) after the impact on a second target membrane. The pictures were obtained 
using a Keyence VHX-500 F microscope. Scale bars 100 µm. 
 
The glass particles were uniformly covered with the Sudan red dyed adhesive, showing 
that a substantial amount of adhesive was entrained together with the particles during 
detachment from the membrane and acceleration (figure 6.13 A). In comparison to that, 
figure 6.13 B shows the impact of the particles on the second membrane without the 
use of an adhesive, serving as blank test. Summarizing this tentative experiment, it is 
assumed that the adhesive can also be delivered together with the particles into the 
target using a ballistic injection device. However, this assumption has still to be verified 
in subsequent animal studies. 
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2.4 SUMMARY AND CONCLUSION 
A simple method was developed to attach particles on different membrane surfaces by 
using of oily substances. After covering the membrane surface with the oily substances, 
the membrane was dipped into a tray filled with particles, attaching hereby 
approximately the tenfold higher mass of particles on the membrane surface in 
comparison to the mass of the adhesive. Particles were enclosed into a thin film of the 
oily substance, hence resulting in a partly or, if the amount of the oily substance was 
increased, full coverage of the surface of the particles. Using this approach, the 
particles can be potentially protected from air, humidity and other environmental factors. 
In order to challenge the adhesive strength in between the device surface and the 
particles, firstly a jolting volumeter was used to simulate the mechanical stress exerted 
during handling, shipping and storage of the device. As all tested oily substances 
showed excellent adhesive properties, the mechanical stress exerted by the jolting 
volumeter was further increased by the use of a custom made drop apparatus. Different 
membrane materials were investigated for their use to cover the device surface, 
whereby aluminum was found to show excellent properties. Several oily substances, 
including also oily adjuvants or single components of oily adjuvants, were explored as 
adhesives on aluminum and PE membranes. The adherence strength was despite of 
the tough mechanical challenge outstanding for several oily substances, including the 
oily components of MF59 and Freund’s incomplete adjuvant. Furthermore it was found, 
that the surface structure of the membranes and the influence of electrostatic 
interactions as adhesive force between particles and the membranes plays a 
subordinate role. The adhesive strength of selected combinations of oily adjuvants and 
membrane materials, including Freund’s incomplete adjuvant and the oily components 
of MF59 in combination with aluminum and PE-membranes, was investigated 
throughout a storage period of 12 weeks under different temperature conditions. Most 
notably the mixture of the oily components of MF59 was capable to attach particles on 
the different membrane surfaces for the monitored time period also at elevated 
temperature conditions. 
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Finally, the proof of concept was given by the release of the particles from the 
attachment situation upon actuation of the ballistic device. In doing so it was observed, 
that the adhesive was entrained together with the particles. Hence, the entrainment of 
the oily substances together with the particles offer the possibility to be co-injected into 
the skin and herein exert an adjuvant effect. Whether the amount of adhesive, which is 
entrained together with the particles, is sufficient to elicit an appropriate immune 
response, has to be proven in subsequent animal studies. 
It has to be emphasized, that the experiments were made with model particles, since 
the use of glass particles enabled high reproducibility of the experiments. In future, the 
model has to be additionally challenged by the use of antigen loaded powder particles, 
in order to investigate the transferability of the model.  
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3 STORAGE STABILITY OF CRYO-MILLED PARTICLES ON OILY COVERED 
SURFACES 
 
In section 2 of this chapter several oily substances were proven to be suitable to attach 
the powdered particles to the device surface, so that the dose could be fixed on place 
even under mechanical stress situations as this is the case during handling and storage. 
The oily substances were as well capable to release the particles upon actuation of the 
device. In a second step the storage stability and possible interaction between the oily 
substances and the antigen loaded powder particles was investigated. 
Ovalbumin served as a model antigen in a formulation based on a secondary mixture of 
trehalose and mannitol (hereafter abbreviated as TM) at a weight ratio of 1:1 and a total 
solid content of 15% (w/w) herein with 2.5% (w/w) ovalbumin. The formulation was 
collapse freeze-dried and cryo-milled as described before. Five different kinds of 
adjuvants were assessed in a short term stability study at elevated temperatures: the 
oily components of MF59, squalane, squalene, Freund’s incomplete adjuvant and 
paraffin oil. The mixture of the oily components of MF59 was selected for its use as oily 
adjuvant in this study as it comprises not only the ability to act as adhesive at the 
interface between the device surface and the particle load as described in chapter 6.2. 
but it is also known for its good safety and tolerability profile when used as whole water 
in oil emulsion in order to adjuvant vaccines [4-6]. MF59 is meanwhile licensed in more 
than 20 countries. Squalene is one component in this mixture and is also a natural 
component of cell membranes and part of the cholesterol biosynthesis. Consequently, 
squalene is both biodegradable and biocompatible. Its role as immunological adjuvant is 
controversy discussed in literature [7, 8]. Squalane is derived by hydrogenation of 
squalene and is, in contrast to squalene, not subjected to auto-oxidation [9-15]. 
Squalane was also included into this study due to its potential to be used as adhesive at 
the interface between vaccine particles and the device surface and its potential function 
as adjuvant. Freund’s incomplete adjuvant has already been used in a number of 
veterinary vaccines and its adjuvant effect was also explored in combination with 
influenza and killed poliomyelitis vaccines in humans [16-18]. Its main components are 
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the mineral oil paraffin and mannide monooleate, also known as Arlacel-A. Arlacel-A is 
used as emulsifying agent. Prior to use, typically water is added to Freund’s incomplete 
adjuvant in order to create a water-in-oil emulsion. For its application as adhesive at the 
interface between the device surface and vaccine particles, only the oily components 
were used without the addition of water. In consequence to its side-effects such as local 
reactions at the injection side, Arlacel-A induced carcinogenicity in mice and oil- induced 
neoplasmas in mice, it is currently not used in humans [2]. Paraffin oil is one of the 
components of Freund’s incomplete adjuvant and was also included into this study. 
However, its potential to act as adjuvant as well as its efficacy and safety profile have 
still to be evaluated in further animal studies. 
The samples were stored at 2-8°C, 25°C and 40°C for a time period of 12 weeks. In 
addition to the evaluation of the stability of the combination of vaccine powder and oily 
adjuvant, the stability of each component itself (either the powder containing ovalbumin 
or the oily substance) was investigated. Protein stability was assed using different 
analytical methods. Primary protein structure was assessed by HP-SEC and changes in 
the secondary structure by FTIR. The formation of protein aggregates was analyzed by 
light obscuration and turbidimetry. Changes in particle morphology were tracked by the 
measurement of the residual moisture of the powders and differential scanning 
calorimetry. The recovery and the degradation of the oily adjuvants after storage was 
assessed using gas chromatography in combination with mass spectroscopy. 
 
3.1 REPROCESSING OF THE SAMPLES 
In order to investigate protein stability of the samples, first a method had to be 
developed for the separation of the oily substances from the protein powder formulation 
as the oily adjuvants were shown to interfere with the established analytical methods. 
Tert-butyl-methyl ether (MTBE) was chosen as washing agent for the samples, as it was 
on the one hand side a suitable solvent for all oily substances selected for this study (as 
shown by the recovery of the oily substances determined by GC-MS, shown later in this 
chapter), and on the other hand side, the model antigen ovalbumin was not soluble in 
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MTBE (as shown by the recovery of the total protein content of ovalbumin after the 
reprocessing step using MTBE determined by HP-SEC, shown later in this chapter).  
SAMPLE PREPARATION 
For the preparation of the samples approximately 50 mg of protein powder formulation 
was bedded on a 10 µl thin film of the oily adjuvant on the surface of a 2R glass vial. 
The samples were washed three times in MTBE as described in chapter 2. The 
obtained powder pellet was subsequently vacuum dried in order to remove MTBE-
solvent residues. The dried powder pellet was subsequently used for protein stability 
analysis. 
INFLUENCE OF THE REPROCESSING OF THE SAMPLES ON PROTEIN STABILITY 
The influence of the washing steps using MTBE on physical protein stability, the 
formation of soluble and insoluble aggregates, was assessed by light obscuration, 
turbidity measurements and size exclusion chromatography. The conformational 
stability of ovalbumin after the treatment with MTBE was assessed by FTIR 
transmission spectroscopy.  
The extraction of the oils with MTBE was effective as the turbidity-levels of the samples 
were reduced to an appropriate level (between 3.23 and 4.36 FNU) which is within the 
detectable range of the analytical method (table 6.2). Generally, the reprocessing steps 
of the samples using MTBE caused an increase in turbidity (table 6.2) as well as an 
increase in cumulative particle counts greater than 1, 10 and 25 µm per mL (figure 6.14 
and table 6.2) in both, trehalose-mannitol formulations containing ovalbumin (referred to 
TM) as well as in formulations without ovalbumin (referred to placebo).  
The turbidity of trehalose-mannitol formulations containing ovalbumin increased from 
0.94 FNU to 2.93 FNU after the reprocessing step with MTBE. Similarly cumulative 
particle counts increased from 17402 to 52423 for particles > 1 µm per mL, from 327 to 
2422 for particles > 10 µm per mL and from 29 to 139 for particles > 25 µm per mL 
before and after the washing steps of the trehalose-mannitol formulations with MTBE 
(table 6.2 and figure 6.14).  
INTERFACE PARTICLES AND DEVICE SURFACE 
 
158 
 
Likewise the turbidity of the placebo formulations increased from 0.87 FNU to 3.88 FNU 
after the reprocessing step with MTBE. Cumulative particle counts increased from 5179 
to 20361 for particles > 1 µm per mL, from 96 to 317 for particles > 10 µm per mL and 
from 9 to 28 for particles > 25 µm per mL, respectively, after the reprocessing step of 
the placebo samples with MTBE (table 6.2 and figure 6.14).  
In conclusion, the comparison of placebo samples and samples containing ovalbumin 
revealed that the extraction procedure itself caused the formation of particles 
independently whether the samples contained protein or not (table 6.2 and figure 6.14). 
Hence, the nature of the particles could not be explained by the formation of insoluble 
aggregates. 
 
Figure 6.14: Cumulative particle counts > 1 µm per mL of reprocessed samples (three 
times washing with MTBE, black bars) or native samples (grey bars). 
Samples consisted of ovalbumin powder based on trehalose/mannitol (TM), placebo powder based on 
trehalose/mannitol (placebo), or a mixed sample of ovalbumin powder based on trehalose/mannitol and 
an oily substance (e.g. squalan).  
The mixed samples consisted of 50 mg ovalbumin powder based on trehalose/mannitol and 10 µl of the 
oily substance. Three of the mixed samples were pooled prior to analysis. The powder was reconstituted 
in 2 mL purified water prior to analysis. 
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Table 6.2: Cumulative particle counts > 10 µm per mL and > 25 µm per mL of reprocessed 
samples (three times washing with MTBE) or native samples. 150 mg of the powder was 
reconstituted in 2 mL purified water prior to analysis. 
 Sample* 
particles > 10 µm 
per mL ± SD 
particles > 25 µm 
per mL ± SD 
turbidity [FNU]          
± SD 
native 
samples 
TM 327 ± 54 29 ± 14 0.94 ± 0.03 
Placebo 96 ± 11 9 ± 2 0.87 ± 0.02 
reprocessed 
samples 
TM 2422 ± 75 139 ± 17 2.93 ± 0.17 
Placebo 317 ± 23 28 ± 11 3.88 ± 0.01 
Oily comp. of MF59 1459 ± 107 101 ± 28 3.36 ± 0.12 
Squalane 1612 ± 115 93 ± 20 3.23 ± 0.18 
Squalene 2388 ± 84 106 ± 15 3.98 ± 0.14 
Freund’s incomplete adj. 2803 ± 277 130 ± 31 4.36 ± 0.10 
Paraffin oil 1829 ± 79 104 ± 28 3.47 ± 0.13 
*Samples consisted of ovalbumin powder based on trehalose/mannitol (TM), placebo powder based on 
trehalose/mannitol (placebo), or a mixed sample of ovalbumin powder based on trehalose/mannitol and 
an oily substance (e.g. squalan).  
The mixed samples consisted of 50 mg ovalbumin powder based on trehalose/mannitol and 10 µl of the 
oily substance. Three of the mixed samples were pooled prior to analysis. The powder was reconstituted 
in 2 mL purified water prior to analysis. 
 
It was not possible to quantitatively remove the oily substances from the powder 
formulations. Slightly higher turbidity levels were observed most notably in samples 
containing Freund’s incomplete adjuvant. However, it was possible to remove the oily 
substances to an adequate level to assess protein stability within the detection range of 
the analytical method.  
The stability of the reprocessed samples was investigated at elevated temperatures 
over a time period of 12 weeks, in order to reveal delayed effects of the reprocessing 
steps on protein integrity. After the reprocessing steps the turbidity level of the samples 
as well as the cumulative particle counts > 1, 10 and 25 µm (figure 6.15 and table 6.3) 
were increased in comparison to untreated samples. However, they did not further 
increase after 12 weeks of storage at 2-8°C, 25°C and 40°C (figure 6.15 A, B), similarly 
to unprocessed, native samples (figure 6.15 C, D). 
Size exclusion chromatography showed 99.83% recovery of the soluble monomer of 
reprocessed trehalose-mannitol samples containing ovalbumin. The remaining soluble 
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monomer content of the liquid formulation was used as reference for the calculation of 
the soluble monomer recovery in the reprocessed samples. The recovery of the soluble 
monomer indicated that the reprocessing of the samples with MTBE did not affect 
protein stability in terms of the formation of soluble aggregates (figure 6.16).  
The total protein recovery of the samples was 96.12% after the reprocessing procedure 
with MTBE. Hence, the reprocessing procedure was considered as suitable for the 
separation of the protein powder and the oily substances. Both, the soluble monomer 
recovery as well as the total protein recovery remained unchanged after storing at 2-
8°C, 25°C and 40°C for 12 weeks, hence, the reprocessing step with MTBE did not 
influence protein integrity (figure 6.16). 
 
Figure 6.15: Cumulative particle counts > 1 µm per mL of reprocessed samples (three 
times washing with MTBE) (A) or native samples (C). Turbidity levels of reprocessed 
samples (B) and native samples (D). Samples were stored up to 12 weeks at 2-8°C (black 
bars), 25°C (light grey bars) or 40 °C (dark grey bars). 150 mg of the powder was 
reconstituted in 2 mL purified water prior to analysis. 
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To complete investigations on the effect of the reprocessing step with MTBE on protein 
stability, protein secondary structure and conformational stability of ovalbumin was 
assessed by FTIR transmission spectroscopy (figure 6.16 D). Figure 6.16 D shows the 
second derivative of FTIR transmission spectra of ovalbumin from trehalose-mannitol 
formulations after reprocessing with MTBE and reconstitution of the vacuum dried 
powder in purified water. Samples stored at 2-8°C, 25°C and 40°C for 12 weeks were 
compared to a standard sample that was not stored (t0). The amide I band is known to 
be sensitive to protein secondary structures and conformational changes. It arises from 
C=O stretching vibrations (1690-1620 cm-1) of the peptide linkages, whereas the amide 
II band arises from C-N stretching vibrations and N-H in plane bendings [19-21]. It is 
known form literature, that ovalbumin exhibits the amide I band at two equal peaks at 
1654 and 1640 cm-1 [22].  
 
Table 6.3: Cumulative particle counts > 10 and > 25 µm per mL of reprocessed samples 
(three times washing with MTBE) or native samples. Samples were stored up to 12 weeks 
at 2-8°C, 25°C or 40 °C. 150 mg of the powder was reconstituted in 2 mL purified water 
prior to analysis. 
 cumulative particle 
count 
after 12 weeks of 
storage at 2-8°C 
after 12 weeks of 
storage at 25°C 
after 12 weeks of 
storage at 40°C 
reprocessed 
samples 
particles > 10 µm 
per mL ± SD 
2436 ± 134 1032 ± 204 1328 ± 154 
particles > 25 µm 
per mL ± SD 
152 ± 16 44 ± 10 89 ± 5 
native 
samples 
particles > 10 µm 
per mL ± SD 
234 ± 29 230 ± 28 300 ± 31 
particles > 25 µm 
per mL ± SD 
2 ± 2 10 ± 6 33 ± 20 
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Figure 6.16: Higher molecular weight aggregates (black bars), dimers (light grey bars) 
and fragment (dark grey bars) protein species [%], total monomer recovery [%] (filled 
circles) and total protein recovery [%] (open circles) of reprocessed trehalose-mannitol 
samples containing ovalbumin (TM_reprocessed) as determined by size exclusion 
chromatography. Samples were incubated at 2-8°C (A), 25°C (B) and 40°C (C). Area-
normalized 2nd derivative FTIR transmission spectra of samples after 12 weeks of 
storage at 2-8°C, 25°C and 40°C (D). 
 
Figure 16.6 D shows the second derivative spectra of ovalbumin. The spectrum of the 
standard sample of ovalbumin, which was not stored (t0), exhibits two major bands at 
1656 and 1638 cm-1 and a minor band at 1683 cm-1. The band at 1638 cm-1 can be 
assigned to low-wavenumber ß-sheets, the bands at 1656 cm-1 to α-helix and the band 
at 1683 cm-1 to ß-turns [22]. After storage at 2-8°C, 25°C and 40°C for a duration of 12 
weeks, two minor bands in the ß-turn region at 1687 cm -1 and 1672 cm -1 arose as well 
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as a band in the low wave-number ß-sheets at 1615 cm -1. These alterations were 
indicative for only minor changes in the secondary structure of the protein, whereas 
changes in the intensities of the 1635/1638 cm -1 and 1655/1657 cm -1 bands are known 
to be indicative for thermally induced conformational changes in the ß-sheet and α-helix 
structures [22]. Background noise originated form the reprocessing step with MTBE was 
responsible for baseline slopes and distorted peak shapes. Only minor band shifts in 
these areas were observed, indicating conformational stability of ovalbumin. This was 
also in accordance with the findings of the size exclusion chromatography, showing that 
the reprocessing step with MTBE did not influence protein integrity. 
In summary, the reprocessing step with MTBE of the samples and the subsequent 
vacuum drying step were a suitable method to remove the oily substances from the 
formulation without altering excessively protein integrity.  
 
3.1.1 MORPHOLOGICAL STABILITY OF THE SAMPLES 
Morphological changes in the formulation in terms of thermal events, glass transition 
temperature and residual moisture of the samples could be investigated without the 
need of the reprocessing step with MTBE as described previously (section 3.1.) 
The physicochemical properties of ovalbumin formulations based on a binary mixture of 
trehalose and mannitol and changes thereof after storage at elevated temperatures was 
scrutinized.  
Differential scanning calorimetry analysis showed that mannitol crystallized during 
collapse freeze-drying as two characteristic melting endotherms in the range of 135.5 to 
138.2 °C and 147.9 to 151.5 °C were observed in the DSC thermograms (table 6.4). 
According to literature δ-mannitol is first transformed to β-mannitol at 130-140°C and 
shortly after the in-situ formed β-mannitol shows a second characteristic melting 
endotherm at 150-158°C. In the secondary mixture of trehalose and mannitol, the 
melting points of mannitol were lowered as compared to those of pure mannitol due to 
the presence of ovalbumin, trehalose and buffer salts. This was also in agreement with 
melting temperatures of mannitol observed by Hawe et al [23]. 
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Table 6.4: Physicochemical properties of ovalbumin-containing trehalose-mannitol 
samples determined by differential scanning calorimetry after storage at 2-8°C, 25°C and 
40°C for 12 weeks. 
formulation 
storage 
temperature  
storage time 
[weeks] 
Tg [°C] ± SD ∆ Cp [J/g*K] 
± SD 
characteristic melting 
endotherms [°C] ± SD 
TM 
lyophilizate 
- 0 85.3 ± 2.0 0.327 ± 0.388 138.2 ± 0.6 151.5 ± 0.3 
TM cryo-
milled 
powder 
- 0 62.0 ± 0.7 0.255 ± 0.052 138.2 ± 0.5 148.8 ± 0.2 
2-8°C 
8 59.7 ± 1.8 0.394 ± 0.024 138.2 ± 0.9 148.4 ± 0.6 
12 64.4 ± 5.4 0.348 ± 0.027 138.2 ± 0.4 149.4 ± 0.5 
25°C 
8 56.4 ± 1.5 0.345 ± 0.056 138.2 ± 0.9 147.9 ± 0.5 
12 59.7 ± 0.1 0.329 ± 0.034 138.2 ± 1.0 148.7 ± 0.3 
40°C 
8 55.0 ± 4.6 0.379 ± 0.015 138.2 ± 0.1 148.0 ± 0.3 
12 54.7 ± 3.0 0.324 ± 0.015 138.2 ± 1.0 148.2 ± 0.7 
 
Glass transition temperatures of the amorphous trehalose phase were 85.3± 2.0°C 
immediately after lyophilization. Glass transition values decreased during storage (table 
6.4) due to the increase in residual moisture (figure 6.17). The glass transition 
temperature of lyophilized products can be lowered by 10K for each percent of moisture 
in the product, as water acts as plasticizer [24]. 
After cryo-milling the glass transition value decreased from 85.3 ± 2.0 °C to 62.0 ± 
0.7°C and remained stable for a time period of 12 weeks at 2-8°C and 25°C. A further 
decrease of the glass transition temperature to 54.7 ± 3.0°C was only observed in 
samples stored for 12 weeks at 40°C. Similarly, the extent of change in heat capacity at 
the glass transition was just slightly decreased for cryo-milled samples after 12 weeks of 
storage. However, most importantly, glass transition temperatures of the samples were 
well above the highest storage temperature of 40°C, indicating good storage stability of 
the formulation. 
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Figure 6.17: Residual moisture levels of trehalose-mannitol samples containing 
ovalbumin stored at 2-8°C (black bars), 25°C (light grey bars) and 40°C (dark grey bars) 
for 12 weeks. 
 
3.2 STORAGE STABILITY OF THE OILY COMPONENTS OF MF59, SQUALENE AND SQUALANE  
In order to find out if the oily substances degrade upon storage at elevated 
temperatures and if they interact with the protein powder particles, an accelerated 
stress test was initiated. Chemical stress was applied by incubation of the samples with 
30% hydrogen peroxide and 1 N sodium hydroxide for 24 hours. Furthermore UV-light 
stress was applied for a time period of 7 days (as described in chapter 2). As UV-light 
stress caused also heat and thus resulted in increased sample temperatures of 35°C, 
samples were additionally exposed to heat stress at 35°C whilst being protected from 
light by an aluminum cover, respectively. 
The mixture of the oily components of MF59 as well as its ingredient squalene were 
highly sensitive to UV-light and heat stress, resulting in a strong decrease in recovery 
as determined by GC/MS (figure 6.18).  
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Figure 6.18: Recovery of the oily components of MF59, squalane and squalene as 
determined by GC/MS. GC/MS analysis was conducted by Dr. Christoph Müller (LMU, 
Munich). Oily substances incubated with protein powder formulation (black bars) and 
samples containing only oily substances (grey bars). 
 
After UV-light exposure samples containing the mixture of the oily components of MF59 
showed a recovery of 54.6 ± 16.3%. The decrease in recovery of the oily components of 
MF59 was even enhanced if the samples were incubated together with protein powder 
formulation, resulting in 39.0 ± 26.1% recovery. Samples exposed to heat stress 
showed similar results with 66.1 ± 28.8% recovery for samples containing the mixture of 
the oily components of MF59 and 49.0 ± 15.6% recovery for samples, where the 
mixture of the oily components of MF59 was incubated in the presence of the protein 
powder formulation. The surfactants polysorbate 80 and Span® 85 are both known to 
build peroxides and thus is highly promoted by light stress and temperature [25, 26]. 
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Squalene samples showed a recovery of 55.5 ± 14.3% after UV-light exposure and 56.2 
± 13.2% recovery after heat stress. Samples incubated together with protein powder 
and squalene showed 45.0 ± 11.0% recovery after UV-light exposure and 73.0 ± 9.0% 
recovery after heat stress (figure 6.18).  
The mixture of the oily components of MF59 as well as squalene samples responded 
less sensitive to chemical stress that was induced by hydroxide peroxide and sodium 
peroxide, independent of the presence of the protein powder. Squalane samples 
showed throughout less receptiveness for the applied stress conditions. Squalane was 
generally more chemically stable as it had no double bonds which were susceptible to 
oxidation [7]. The accelerated stress test showed that especially the oily components of 
MF59 and its ingredient squalene were sensitive to both, UV-light exposure and heat 
stress. 
 
3.2.1 STABILITY OF OVALBUMIN IN A TREHALOSE-MANNITOL FORMULATION IN THE PRESENCE 
OF THE OILY COMPONENTS OF MF59 USED AS OILY ADJUVANT 
A short term stability study was performed, in which the stability of ovalbumin and the 
stability of the oily components of MF59 was assessed for a time period of 12 weeks at 
elevated temperatures.  
After 8 weeks of storage at 40°C a strong decrease up to 50% in the recovery of the 
mixture of the oily substances of MF59 stored together with the ovalbumin containing 
trehalose-mannitol powder particles was observed (figure 6.19). 
The interaction of the oily adjuvant MF59 and ovalbumin containing trehalose-mannitol 
particles was already macroscopically visible (figure 6.20) in form of a yellow 
discoloration of the samples. A decrease in recovery of the oily substance in such an 
extent could not be observed in samples which were stored without the presence of the 
protein-sugar matrix. This indicated, that the instability was a matter of the interaction 
between the protein-sugar matrix and the oily adjuvant rather than due to the 
degradation of MF59 itself. As no degradation products in form of smaller chemical 
entities could be detected in the GC/MS spectra, the assumption was supported that 
INTERFACE PARTICLES AND DEVICE SURFACE 
 
168 
 
higher ordered agglomerates were reasonable for the decrease in the recovery of the 
oily substance. 
 
 
Figure 6.19: Recovery of the oily components of MF59, as determined by GC/MS. GC/MS 
analysis was conducted by Dr. Christoph Müller (LMU, Munich). Samples were incubated 
up to 12 weeks at 2-8°C (black bars), 25°C (light grey bars) and 40°C (dark grey bars). The 
oily components of MF59 were incubated either without the presence of the ovalbumin 
powder formulation (A) or in combination with the ovalbumin powder formulation (B). 
 
 
Figure 6.20: Picture of trehalose-mannitol formulations stored at 40°C over a time period 
of 8 weeks together with the oily adjuvant MF59, showing a yellow discoloration of the 
powder. 
 
In order to gain further insight into the effect of the oily substances of MF59 on 
ovalbumin, size exclusion chromatography was used to evaluate the formation of 
soluble and insoluble aggregates (using the recovery data), and FTIR transmission 
spectroscopy was applied to assess potential changes in the secondary structure of 
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ovalbumin. Figure 6.21 A-C displays the remaining monomer, total protein recovery as 
well as the recovery of the different protein species by size exclusion chromatography. 
A decrease in soluble monomer recovery as well as total protein recovery was observed 
after 8 weeks of storage at 2-8°C and 25°C (figure 6.21 A and B). Additionally, the 
formation of higher molecular weight aggregates was observed after 8 weeks of storage 
at 40°C, indicating the formation of soluble as well as insoluble aggregates (figure 6.21 
C). 
 
Figure 6.21: Higher molecular weight aggregates (black bars), dimers (light grey bars) 
and fragment (dark grey bars) protein species [%], total monomer recovery [%] (filled 
circles) and total protein recovery [%] (open circles) as determined by size exclusion 
chromatography. Samples were incubated with the oily components of MF59 at 2-8°C (A), 
25°C (B) and 40°C (C). Area-normalized 2nd derivative FTIR transmission spectra of 
samples incubated with the oily components of MF59 (D). 
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The second derivate FTIR-transmission spectra of the samples are depicted in figure 
6.21 D. After storage at 25°C and 40°C, respectively, the intensity of the 1638 cm-1 
band of ovalbumin was decreased dramatically, indicating a thermally induced 
conformational change in the ß-sheet structures. Dong et al. showed, that the intensity 
change in the 1635/1638 cm-1 band of ovalbumin was highly sensitive to changes in 
temperature and was used to monitor the aggregation process of the protein [22]. The 
results of the FTIR measurements were confirmed by the results of size-exclusion 
chromatography, showing the onset of protein denaturation after 8 weeks of storage 
due to the interaction ovalbumin with the oily components of MF59. 
Figure 6.22 shows turbidity levels and the formation particles determined by light 
obscuration of samples containing the oily components of MF59, supporting the results 
obtained by size exclusion chromatography and FTIR spectroscopy. A dramatic 
increase in turbidity up to > 8 NFU was observed in samples stored at 40°C after 8 and 
12 weeks of storage. Likewise the cumulative particle counts > 1 µm per mL (figure 6.22 
A) and > 10 µm per mL (table 6.5) increased after 8 and 12 weeks of storage at 40°C. 
 
 
Figure 6.22: Cumulative particle counts > 1µm per mL of samples incubated with the oily 
components of MF59 (A) and turbidity levels (B) after 12 weeks of storage at 2-8°C (grey 
bars), 25°C (dark grey bars) and 40°C (black bars). Samples were reprocessed as 
described in chapter 3.1 in MTBE and were vacuum dried prior to analysis. 
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Table 6.5: Cumulative particle counts > 10 and 25 µm per mL of samples incubated with 
the oily components of MF59 after 12 weeks of storage at 2-8°C, 25°C and 40°C. Samples 
were reprocessed as described in chapter 3.1 in MTBE and were vacuum dried prior to 
analysis. 
 
 
after 12 weeks of 
storage at 2-8°C 
after 12 weeks of 
storage at 25°C 
after 12 weeks of 
storage at 40°C 
particles > 10 µm per mL ± SD 1087 ± 12 896 ± 18 2831 ± 246 
particles > 25 µm per mL ± SD 60 ± 15 99 ± 44 86 ± 13 
 
 
 
 
 
 
 
 
 
Figure 6.23: Residual moisture levels of trehalose-mannitol samples containing 
ovalbumin stored at 2-8°C (black bars), 25°C (light grey bars) and 40°C (dark grey bars) 
for 12 weeks in the presence of the oily components of MF59. 
 
Figure 6.23 summarizes the residual moisture levels of trehalose-mannitol samples 
containing ovalbumin stored at 2-8°C, 25°C and 40°C in the presence of the oily 
components of MF59 for 12 weeks. A slight increase of residual moisture levels was 
observed for samples stored at 25°C and 40°C after 4 weeks of storage, which is also 
commonly reported in literature [27]. The residual moisture level of trehalose-mannitol 
formulations containing ovalbumin (figure. 6.17) was comparable to the samples stored 
in the presence of oily adjuvants.  
Changes in particle morphology were also assessed by differential scanning 
calorimetry. Glass transition values decreased during storage at 25°C and 40°C after 12 
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weeks of storage, to 58.8 °C ± 1.1°C and 51.3°C ± 0.3°C, respectively, which was also 
in accordance with a slight increase in residual moisture (table 6.6). However, glass 
transition temperatures of the samples were still above the highest storage temperature 
at 40°C. 
Table 6.6: Physicochemical properties of trehalose-mannitol samples stored in the 
presence of the oily components of MF59 as determined by differential scanning 
calorimetry after storage at 2-8°C, 25°C and 40°C for 12 weeks. 
formulation 
storage 
temperature  
storage time 
[weeks] 
Tg [°C] ± SD ∆ Cp [J/g*K] 
± SD 
characteristic melting 
endotherms [°C] ± SD 
oily 
components 
of MF59 
- 0 59.1 ± 3.8 0.256 ± 0.082 137.3 ± 1.2 149.1 ± 1.1 
2-8°C 
8 64.7 ± 0.6 0.292 ± 0.008 137.6 ± 1.0 149.6 ± 0.7 
12 60.1 ± 0.5 0.315 ± 0.013 137.0 ± 0.4 149.3 ± 0.3 
25°C 
8 58.7 ± 1.1 0.301 ± 0.031 137.1 ± 1.2 149.2 ± 0.7 
12 58.8 ± 1.1 0.344 ± 0.020 135.5 ± 0.6 148.6 ± 0.3 
40°C 
8 47.6 ± 2.6 0.283 ± 0.012 134.8 ± 0.8 146.8 ± 0.7 
12 51.3 ± 0.3 0.282 ± 0.030 135.2 ± 0.6 147.5 ± 0.5 
 
The two characteristic melting endotherms of mannitol in the range of 134.8 to 137.6 °C 
and 146.6 to 149.6 °C (table 6.6) for samples stored in the presence of MF59 were 
unvaried in comparison to samples stored without the presence of any oily substance 
(table 6.4). 
 
3.2.2 STABILITY OF OVALBUMIN IN A TREHALOSE-MANNITOL FORMULATION IN THE PRESENCE 
OF SQUALENE USED AS OILY ADJUVANT 
GC/MS analysis of squalene samples stored for up to 12 weeks at 2-8°C, 25°C and 
40°C showed only marginal alterations in the recovery of the oily substance (figure 6.24 
A). Whereas the combination squalene together with powder particles containing 
ovalbumin showed a decrease in squalene recovery after 4 weeks of storage at 40°C 
(figure 6.24 B). This was also in accordance to the results obtained for the oily 
components of MF59. However, the decrease in squalene recovery was clearly lower 
with 88% recovery after 8 weeks of storage at 40°C in comparison to the recovery of the 
mixture of the oily components of MF59 with 48% recovery after 8 weeks of storage at 
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40°C. As no degradation products in form of smaller chemical entities were detected in 
the GC/MS spectra, again, the assumption was supported that higher ordered 
agglomerates were reasonable for the decrease in the recovery of the oily substance. 
 
Figure 6.24: Recovery of squalene, as determined by GC/MS. GC/MS analysis was 
conducted by Dr. Christoph Müller (LMU, Munich). Samples were incubated up to 12 
weeks at 2-8°C (black bars), 25°C (light grey bars) and 40°C (dark grey bars). Squalene 
was incubated either without the presence of the ovalbumin powder formulation (A) or in 
combination with the ovalbumin powder formulation (B). 
 
Size exclusion chromatography was performed to investigate the protein stability of the 
samples stored in the presence of squalene (figure 6.25). Only marginal changes were 
observed after 12 weeks of storage at 40°C in form of a slight increase of higher 
molecular aggregates and a slight decrease in total protein recovery and recovery of 
soluble monomer (figure 6.25 C). Figure 16.25 D shows the second derivative spectra 
of ovalbumin after storage in the presence of squalene. Samples were reprocessed 
prior to analysis with MTBE as described before. The spectrum of the standard sample, 
which was not stored (t0), did just marginally alter from the spectrum of samples stored 
for 12 weeks at 2-8°C, 25°C or 40°C. This was attributed to the fact that the background 
noise, arising from the reprocessing step with MTBE, could not be completely 
eliminated and appeared in baseline slopes and distorted peak shapes. No changes in 
the intensities of the 1635/1638 cm -1 and 1655/1657 cm -1 bands were observed, which 
were known to be indicative for thermally induced conformational changes in the ß-
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sheet and α-helix structures [22]. This suggested conformational stability of ovalbumin if 
stored together with squalene. 
 
Figure 6.25: Higher molecular weight aggregates (black bars), dimers (light grey bars) 
and fragment (dark grey bars) protein species [%], total monomer recovery [%] (filled 
circles) and total protein recovery [%] (open circles) as determined by size exclusion 
chromatography. Samples were incubated with the oily components of MF59 at 2-8°C (A), 
25°C (B) and 40°C (C). Area-normalized 2nd derivative FTIR transmission spectra of 
samples incubated with squalene (D). 
 
The cumulative particle counts as well as turbidity levels of samples stored in the 
presence of squalene showed no remarkable changes (figure 6.26). Cumulative particle 
counts ranged between 79262 ± 8356 particles > 1 µm, 48330 ± 3185 particles > 1 µm 
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per mL and 58608 ± 2746 particles > 1 µm after storage for 12 weeks at 2-8°C, 25°C 
and 40°C, respectively, in comparison to an initial cumulative particle count of 56576 ± 
3003 particles > 1 µm per mL. 
 
Figure 6.26: Cumulative particle counts > 1 µm per mL of samples incubated with 
squalene (A) and turbidity levels (B) after 12 weeks of storage at 2-8°C (grey bars), 25°C 
(dark grey bars) and 40°C (black bars). Samples were reprocessed as described in 
chapter 3.1 in MTBE and were vacuum dried prior to analysis. 
 
Table 6.7: Cumulative particle counts > 10 and 25 µm per mL of samples incubated with 
squalene after 12 weeks of storage at 2-8°C, 25°C and 40°C. Samples were reprocessed 
as described in chapter 3.1 in MTBE and were vacuum dried prior to analysis. 
 
after 12 weeks of 
storage at 2-8°C 
after 12 weeks of 
storage at 25°C 
after 12 weeks of 
storage at 40°C 
particles > 10 µm per mL ± SD 3548 ± 84 1856 ± 178 1940 ± 112 
particles > 25 µm per mL ± SD 203 ± 9 81 ± 21 86 ± 10 
 
Similarly no remarkable changes in particle morphology regarding the residual moisture 
or differential scanning thermograms were observed for samples stored together with 
squalene in comparison to samples which were stored without the presence of any oily 
substance (figure 6.27, table 6.8). 
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Figure 6.27: Residual moisture levels of trehalose-mannitol samples containing 
ovalbumin stored at 2-8°C (black bars), 25°C (light grey bars) and 40°C (dark grey bars) 
for 12 weeks in the presence of squalene. 
 
Table 6.8: Physicochemical properties of trehalose-mannitol samples stored in the 
presence of squalene as determined by differential scanning calorimetry after storage at 
2-8°C, 25°C and 40°C for 12 weeks. 
formulation 
storage 
temperature  
storage time 
[weeks] 
Tg [°C] ± SD ∆ Cp [J/g*K] 
± SD 
characteristic melting 
endotherms [°C] ± SD 
squalene 
- 0 57.5 ± 9.1 0.278 ± 0.033 135.5 ± 3.0 149.1 ± 1.1 
2-8°C 
8 65.9 ± 0.7 0.294 ± 0.035 138.9 ± 0.7 149.6 ± 0.7 
12 61.1 ± 0.3 0.313 ± 0.029 136.7 ± 0.4 149.3 ± 0.3 
25°C 
8 61.9 ± 6.8 0.269 ± 0.036 136.8 ± 0.5 149.2 ± 0.7 
12 61.3 ± 1.5 0.308 ± 0.030 136.0 ± 1.1 148.6 ± 0.3 
40°C 
8 55.8 ± 2.5 0.316 ± 0.014 136.2 ± 0.6 146.8 ± 0.7 
12 56.7 ± 1.6 0.282 ± 0.041 135.2 ± 0.4 147.5 ± 0.5 
 
3.2.3 STABILITY OF OVALBUMIN IN A TREHALOSE-MANNITOL FORMULATION IN THE PRESENCE 
OF SQUALANE USED AS OILY ADJUVANT 
The stability of ovalbumin in a trehalose-mannitol formulation that was incubated 
together with squalane over a time period of 12 weeks at 2-8°C, 25°C and 40°C was 
investigated. GC/MS results showed that the recovery of squalane was not altered if the 
samples were stored as single components (figure 6.28 A). Only a slight decrease in the 
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recovery of squalane could be observed after 12 weeks of storage at 25°C (83.6% ± 
16%) and 40°C (88.8% ± 13%), if the samples were stored together with powder 
particles containing ovalbumin (figure 6.28 B). This is in accordance with the previously 
performed stress test (figure 6.18), confirming the negligible sensitivity of squalane to 
heat stress. 
 
Figure 6.28: Recovery of squalane, as determined by GC/MS. GC/MS analysis was 
conducted by Dr. Christoph Müller (LMU, Munich). Samples were incubated up to 12 
weeks at 2-8°C (black bars), 25°C (light grey bars) and 40°C (dark grey bars). Squalane 
was incubated either without the presence of the ovalbumin powder formulation (A) or in 
combination with the ovalbumin powder formulation (B). 
 
Regarding the protein stability of ovalbumin samples stored in presence of squalane 
size exclusion chromatography (figure 6.29 A, B, C), FTIR (figure 6.29 D), light 
obscuration (figure 6.30 and table 6.9) as well as turbidity measurements (figure 6.30) 
confirmed that the oily substance squalane had no negative influence on protein 
integrity. 
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Figure 6.29: Higher molecular weight aggregates (black bars), dimers (light grey bars) 
and fragment (dark grey bars) protein species [%], total monomer recovery [%] (filled 
circles) and total protein recovery [%] (open circles) as determined by size exclusion 
chromatography. Samples were incubated with squalane at 2-8°C (A), 25°C (B) and 40°C 
(C). Area-normalized 2nd derivative FTIR transmission spectra of samples incubated with 
squalane(D). 
 
Similarly to the results of the protein stability, no additional changes in particle 
morphology were observed in the presence of squalane, regarding residual moisture 
(figure 6.31) or differential scanning calorimetry (table 6.10) of samples stored in the 
presence of squalane in comparison to samples without the presence of any oily 
substance (table 6.4 and figure 6.17). 
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Figure 6.30: Cumulative particle counts > 1 µm per mL of samples incubated with 
squalane (A) and turbidity levels (B) after 12 weeks of storage at 2-8°C (grey bars), 25°C 
(dark grey bars) and 40°C (black bars). Samples were reprocessed as described in 
chapter 3.1 in MTBE and were vacuum dried prior to analysis. 
 
Table 6.9: Cumulative particle counts > 10 and >25 µm per mL of samples incubated with 
squalane after 12 weeks of storage at 2-8°C, 25°C and 40°C. Samples were reprocessed 
as described in chapter 3.1 in MTBE and were vacuum dried prior to analysis. 
 
after 12 weeks of 
storage at 2-8°C 
after 12 weeks of 
storage at 25°C 
after 12 weeks of 
storage at 40°C 
particles > 10 µm per mL ± SD 2322 ± 42 1531 ± 97 1510 ± 43 
particles > 25 µm per mL ± SD 156 ± 3 76 ± 13 86 ± 14 
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Figure 6.31: Residual moisture levels of trehalose-mannitol samples containing 
ovalbumin stored at 2-8°C (black bars), 25°C (light grey bars) and 40°C (dark grey bars) 
for 12 weeks in the presence of squalane. 
 
Table 6.10: Physicochemical properties of trehalose-mannitol samples stored in the 
presence of squalane as determined by differential scanning calorimetry after storage at 
2-8°C, 25°C and 40°C for 12 weeks. 
formulation 
storage 
temperature  
storage time 
[weeks] 
Tg [°C] ± SD ∆ Cp [J/g*K] 
± SD 
characteristic melting 
endotherms [°C] ± SD 
squalane 
- 0 64.7 ± 1.4 0.236 ± 0.032 138.4 ± 0.4 150.1 ± 0.3 
2-8°C 
8 67.0 ± 0.6 0.268 ± 0.013 138.3 ± 0.1 150.0 ± 0.2 
12 63.6 ± 0.4 0.288 ± 0.012 136.9 ± 0.3 149.2 ± 0.2 
25°C 
8 57.0 ± 7.3 0.282 ± 0.051 135.8 ± 0.8 148.3 ± 0.7 
12 62.0 ± 2.1 0.330 ± 0.042 137.1 ± 0.3 149.2 ± 0.6 
40°C 
8 59.0 ± 0.6 0.327 ± 0.019 137.0 ± 0.8 146.2 ± 0.6 
12 53.8 ± 3.2 0.377 ± 0.144 132.9 ± 1.2 147.9 ± 0.6 
 
Only a slight decrease of the glass transition temperature was observed, which was in 
accordance to the increase of residual moisture at elevated storage temperature (figure 
6.31 and table 6.10). The glass transition temperature of lyophilized products can be 
lowered by 10K for each percent of moisture in the product, as water acts as plasticizer 
[24]. 
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3.3 STORAGE STABILITY OF THE OILY COMPONENTS OF FREUND’S INCOMPLETE ADJUVANT 
AND PARAFFIN OIL USED AS OILY ADJUVANT 
An accelerated stress test, inducing chemical stress by the incubation of the samples 
with 30% hydrogen peroxide or 1 N sodium hydroxide for 24 hours was performed. 
Chemical stress was applied to samples containing either Freund’s incomplete 
adjuvant, paraffin oil or either of them in combination with powder particles containing 
ovalbumin in a trehalose-mannitol formulation. The stress test served to estimate if the 
oily substances interact with protein powder particles and if they degrade upon the 
applied stress conditions. 
 
 
Figure 6.32: Recovery of Freund’s incomplete adjuvant and paraffin oil as determined by 
GC-FID. GC-FID analysis was conducted by Dr. Florian Plößl (ZInstSanBW, Munich). Oily 
substances incubated with protein powder formulation (dark blue bars) and samples 
containing only oily substances (light blue bars). 
 
No significant differences between Freund’s incomplete adjuvant or paraffin oil 
incubated in combination with protein powder formulation or the oily substance by itself 
was observed, regardless whether the samples were stressed with H2O2 or NaOH 
(figure 6.32). 
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Due to the chemical structure of both, Freund’s incomplete adjuvant and paraffin oil, 
degradation due to UV-light stress or heat stress was not expected. 
 
3.3.1 STABILITY OF OVALBUMIN IN A TREHALOSE/MANNITOL FORMULATION IN THE PRESENCE 
OF FREUND’S INCOMPLETE ADJUVANT 
Size exclusion chromatography was applied to evaluate the formation of soluble and 
insoluble aggregates (using the recovery data), and FTIR transmission spectroscopy 
was applied to assess potential changes in the secondary structure of ovalbumin after 
incubation with Freund’s incomplete adjuvant for 12 weeks at elevated temperatures.  
Figure 6.33 A-C displays the remaining monomer, total protein recovery as well as the 
recovery of the different protein species by size exclusion chromatography.No 
significant changes in soluble monomer recovery as well as total protein recovery were 
observed after 12 weeks of storage at 2-8°C and 25°C (figure 6.33 A and B). However, 
the formation of higher molecular weight aggregates was observed after 8 and 12 
weeks of storage at 40°C (4.0% after 8 weeks and 4.5% after 12 weeks in comparison 
to initially 2.9%) (figure 6.33 C). 
The second derivate FTIR-transmission spectra of the samples incubated with Freund’s 
incomplete adjuvant are depicted in figure 6.33 D. After storage at 25°C and 40°C, 
respectively, the intensity of the 1638 cm-1 band of ovalbumin was decreased and the 
bands were shifted to lower wavenumbers. This indicated a thermally induced 
conformational change in the ß-sheet structures of ovalbumin [22]. The onset of protein 
conformational changes in samples containing Freund’s incomplete adjuvant after 8 
weeks of storage due to heat exposure supports also the findings of the size exclusion 
chromatography.  
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Figure 6.33: Higher molecular weight aggregates (black bars), dimers (light grey bars) 
and fragment (dark grey bars) protein species [%], total monomer recovery [%] (filled 
circles) and total protein recovery [%] (open circles) as determined by size exclusion 
chromatography. Samples were incubated with Freund’s incomplete adjuvant at 2-8°C 
(A), 25°C (B) and 40°C (C). Area-normalized 2nd derivative FTIR transmission spectra of 
samples incubated with Freund’s incomplete adjuvant (D). 
 
Table 6.11: Cumulative particle counts > 10 and 25 µm per mL of samples incubated with 
Freund’s incomplete adjuvant after 12 weeks of storage at 2-8°C, 25°C and 40°. Samples 
were reprocessed as described in chapter 3.1 in MTBE and were vacuum dried prior to 
analysis. 
 
after 12 weeks of 
storage at 2-8°C 
after 12 weeks of 
storage at 25°C 
after 12 weeks of 
storage at 40°C 
particles > 10 µm per mL ± SD 2407 ± 184 1746 ± 198 1460 ± 79 
particles > 25 µm per mL ± SD 149 ± 32 109 ± 45 81 ± 8 
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Figure 6.34: Cumulative particle counts > 1 µm per mL of samples incubated with 
Freund’s incomplete adjuvant (A) and turbidity levels (B) after 12 weeks of storage at 2-
8°C (grey bars), 25°C (dark grey bars) and 40°C (black bars). Samples were reprocessed 
as described in chapter 3.1 in MTBE and were vacuum dried prior to analysis. 
 
Figure 6.34 A and table 6.11 show cumulative particle counts of samples incubated with 
Freund’s incomplete adjuvant as determined by light obscuration. The formation of 
particles could not be observed in samples incubated with Freund’s incomplete 
adjuvant. However, an increase in turbidity levels was visible after storage at 40°C, with 
an onset after 2 weeks (figure 6.34 B). This was consistent with the results obtained by 
size exclusion chromatography. 
 
Table 6.12: Physicochemical properties of trehalose-mannitol samples stored in the 
presence of Freund’s incomplete adjuvant as determined by differential scanning 
calorimetry after storage at 2-8°C, 25°C and 40°C for 12 weeks. 
formulation 
storage 
temperature  
storage time 
[weeks] 
Tg [°C] ± SD ∆ Cp [J/g*K] 
± SD 
characteristic melting 
endotherms [°C] ± SD 
Freund’s 
incomplete 
adjuvant 
- 0 76.4 ± 0.6 0.556 ± 0.041 133.9 ± 6.1 146.4 ± 4.9 
2-8°C 
8 63.3 ± 0.5 0.317 ± 0.029 137.1 ± 0.2 149.4 ± 0.2 
12 59.3 ± 2.4 0.320 ± 0.015 136.8 ± 0.3 149.1 ± 0.3 
25°C 
8 52.4 ± 3.6 0.283 ± 0.039 135.1 ± 1.1 148.2 ± 1.1 
12 58.7 ± 0.5 0.339 ± 0.021 135.2 ± 0.5 149.0 ± 0.5 
40°C 
8 50.1 ± 6.2 0.279 ± 0.009 134.9 ± 1.9 147.0 ± 1.8 
12 54.8 ± 1.0 0.334 ± 0.064 135.9 ± 0.4 148.4 ± 0.4 
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Figure 6.35: Residual moisture levels of trehalose-mannitol samples containing 
ovalbumin stored at 2-8°C (black bars), 25°C (light grey bars) and 40°C (dark grey bars) 
for 12 weeks in the presence of Freund’s incomplete adjuvant. 
 
Residual moisture levels of the samples incubated with Freund’s incomplete adjuvant 
did just slightly increase after 4 weeks of storage at 40°C (figure 6.35), similarly to the 
residual moisture levels of samples stored without the presence of any oily substances. 
Changes in particle morphology were monitored by differential scanning calorimetry. 
Glass transition values decreased during storage with increasing temperature (table 
6.12), which was in accordance with a slight increase in residual moisture (figure 6.35). 
The glass transition temperature of lyophilized products can be lowered by 10K for each 
percent of moisture in the product, as water acts as plasticizer [24]. 
The two characteristic melting endotherms of mannitol in the range of 133.9 to 137.1 °C 
and 146.6 to 149.4 °C in the DSC thermograms (table 6.12) for samples stored in the 
presence of Freund’s incomplete adjuvant did not vary in comparison to samples stored 
without the presence of any oily substance (table 6.4). 
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3.3.2 STABILITY OF OVALBUMIN IN A TREHALOSE-MANNITOL FORMULATION IN THE PRESENCE 
OF PARAFFIN OIL 
Size exclusion chromatography was performed to investigate the protein stability of 
trehalose-mannitol samples containing ovalbumin stored in the presence of paraffin oil 
(figure 6.36). Samples were reprocessed prior to analysis with MTBE as described 
before. Only a slight decrease in total protein recovery could be observed after 12 
weeks of storage at 40°C (figure 6.36 C).  
 
Figure 6.36: Higher molecular weight aggregates (black bars), dimers (light grey bars) 
and fragment (dark grey bars) protein species [%], total monomer recovery [%] (filled 
circles) and total protein recovery [%] (open circles) as determined by size exclusion 
chromatography. Samples were incubated with the oily components of MF59 at 2-8°C (A), 
25°C (B) and 40°C (C). Area-normalized 2nd derivative FTIR transmission spectra of 
samples incubated with paraffin oil (D). 
CHAPTER 6 
 
187 
 
Figure 6.36 D shows the second derivative spectra of ovalbumin after storage in the 
presence of paraffin oil. Shifts to lower wavenumbers were observed for the bands at 
1635/1638 cm -1 and 1655/1657 cm -1 bands, indicating a decrease in conformational 
stability of ovalbumin if stored together with paraffin oil.  
Figure 6.37 shows the turbidity levels and the formation of particles determined by light 
obscuration of samples incubated in the presence of paraffin oil. No remarkable 
changes were observed in the turbidity levels as well as in the cumulative particle 
counts > 1 µm (figure 6.37) per mL, > 10 µm per mL and > 25 µm per mL (table 6.13) 
after storage at 2-8°C, 25°C or 40°C for 12 weeks. An increase in turbidity as well as in 
the cumulative particle counts was observed after 2 weeks of storage at 25°C and 40°C, 
however, these results could not be confirmed after 4, 8 and 12 weeks of storage.  
 
 
Figure 6.37: Cumulative particle counts > 1µm per mL of samples incubated with paraffin 
oil (A) and turbidity levels (B) after 12 weeks of storage at 2-8°C (grey bars), 25°C (dark 
grey bars) and 40°C (black bars). Samples were reprocessed as described in chapter 3.1 
in MTBE and were vacuum dried prior to analysis. 
 
A slight increase in the residual moister levels in samples incubated with paraffin oil was 
observed during storage (figure 6.38), though being consistent with the residual 
moisture levels of trehalose-mannitol formulations containing ovalbumin, which were 
stored without the presence of an oily substance in reference (figure 6.17). 
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Table 6.13: Cumulative particle counts > 10 and 25 µm per mL of samples incubated with 
paraffin oil after 12 weeks of storage at 2-8°C, 25°C and 40°C. Samples were reprocessed 
as described in chapter 3.1 in MTBE and were vacuum dried prior to analysis. 
 
after 12 weeks of 
storage at 2-8°C 
after 12 weeks of 
storage at 25°C 
after 12 weeks of 
storage at 40°C 
particles > 10 µm per mL ± SD 2556 ± 274 2119 ± 37 1953 ± 62 
particles > 25 µm per mL ± SD 154 ± 21 138 ± 20 124 ± 15 
 
 
Figure 6.38: Residual moisture levels of trehalose-mannitol samples containing 
ovalbumin stored at 2-8°C (black bars), 25°C (light grey bars) and 40°C (dark grey bars) 
for 12 weeks in the presence of paraffin oil. 
 
Table 6.14: Physicochemical properties of trehalose-mannitol samples stored in the 
presence of paraffin oil as determined by differential scanning calorimetry after storage 
at 2-8°C, 25°C and 40°C for 12 weeks. 
formulation 
storage 
temperature  
storage time 
[weeks] 
Tg [°C] ± SD ∆ Cp [J/g*K] 
± SD 
characteristic melting 
endotherms [°C] ± SD 
paraffin oil 
- 0 63.1 ± 0.8 0.305 ± 0.015 137.0 ± 0.3 149.4 ± 0.2 
2-8°C 
8 59.6 ± 6.0 0.237 ± 0.030 137.6 ± 1.0 150.1 ± 1.4 
12 60.6 ± 1.1 0.308 ± 0.016 136.8 ± 0.7 149.2 ± 0.7 
25°C 
8 57.5 ± 0.0 0.320 ± 0.002 137.4 ± 1.6 149.9 ± 1.3 
12 61.0 ± 2.5 0.322 ± 0.027 136.4 ± 0.6 147.8 ± 1.7 
40°C 
8 55.7 ± 0.6 0.267 ± 0.038 135.3 ± 2.1 147.8 ± 1.7 
12 58.0 ± 2.7 0.301 ± 0.018 135.6 ± 0.5 148.6 ± 0.3 
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Changes in particle morphology of trehalose-mannitol samples containing ovalbumin 
incubated together with paraffin oil were also investigated by differential scanning 
calorimetry. Glass transition values decreased only marginally during storage at 25°C 
and 40°C after 12 weeks of storage, which is in accordance with a slight increase in 
residual moisture (table 6.14). However, glass transition temperatures of the samples 
were still above the highest storage temperature at 40°C, indicating good storage 
stability of the formulation. 
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3.4 SUMMARY AND CONCLUSION 
The storage stability and possible interaction between oily adjuvants and ovalbumin 
loaded powder particles was investigated in a short term stability study at elevated 
temperatures. Prior to analysis a reprocessing step of the samples was necessary. The 
samples were washed three times with MTBE and the powder pellet was subsequently 
vacuum dried. This was effective to separate the oily substances from the protein 
powder and a mandatory step prior to the assessment of protein stability using 
established analytical methods, as the oily substances did interfere with the analytical 
methods. Size exclusion chromatography of the reprocessed samples showed, that 
MTBE did not affect protein integrity. Turbidity measurements and the assessment of 
the cumulative particle counts of the reprocessed samples revealed, that it was not 
possible to remove the oily substances quantitatively, however, to an adequate level in 
order to assess protein stability.  
An accelerated stress test, inducing UV-light stress, heat stress and chemical stress 
showed that the oily components of MF59 and squalene were both highly sensitive to 
UV-light exposure and heat stress. Squalane was not sensitive to the applied stress 
conditions, contrary to squalene and MF59, which are both subjected to auto-oxidation 
[11, 12]. The surfactants polysorbate 80 and Span® 85, which are both ingredients in 
the mixture of the oily components of MF59, are known to be sensitive to oxidative 
stress, which is further promoted by heat stress [25, 26]. The recovery of the mixture of 
the oily components of MF59 decreased dramatically, up to 50%, after incubation with 
ovalbumin containing trehalose-mannitol particles at 40°C for eight weeks. As only a 
slight decrease in the recovery of the oily components of MF59 was observed when 
incubated without the presence of the powder particles, the loss in recovery could be 
addressed to an interaction between the oily components of MF59 and the powder 
particles. This was also supported by size exclusion chromatography, FTIR 
measurements as well as by light obscuration and turbidity measurements of the 
samples. Only marginal alterations in the recovery of squalene were observed after 
storage of the samples at 40°C for 12 weeks. However, squalene in combination with 
ovalbumin containing trehalose-mannitol particles showed a slight decrease in squalene 
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recovery after four weeks of storage at 40°C. This trend was further reflected by size 
exclusion chromatography, light obscuration and turbidity measurements. The 
secondary structure of ovalbumin was not altered when incubated with squalene. 
Particle morphology regarding residual moisture and physicochemical properties of the 
powder were comparable to samples stored without the presence of squalene.  
Freund’s incomplete adjuvant was not sensitive towards chemical stress. However, size 
exclusion chromatography showed a slight increase in higher molecular weight 
aggregates after eight weeks of incubation at 40°C. This was also confirmed by FTIR 
and turbidity measurements, however not by light obscuration measurements. Samples 
stored in the presence of paraffin oil showed only a slight decrease in total protein 
recovery after 12 weeks of storage at 40°C. A slight decrease in conformational stability 
was observed by FTIR measurements after 12 weeks of storage at 40°C, thus 
confirming the results obtained by size exclusion chromatography. Only marginal 
changes were found in turbidity levels and cumulative particle counts as well as in 
particle morphology. As the composition of Freund’s incomplete adjuvant is mainly 
based on paraffin oil, the increase in turbidity and the formation of higher molecular 
weight aggregates in samples incubated with Freund’s incomplete adjuvant could be 
attributed to its second compound, the surfactant mannide monooleat. 
Generally, glass transition values of samples incubated with oily substances were 
slightly decreased with increasing residual moisture levels, however, to a comparable 
extent as in ovalbumin containing trehalose-mannitol samples, which were not stored in 
combination with oily substances. 
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4  FINAL SUMMARY AND CONCLUSION 
Several oily adjuvants were explored as adhesives at the interface between vaccine 
loaded particles and the surface of a ballistic device for intradermal injection. The oily 
adjuvants were intended to fulfill several requirements: first, to attach the particles safely 
during storage and handling onto the device surface and second, to release the 
particles upon actuation of the device. The oily components of MF59 and Freund’s 
incomplete adjuvant, as well as their components squalene and paraffin oil, 
respectively, showed good adherence strength when challenged by applying 
mechanical stress. Different membrane materials were explored for their use to cover 
the surface of the ballistic device, beneath aluminum showed excellent properties. The 
adherence strength of the oily components of MF59 and Freund’s incomplete adjuvant 
was also assessed after storage for 12 weeks under different temperature conditions. 
The mixture of the oily components of MF59 showed good adherence strength, 
particularly at elevated temperatures. As the particles were enclosed into a thin film of 
the oily substance, the oily substance was entrained together with the particles upon 
actuation of the device. Thus, offering the possibility to co-inject the oily substance 
together with the particles into the skin and herein to exert an adjuvant effect.  
O’Hagan et al. stated that the mechanism of action of MF59 is based on the cellular 
recruitment to the injection site, creating hereby a local immunocompetent environment 
[5, 28]. Calabro et al. found out that only the fully formulated MF59 (squalene oil, the 
surfactants Span® 85 and polysorbate 80 in citrate buffer) were able to induce innate 
and adaptive immune activation. They came to this conclusion by co-injection an 
influenza vaccine with MF59 in mice or in combination with one of the individual 
components. It is still controversy discussed, if the formation of small emulsion droplet is 
necessary for the adjuvant efficacy [5, 29-31]. The feasibility that vaccine particles, 
which are covered with oily adjuvants are presented as a microparticulate system in the 
superficial layers of the skin has to be explored in subsequent animal studies. Also the 
efficacy of the co-injection of the oily substance as well as its adjuvant effect when 
applied into the skin has still to be proven. 
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In addition to the experiments investigating the adherence strength of particles at the 
interface to the device surface, the storage stability and possible interaction between 
selected oily substances and ovalbumin loaded powder particles was explored in a 
short term stability study at elevated temperatures. 
In summary, HP-SEC and FTIR-spectroscopy demonstrated that protein integrity was 
kept during storage at 40°C for 12 weeks if samples were incubated with squalane, 
squalene, or paraffin oil. Only a slight decrease in protein stability was found for 
samples incubated with Freund’s incomplete adjuvant. In contrast, the occurrence of 
higher-ordered aggregates and significant perturbations of the secondary protein 
structure was observed after a minimum incubation time of 8 weeks at 40°C in samples 
incubated with the oily components of MF59. Therefore, the application of its 
component squalene should be given preference, when incubated at accelerated 
temperatures. 
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CHAPTER 7 
 
DEVICE DEVELOPMENT 
 
1 INTRODUCTION 
 
Vaccines are commonly delivered by injection through conventional needles. Whilst this 
method is widely practised, the use of hypodermic needles holds the risk of 
transmission of blood borne diseases like HIV and hepatitis by needle-stick injuries or 
reuse of needles [1]. Therefore, novel needle-free technologies offer a safe and 
effective method for vaccination. 
The skin is an attractive target for vaccine delivery, as the epidermal layer of the skin 
comprises a dense population of immunocompetent cells, which are able to trigger an 
appropriate immune reaction [2-4]. The lack of vasculature and the low density of 
sensory nerve endings in the epidermal layer of the skin provide the opportunity for 
save and painless vaccine administration [5]. One major challenge for targeting this skin 
site is its accessibility The low thickness of this tissue layer of about 50–100 µm makes 
the deposition of an accurate vaccine dose difficult [2]. Ballistic particle injection is a 
needle-free injection method accelerating dry particles, so that they penetrate the 
stratum corneum and are deposited in the epidermis or the superficial layers of the 
dermis [2]. The use of dry vaccine formulation provides enhanced stability and thus 
avoids the need of a cold chain for drug supply [6-8]. Hence, dry vaccine formulations 
offer an economic alternative which can cover the supply of a broad population. Delivery 
of powder particles into superficial skin layers by entrapping the particles into a helium 
gas flow [9-12] was reported in literature and showed promising results in preclinical 
and clinical trials [12-15]. Hereby DNA or protein based vaccine antigens were 
precipitated onto gold particles or formulated with sugar excipients into powder particles 
and were injected into the skin [5, 12, 16-18]. The use of medical grade helium gas or 
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gold particles, however, makes the competitiveness of these devices with single use 
syringes questionable. 
The effectiveness of ballistic particle injection depends on different parameters. These 
include the performance of the delivery device, the device-target interaction and diverse 
particle parameters, such as the shape of the particles, their density and size, velocity, 
impact on the skin surface, penetration of the particles as well as their distribution in the 
epidermal layer of the skin.  
In this study a novel principle of particle acceleration to deliver vaccine loaded powder 
particles by a needle-free approach was investigated. In this approach particles were 
not entrapped in a gas stream but accelerated by momentum transfer. Therefore a 
surrogate apparatus, the Lell’s Foucault accelerator (LWB), was evaluated in 
preliminary experiments to determine different parameters mandatory for the 
development of new devices for epidermal ballistic powder injection. The effective 
application of a pharmaceutical by ballistic injection requires a thorough understanding 
of the delivery device, the physical properties of the formulation as well as the functional 
interaction of both. A method to determine the velocity of particles, the dependency of 
particle velocity on major particle parameters like size and density as well as a method 
to load the device with particles were established.  
The penetration of particles into model gelatine gels imitating the mechanical properties 
of skin [19] was explored in order to determine the threshold velocity to breach the 
outermost layers of the skin. The collected information of the preliminary experiments 
was transferred on the development of a pyrotechnically driven delivery device. After 
optimization of the pyrotechnically driven device, proof of concept was showed in ex-
vivo excised pig skin. 
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2  EVALUATION OF A SURROGATE APPARATUS FOR THE BALLISTIC 
ACCELERATION OF PARTICLES 
 
The surrogate apparatus used in the following study, Lell’s Foucault accelerator (LWB 
3/20 kV, Pyroglobe, Hettenshausen, Germany), was invented and built by Dr. Lell. All 
experiments were carried out cooperatively with Dr. Lell and his team.  
The technical know-how was contributed by Dr. Lell. 
 
2.1 THE FUNCTIONAL PRINCIPLE OF LELL’S FOUCAULT ACCELERATOR 
Lell’s Foucault accelerator is a custom made apparatus that can be used i.a. for the 
evaluation of parameters necessary for the development of needle-free ballistic injection 
devices. A schematic setup of the Lell’s Foucault accelerator is depicted in figure 7.1.  
 
 
Figure 7.1: Schematic illustration of the experimental set-up of the acceleration of the 
particles using an electromagnetic coil actuated with Lell’s foucault-current accelerator 
(LWB). 
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The functional principle of the Lell’s Foucault accelerator can be described as follows. A 
capacitor bank serves as electrical current source for the system. The repulsive force to 
accelerate particles is generated by a magnetic field in an electromagnetic helical coil, 
which induces a turbulent electrical current in a metal carrier. Aluminum disks (Al-disk) 
with a diameter of 30 mm, a punched hole in the middle of the disk with 10 mm diameter 
and disk thickness of 0.5 mm or 1.0 mm are used as metal carriers. The surface of the 
metal carriers was loaded with particles. Upon acceleration, the aluminum disk was 
abruptly stopped by a stopper plate, while the particles on the disk surface continued 
their flight course through holes in the stopper plate and flew towards a target (figure 7.1 
and 7.2).  
 
 
 
Figure 7.2: Schematic illustration of an Al-disk (A) and (B) of a stopper plate. 
 
2.2 VELOCITY MEASUREMENT OF AL-DISKS 
In order to determine the velocity of the carrier plates/Al-disks a Flash Cam PCO high 
speed camera was attached to the LWB. The triggering points of the LWB and the high 
speed cameras were controlled by a programmable 20 MHz function generator and 
initiated by a photo flash (Metz, Zirndorf, Germany). After receiving the trigger signal of 
the LWB upon actuation, the camera took several pictures in series in a certain 
timeframe. The timeframe was given by the interval of shots (in µs) of the high speed 
camera. The velocity of the Al-disks was calculated from the distance between two 
disks in the serial pictures divided by the timeframe between these two pictures. The 
distance between the disks was calibrated using a scale (figure 7.3). 
A B 
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Figure 7.3: Determination of the velocity of Al–disks using a Flash Cam PCO high speed 
camera. The distance between the disks was measured by aligning the distance to a 
scale. A serial picture of an Al-disk during flight is depicted in (A). The scale for the 
calibration of the distance is depicted in (B). 
 
 
Figure 7.4: Velocity measurement of 0.5 mm (black dots) and 1.0 mm (white dots) Al-
disks as a function of the voltage of the capacitor bank determined using a Flash Cam 
PCO high speed camera (average +/- SD, n=3). 
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The velocity of aluminum disks, accelerated at a pre-selected voltage of 6 kV up to 
12 kV on the LWB, was determined (figure 7.4). Aluminum disks with 0.5 mm and 
1.0 mm thickness were used.  
It was observed that the velocity of the Al-disk was dependent on the mass of the disk. 
Al-disks with a thickness of 1.0 mm had a higher mass and hence, a different velocity 
profile than Al-disk with a thickness of 0.5 mm. Aluminum disks with 0.5 mm were 
accelerated up to 136 m/s at 12 kV. Aluminum disks with 1.0 mm were accelerated up 
to 82 m/s at 12 kV. A linear regression was observed between the velocity of the AL-
disks and the voltage of the capacitor bank. 
The method to determine of the disk velocity using the high speed camera was 
appropriate, as the standard deviations of the triplicate measurement varied between 0 
and 3 m/s. 
 
2.3 FIXATION OF PARTICLES ON AL-DISKS PRIOR TO ACCELERATION 
Particles were fixed on Al-disks by covering the disks with a thin layer of adhesive as 
outlined in chapter 6. The amount of adhesive as well as the weight of the particles was 
determined gravimetrically. Figure 7.5 depicts exemplarily glass particles of 40 – 63 µm 
size on an Al-disk adhered with a thin layer of paraffin. In the following velocity 
measurements of particles were carried out using paraffin as type of adhesive if not 
stated otherwise. 
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Figure 7.5: Microscopic photograph of glass particles (fraction 40 - 63 µm) on an Al-disk 
(d = 0.5 mm) using a Keyence VHX-500 F microscope. A: Magnification 100 x 50. B: 
Magnification 100 x 500. 
 
2.4 VELOCITY MEASUREMENT OF PARTICLES 
The velocity of particles and powders in the µm-range respectively, was measured 
using a set of two synchronised Flash Cam PCO high speed cameras (PCO, Kehlheim 
am Ufer, Germany). As powders in the µm-range cannot be singularized in individual 
particles macroscopically, the powder cloud was examined. The cameras were 
positioned in a 90° angel to each other. The setup of the LWB and the high speed 
cameras was actuated with a photo flash (Metz, Zirndorf, Germany). The distance of the 
particle cloud starting from the electromagnetic coil to the front line of the powder cloud, 
was calibrated using a scale, analogue to the velocity measurement of the Al-disks. The 
velocity of the powder cloud was calculated by the distance travelled of the powder 
cloud (determined from two pictures taken by the synchronised high speed cameras 
and aligned with the scale) divided by the timeframe between the first and the second 
camera (figure 7.6).  
The velocity of the particle cloud was calculated according to equation (7.1): 
velocity m/s = 
flight distance particle cloud #1 m 	- flight distance particle cloud #2 [m]
time of actuation camera #1 s 	- time of actuation camera #2 [s]
																		 7.1  
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Figure 7.6: Determination of the velocity of particles using two synchronised Flash Cam 
PCO high speed cameras. (A) and (B) depict two pictures of a particle cloud taken by 
camera #1 (A) 25 µs and camera #2 (B) 100 µs after actuation of the LWB. The distance 
from the stopper plate to the particle cloud (indicated by the arrows) was measured for 
each picture using a calibrated scale (C). The flight distance of the particle cloud was 
calculated as the deviation of both. Velocity of the particle cloud was calculated by the 
quotient of the flight distance and the therefore required time. 
 
2.5 PRELIMINARY EXPERIMENTS: DEPENDENCY OF PARTICLE VELOCITY ON PARTICLE 
PARAMETERS 
One major aim of the study using the LWB was to experimentally evaluate the 
dependency of particle velocity on major particle parameters like size and density.  
Firstly, regularly shaped round polystyrene and glass particles were used as model 
particles to investigate the influence of particle size and density on particle velocity as 
they are known for their well- characterized and reproducible physical properties (figure 
7.7). Secondly, the behaviour of irregularly shaped sugar particles upon acceleration 
was investigated. Table 7.1 summarize the different particle parameters. 
 
 
Figure 7.7: Digital micrographs of glass particles (density 2.5 g/cm³, 20-40 µm) (A), freeze-
dried and subsequently cryo-milled sugar particles (density 1.45 g/cm³, 20-40 µm)(B) and 
(C) blue polystyrene particles (density 1.1 g/cm³, 40 µm. Scale bar 25 µm. 
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Table 7.1: Size and density of different types of particles 
Particles size [µm] density [g/cm³] 
glass  20-40 2.5 
glass  40-63 2.5 
glass  63-70 2.5 
hollow glass  11 1.1 
hollow glass  18 0.6 
sugar 20-40 1.45 
sugar 40-63 1.45 
polystyrene 20 1.1 
polystyrene 40 1.1 
polystyrene 60 1.1 
 
Figure 7.8 depicts the velocity of polystyrene particles upon acceleration at 12 kV using 
the LWB equipped with an electromagnetic coil made of a 1.12 mm copper wire and 
6*11 windings. Particle velocity was measured using a set of two synchronised Flash 
Cam PCO high speed cameras as described before. Clearly, the velocity of polystyrene 
particles increased with increasing size of the particles. Contrary to our findings Kendall 
et al. observed that smaller particles were accelerated to higher velocity using a needle-
free device where particles were entrained in a high-speed gas flow [3]. As expected, 
particle kinetics is subjected to the kind of acceleration and hence differs basically from 
delivery device to delivery device. 
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Figure 7.8: Velocity measurements of polystyrene particles (density 1.1 g/cm³). Particles 
were accelerated at 12 kV using the LWB and an electromagnetic coil made of a 1.12 mm 
copper wire and 6*11 windings (average +/- SD, n=2). 
 
Hollow glass particles with different density and size were used to evaluate their 
influence on particle velocity. A pre-selected voltage of 12 kV was adjusted at the LWB. 
The velocity of glass particles depends on both, size and density of the particles (figure 
7.9). An increase of particle velocity was observed with increasing density and size of 
the particles. However, overlapping effects of size and density have to be taken into 
consideration. Glass particles of 18 µm diameter sizes had a density of 0.6 g/cm³ and 
were therefore accelerated to lower velocity than particles of 11 µm diameter size and 
1.1 g/cm³ density. No linear correlation was found between density of the particles and 
particle velocity. 
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Figure 7.9: Influence of particle size and density on the velocity of glass particles. 
Particles were accelerated at 12 kV using the LWB and an electromagnetic coil made of a 
1.12 mm copper wire and 6*12 windings (average +/- SD, n=3). 
 
The kinetics of irregularly shaped sugar particles upon acceleration was compared to 
spherical glass particles. Sugar particles were obtained by collapse-freeze drying and 
subsequent cryo-milling of trehalose-mannitol lyophilizates as described in chapter 4. 
Due to kind of the manufacturing process of the sugar particles, it was not possible to 
separate single particles of defined size for the experiments. Therefore, defined particle 
fractions of the sugar particles in the range of 20-40 µm and 40-63 µm were generated 
by sieving of the cryo-milled particles using custom made stainless steel sieves. 
Likewise, comparable size fractions of spherical glass spheres were generated. Figure 
7.10 depicts the velocity of non-spherical sugar particles next to spherical glass 
particles after acceleration of the particles at 12 kV using the LWB. 
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Figure 7.10: Velocity measurements of glass and sugar particles, accelerated at 12 kV 
using the LWB and an electromagnetic coil made of a 1.12 mm copper wire and 6*12 
windings (average +/- SD, n=3). 
 
Velocity of both particle populations showed an increase with increasing size of the 
particles. Glass particles could be accelerated to slightly higher velocity due to their 
higher density with 2.50 g/cm³ in comparison to 1.45 g/cm³ of the sugar particles. The 
difference in the velocity of regularly round shaped glass particles and angular shaped 
sugar particles was too small to draw conclusion regarding the influence of the shape of 
particles on particle velocity. 
Generally, at least two forces act on the particle during acceleration. The kinetic energy 
which drives the particle towards the target and the ambient resistance force acting 
against it. The kinetic energy of the particle is proportional to the volume of the particle 
(equation 7.2) whereas resistance force of the particle is proportional to the cross-
sectional area of the particle (equation 7.3).  
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Hence, larger particles of a population with equal density can store more kinetic energy 
and fly faster. 
	E 	~		V 	~	r 																																																																																																																																			 7.2  
F 	~		A 	~	r 																																																																																																																														 7.3  
Figure 7.11 shows the velocity profiles of glass and sugar particles accelerated at pre-
selected voltages of 6 to 12 kV. Sugar particles show similar velocity profiles to glass 
particles ranging from 42.5 to 123.0 m/s and 51.5 to 147.4 m/s, respectively, depending 
on the pre-selected voltage of the capacitor bank. Sugar particles reach in general lower 
absolute velocities due to their lower density. Interestingly, the difference in the absolute 
velocity between glass and sugar particles was higher the higher the pre-selected 
voltage of the capacitor bank was. Though a linear correlation can be drawn between 
the velocity of particles and the pre-selected voltage of the LWB, comparison of the 
velocity of different particles can only be made at pre-defined acceleration conditions. 
 
Figure 7.11: Velocity measurement of sugar particles (black dots) and glass particles 
(white dots) as a function of the voltage of the capacitor bank of the LWB determined 
using a Flash Cam PCO high speed camera (average +/- SD, n=3). 
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The influence of the type of adhesive on the velocity of glass particles was determined 
in the same manner. Approximately 5 µl of the oily components of MF59, silicon oil or 
paraffin oil were used to cover the Al-disks. Glass particles with a diameter range of 20 
to 40 µm and 2.5 g/cm³ density were fixed with the different adhesives onto 0.5 mm 
thick aluminum disks and accelerated using the LWB at pre-selected voltages of 6 to 
12 kV. 
 
Figure 7.12: Velocity of glass beads (fraction 20-40 µm) fixed with different adhesives 
onto 0.5 mm thick aluminum disks. Filled circles represent samples fixed with the oily 
components of MF59. Open circles represent samples fixed with paraffin oil. Filled 
triangles represent samples fixed with silicon oil. Open triangles represent samples fixed 
without the use of an adhesive. Particles were accelerated at 12 kV using the LWB and an 
electromagnetic coil made of a 1.12 mm copper wire and 6*12 windings (average +/- SD, 
n=3). 
 
No differences in the velocity of glass particles were observed using either the oily 
components of MF59, paraffin oil or silicon oil as adhesive (figure 7.12). Deviations in 
the velocity of samples attached on Al-disks without the use of an adhesive were 
observed at 8 and 10 kV. These differences are most probably attributed to uneven 
distribution of the glass particles on the Al-disks. 
CHAPTER 7 
211 
 
2.6 FURTHER OPTIMIZATION STEPS OF THE SET-UP OF THE LWB 
Several development steps were made on the geometry of the electromagnetic coils 
connected with the LWB as described in section 2.3 in order to increase the velocity of 
particles. Hereby, particle velocity could be increased to a maximum of 275 to 300 m/s 
at 18 kV.  
Due to the escalation of particle and Al-disk velocity and Al-disks were pushed through 
the holes of the stopper plate at 300 m/s. Therefore the geometry of the stopper plate 
had to be adjusted once more. The new geometry of the stopper plate featured three 
holes of each 3 mm diameter, thus providing a larger contact face for the Al-disks but at 
the same time offering equal loading area for the particles. 
Dependent on the shape of the stopper plate the resolution of the particle clouds varied. 
Using the stopper plate with two rectangular holes, two separate particle clouds 
appeared on the images of the high speed cameras (figure 7.13 A). If the velocity of the 
particles exceeded 250 m/s, velocity calculation was performed using a single 600 µm 
glass sphere in favour of a better resolution of the high speed camera images. Particle 
velocity > 250 m/s was determined analogue to the velocity measurement of the Al-
disks as described before. Hence, high speed camera shots of velocity measurements 
using a stopper plate with 3 holes display an overlapped serial picture of a single glass 
sphere as depicted in figure 7.13 B.  
 
 
A B 
Figure 7.13: Determination of the velocity of glass particles using a Flash Cam PCO high
speed camera. (A) depicts two clouds of glass beads corresponding to the geometry of
the stopper plate. (B) depicts a serial picture of a 800 µm glass sphere during flight. 
DEVICE DEVELOPMENT  
 
212 
 
A further attempt to increase the performance of the LWB was the reduction of the mass 
of the Al-disks by broadening the inner diameter of the Al-disk, as the magnetic 
repulsive force generated act mainly on the outer border of the Al-disk. An increase in 
particle velocity to 400 m/s was achieved, however also the Al-disk was destroyed and 
felt apart into pieces. Hence, the use of Al-disks with reduced inner diameter was not 
feasible. 
In summary the experimental setup of the LWB provided a reliable method to evaluate 
the relationship between the velocity of particles and different particle parameters. 
Hence, it is a unique tool for the evaluation of new delivery devices as well as for the 
evaluation of the physical properties of new vaccine formulations intended for ballistic 
powder injection However, the LWB was limited to a maximal achievable particle 
velocity of 300 m/s. 
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3  IN-VITRO PENETRATION OF PARTICLES INTO GEL MODELS AND PIG SKIN 
AFTER BALLISTIC ACCELERATION USING THE LWB 
 
For a thorough understanding of device and target interaction penetration depth of 
particles accelerated by the LWB towards different model gelatine gels was scrutinized.  
A series of gelatine gels with different mechanical properties were used in order to 
investigate the dependency of particle velocity on their penetration depth. The gels were 
developed and validated by a member of our group, Dr. Deng, in order to simulate the 
mechanical properties of the skin [19, 20].  
 
3.1 PRELIMINARY EXPERIMENTS 
Glass particles of 20-40 µm size and a density of 2.5 g/cm³ were accelerated to 137 m/s 
with the LWB as described before. Gelatine gels were placed into 1 cm distance from 
the stopper plate. Penetration depth into different types of gelatine gels (marked as gel 
A-D) with varying mechanical rigidity was measured by light microscopy. Cross sections 
of the gels after particle bombardment are depicted in Figure 7.14. 
Prior to cross-sectioning the surface of the gels were wiped in order to remove particles 
at the surface of the gels which failed to penetrate into the gels upon impact. 
Approximately 1/3 of the particles remained on the gel surface. As expected, deepest 
penetration of glass particles, with a mean penetration depth of 290 µm, was found in 
gelatine gels composed of a gelatine/glycerol mix (w/w) ratio of (3.5/6.5) with lowest 
mechanical rigidity (gel A) (figure 7.15). A mean penetration depth of 112 µm was found 
in gels composed of a gelatine/glycerol mix (w/w) ratio of (5/5). The higher the 
mechanical rigidity of the gels, the lower was the penetration depth and number of glass 
particles found in the gels. 
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Figure 7.14: Gelatine gels composed of different mix-ratios of gelatine and glycerol, with 
different mechanical rigidity rising from A to D: Gel A: gelatine/glycerol (w/w) ratio 
(3.5/6.5), Gel B: gelatine/glycerol (w/w) ratio (4/6), Gel C: gelatine/glycerol (w/w) ratio 
(4.5/5.5), Gel D: gelatine/glycerol (w/w) ratio (5/5). The light micrographs show cross 
sections of the gelatine gels A-D after glass particle bombardment (20-40 µm) with a 
mean velocity of 137 m/s. Penetrations depth of model particles in gel models was 
determined by digital light microscopy. Scale bars Gel A and Gel B 100 µm. Scale bars 
Gel C and Gel D 50 µm. 
 
The impact momentum of the particles necessary to penetrate into the gels depends, 
next to the size and density of the particles, on particle velocity [3]. Polystyrene 
particles, reaching 80-100 m/s, with 40 µm diameter and 1.1 g/cm³ density failed to 
penetrate into gelatine gels. Hence, the threshold of the impact monument was not 
reaches for these particles. 
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Figure 7.15: Mean penetration depth of glass particles (20-40 µm) with a mean velocity of 
137 m/s in different gelatine gels. Gelatine gels were composed of different mix-ratios of 
gelatine and glycerol, with rising mechanical rigidity from A to D: Gel A: gelatine/glycerol 
(w/w) ratio (3.5/6.5), Gel B: gelatine/glycerol (w/w) ratio (4/6), Gel C: gelatine/glycerol 
(w/w) ratio (4.5/5.5), Gel D: gelatine/glycerol (w/w) ratio (5/5). 
 
3.2 PENETRATION STUDIES IN GELATINE GELS USING THE OPTIMIZED SET-UP OF THE LWB 
Penetration studies of glass particles into gelatine gels were accomplished using the 
optimized set-up of the LWB, reaching a maximum particle velocity of 254 m/s. Gelatine 
gels were placed into 1 cm distance from the stopper plate. The penetration of 20-40 µm 
glass particles into the gels was analyzed by histological sectioning and light 
microscopy. Glass particles remaining on the gel surface were removed prior to 
sectioning. Again, approximately 1/3 of the particles remained on the gel surface. 
Despite the higher particle velocity using the optimized set-up of the LWB, glass 
particles did not penetrate deeper into more rigid gels (Gel C and Gel D). Only in gels 
with a mix ratio of gelatine/glycerol (w/w) (3.5/6.5), Gel A, an enhancement of the mean 
penetration depth was visible from 291 µm to 378 µm (figure 7.16).  
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Figure 7.16: Mean penetration depth of 20-40 µm glass particles into gelatine gels, with a 
mean velocity of 137 m/s (black bars) and 254 m/s (grey bars) in gelatine gels A, C and D. 
Gelatine gels were composed of different mix-ratios of gelatine and glycerol, with rising 
mechanical rigidity from A to D: Gel A: gelatine/glycerol (w/w) ratio (3.5/6.5), Gel C: 
gelatine/glycerol (w/w) ratio (4.5/5.5), Gel D: gelatine/glycerol (w/w) ratio (5/5). 
 
Again, polystyrene particles (40 µm) failed to penetrate into the gels. 
The results obtained from the penetration studies in gelatine gels show that there are at 
least three processes regarding particle injection to be considered. First, the 
acceleration of the particles, second the impact of the particles at the gel surface and 
their momentum needed to breach the gel surface and third, the kinetics of the 
deceleration of the particles in the gel matrix, thus determining the penetration depth of 
the particles as a function of gel rigidity. This theory is also supported by the bilayer 
approximation of the epidermis posed by Kendall et al.in a theoretical penetration model 
[21]. 
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3.3 PROOF OF CONCEPT: PENETRATION STUDIES INTO EXCISED PIG SKIN 
Polystyrene particles (40 µm, ≤ 275 m/s) failed to penetrate into the gel models, 
mimicking the mechanical properties of the skin. This indicates that the impact 
momentum of the particles was not sufficient to breach the gel surface. Proof of concept 
was performed in excised pig skin. Pig skin was chosen for the penetration studies as it 
is known from literature that abdominal and ear pig skin respectively, have similar 
mechanical properties to human skin [19].  
FITC-labeled polystyrene particles were chosen as model particles for the penetration 
studies in excised pig skin as they were firstly, easily detectable by confocal laser 
microscopy, a non-invasive detection method, and secondly, they had similar particle 
density as sugar particles. 40 µm FITC-labeled polystyrene particles were accelerated 
using the improved set-up of the LWB at 18 KV and shot into excised pig skin. The 
excised pig skin was placed into 1 cm distance from the stopper plate. Particle velocity 
of approximately 275-300 m/s was measured using a 600 µm glass sphere (density 
2.5 g/cm³). Hence, polystyrene particles may exhibited lower velocity than 275 m/s, as 
particle velocity decreases with decreased particle density and size. 
The penetration depth of the particles into excised pig skin was analyzed by confocal 
laser scanning microscopy (LSM 510 META, Carl ZEISS, Germany). The method to 
determine the depth of particles in a skin sample using CLSM analysis was validated 
and performed by Dr. Deng [20]. CLSM offers the chance to visualize thin optical 
sections through the skin without the need for physical sectioning.  
Prior to analysis, the skin was rinsed with water and wiped with paper tissue in order to 
remove not penetrated particles from the skin surface. CLSM micrographs of FITC-
labeled polystyrene particles in excised pig skin are depicted in figure 7.17. 
The majority of the particles remained on the outermost barrier of the skin, the stratum 
corneum, and failed to penetrate in the epidermal and dermal layers of the skin. This is 
line with the results obtained from the penetration studies into gelatin gels.  
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Figure 7.17: CLSM images of FITC-labeled polystyrene particles in pig skin. Visualization 
of multiple depths in 5.0 µm-steps per recording. Particles penetrated in average 20-
30 µm deep into excised pig skin. Deeper slices show a decrease in fluorescence 
intensity. 
 
 
Figure 7.18: CLSM images of FITC-labeled polystyrene particles in pig skin. Visualization 
of multiple depths in 5.0 µm-steps per recording. FITC-polystyrene particles are located 
string in line in an average penetration depth of 50 to 70 µm. 
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Figure 7.18 shows polystyrene particles string in line in an average penetration depth of 
50 to 70 µm. Due to the special formation of the particles this observation can be 
attributed to abnormalities in the skin tissue, wrinkles in the skin or due to specific 
characteristics resulting of the acceleration of the particles. Hence, a penetration of the 
particles was precluded. 
 
In conclusion, polystyrene particles with 40 µm size and < 254 m/s were not able to 
penetrate into gelatin gels or breach the stratum corneum of excised pig skin.  
Kendall et al. postulated that the penetration depth of particles into skin is a function of 
density (tap density), velocity and radius of particles [3]. They recommended a threshold 
value of 7 kg m-1 s-1 to ascertain the penetration of particles into the skin. According to 
this recommendation the threshold was undercut by the polystyrene particles with a 
value (calculated with the true density of the particles) of 5.6 kg m-1 s-1. However, the 
above mentioned theory was build up on experimental data using a needle-free injection 
device, which accelerated particles by entrapping them into a high speed helium gas 
flow [3, 22, 23]. As the device and target interaction is a determining factor for effective 
drug targeting a thorough investigation of this relationship and proof of concept is vital 
for the development of new devices for powder injection.  
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4  PYROTECHNICAL DEVICE DEVELOPMENT 
 
All device prototypes described in the following were invented and built by our 
cooperation partner Dr. Lell. The experiments were carried out cooperatively with 
Dr. Lell and his team.  
 
4.1 REQUIREMENTS ON THE PYROTECHNICAL DEVICE 
The effective application of a dry powder vaccine into the skin using a needle-free 
method depends decisively on the performance of the application device. A detailed 
literature screening and conclusions drawn out of the experiments using the surrogate 
accelerator LWB identified several requirements on the device:  
 The particle payload of the device has to be accelerated to high velocity, 
achieving a sufficient impact momentum to breach the stratum corneum of the 
skin [3, 24, 25]. Investigations with the surrogate accelerator LWB proved particle 
velocity > 300 m/s necessary for particles with low density and 20-63 µm size 
(like sugar particles).  
 The device has to hold a vaccine dose of at least 1-5 mg, which should be 
homogeneously distributed on the device surface (this aspect was already 
discussed in chapter 6 of this thesis).  
 A precise control of the location and depth of the injected particles is desirable. 
As already outlined in the introduction, the epidermal and upper dermal layers of 
the skin are low on sensory nerve endings and blood vessels and have a high 
density of immunocompetent cells. If this region is precisely targeted, an 
enhanced immune reaction can be expected [2-4]. Furthermore, by avoiding pain 
sensation and bleeding the acceptance of vaccination can be promoted among 
patients.  
 The device has to be economic and ideally be competitive with single use needle 
and syringes. Hence, a low cost production of the device is required. 
 High controllability of the escapement of the device is needed.  
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These requirements can be addressed using pyrotechnical modules in the core principle 
of the device. Pyrotechnical modules are fast, reliable, self-sustaining and independent 
of an external energy source, enabling storage, transport and distribution of the device 
at least over the shelf life of the vaccine without the need for maintenance. At the same 
time they offer maximum security as they can be designed in a manner to not explode, 
not even upon exposure to fire. The following work is based on a patent [26] of our 
cooperation partner and outlines the development of a device targeting the above 
mentioned requirements.  
 
4.2 PROTOTYPE DEVICES 
4.2.1 DEVELOPMENT OF THE GAS-CHAMBER DEVICE 
 
The core principle of the prototype device was based on the expansion of gas, which 
expanded in an airtight burning chamber (figure 7.19). The gas was produced by a gas 
producing pyrotechnical powder. Thereby, a shock pressure was transferred onto a 
membrane. Prior, glass particles were attached to the membrane. Upon actuation of the 
system particles were detached from the membrane surface and accelerated towards a 
target. 
However, the velocity of the glass particles reached only approximately 30 m/s as the 
pressure increase of the gas producing pyrotechnical powder was not fast enough to 
transfer a shock pressure onto the membrane.  
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Figure 7.19: Schematic illustration the gas chamber device.  
 
4.2.2 DEVELOPMENT OF THE LAVAL-NOZZLE DEVICE 
 
In another prototype device a Laval-nozzle was implemented on the exit of the burning 
chamber in order to accelerate the gas produced in the burning chamber towards the 
membrane with the particle payload.  
Membrane integrity could be maintained with several materials; however, none of the 
set-ups with the tested materials and material compositions were able to accelerate the 
particles to the desired velocity (> 300 m/s).  
 
4.2.3 DEVELOPMENT OF THE PROTOTYPE PYROTECHNICAL DEVICE 
The challenge to transfer a shock wave to the membrane without destroying the 
membrane of the device but accelerating the particles to high velocity was resolved in 
the prototype pyrotechnical device by (i) the implementation of a high energy gas 
generator in the device and (ii) by filling the burning chamber with an oleogel (based on 
castor oil and silicon dioxid) and (iii) by the choice of the membrane material. 
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The most important requirements on the membrane were that the material had to be as 
light as possible (low mass) and had to provide a high resistance against the pressure 
of the shock wave, which was generated in the burning chamber. Furthermore it had to 
be flexible enough to transfer the shock wave and hence the kinetic energy on the 
particles on the membrane surface. Another vital requirement of the membrane material 
was its compatibility with the pharmaceutical drug-payload. Therefore several 
membrane materials in several thicknesses and combinations of layered structures 
were investigated. Velocity measurements of different model particles using the 
prototype pyrotechnical device are exemplified in section 4.3. 
4.3 VELOCITY MEASUREMENTS OF MODEL PARTICLES USING THE PROTOTYPE 
PYROTECHNICAL DEVICE 
 
The prototype pyrotechnical device was able to generate particle velocities > 300 m/s. 
In order to reassess the accuracy of the velocity measurements of the particles, as 
described in section 1 of this chapter, a third high speed camera was implemented 
perpendicular to the other two high-speed cameras in the set-up. 
 
 
Figure 7.20: Pictures taken by a set of three Flash Cam PCO high speed cameras of a 
600 µm glass particle (2.5 g/cm³) accelerated by the pyrotechnical device. A: Camera #1 
with a time interval of 5 µs. B: Camera #2 with a time interval of 10 µs. C: Camera #3 with 
a time interval of 30 µs. 
 
Glass particles (600 µm, 2.5 g/cm³) served as model particles for the velocity 
measurements. Figure 7.20 shows a single glass particle in a serial recording after 
A B C
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acceleration by the prototype pyrotechnical device. Depending on the time interval 
between each picture (figure 7.20 A, B and C) a different median velocity of the particle 
was calculated (figure 7.21). Velocity measurement using high speed camera #1 
resulted in an average velocity of 508 ± 28 m/s. Using high speed camera #2 a velocity 
of 453 ± 35 m/s was obtained having a time interval of 10 µs between each serial 
picture. High speed camera #3 showed a mean velocity of 422 ± 41 m/s, recorded using 
a time interval of 30µs. This phenomenon correlated with the accuracy of the 
measurement.  
 
Figure 7.21: Median velocity of a 600 µm glass particle (2.5 g/cm³) after acceleration using 
the pyrotechnical device as calculated using the high-speed pictures of camera #K1, #K2 
and #K3. 
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Figure 7.22: FITC-labelled polystyrene particles (40 µm, 1.1 g/cm³) and a 600 µm glass 
particle after acceleration with the pyrotechnical device. The glass particle is flying 
slightly ahead of the polystyrene powder cloud. A: camera #1. B: camera #2. 
 
The velocity of FITC labelled polystyrene particles and sugar particles based on a 
binary mixture of trehalose and mannitol had to be calculated using the distance 
between two powder clouds divided by the time interval between the two pictures. Using 
this method, only an average velocity distribution of the particles could be calculated 
In comparison to a 600 µm glass particle, the powder cloud of particles in the lower µm-
size < 60 µm had a lower speed as the glass particle. The glass particle was flying 
ahead of the powder cloud, confirming the observations using the LWB (figure 7.22). 
Figure 7.23 shows the median velocity of glass, polystyrene and trehalose-mannitol-
particles. Glass particles had a mean velocity of 461 ± 41 m/s as calculated as the 
mean value of the three high speed camera measurements. FITC-labelled polystyrene 
particles had a velocity of 404 ± 16 m/s and trehalose-mannitol particles of 
380 ± 28 m/s.  
A B 
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Figure 7.23: Median velocity of a 600 µm glass sphere, 40 µm FITC-labelled polystyrene 
particles and trehalose-mannitol particles (20-40 µm). 
 
Though all particles were accelerated using the same conditions, particle velocity of 
polystyrene and trehalose-mannitol particles was lower as of glass particles.  
Thus, the results obtained in the preliminary investigations using the LWB were 
confirmed. As already observed at a lower velocity range, particle velocity depends on 
size and density of the particles, being still valid for high velocity ranges, breaching the 
supersonic speed barrier of 343 m/s.  
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5  IN-VITRO PENETRATION OF PARTICLES INTO EXCISED PIG SKIN AFTER 
BALLISTIC ACCELERATION USING THE PROTOTYPE PYROTECHNICAL DEVICE 
 
The penetration pattern and depth of FITC-labelled-polystyrene-particles into excised 
pig skin using the prototype pyrotechnical device was investigated by confocal laser 
scanning microscopy (LSM 510 META, Carl ZEISS, Germany) and verified by cryo-
sectioning. The skin was rinsed with water and wiped with paper tissue in order to 
remove not penetrated particles from the skin surface, prior to CLSM and histological 
analysis. The method to determine the depth of particles in a skin sample using CLSM 
analysis was validated and performed by Dr. Deng [20] as described before. 
Prior to bombardment of the skin section particle velocity was determined using three 
synchronized Flash Cam PCO high speed cameras. FITC-labelled polystyrene particles 
had a velocity of 404 ± 16 m/s.  
5.1 CONFOCAL LASER SCANNING MICROSCOPY (CLSM) 
 
The CLSM pictures showed a dense impact of a large number of particles in the upper 
layer of the skin (figure 7.24). A red fluorescent dye (TRITC) was used to indicate the 
rough skin surface [20]. Yellow spots appeared upon overlapping areas of the red 
(TRITC) and green (FITC) fluorescent dyes. Optical sectioning in 10 µm steps showed a 
penetration of particles up to 30 to 40 µm depth. Hence, particles breached the stratum 
corneum of the skin (figure 7.25). Deeper located particles were not observed. 
 
In conclusion, FITC-labelled polystyrene particles (40 µm diameter and 1.1g/cm³ 
density) accelerated to a mean velocity of 404 ±16 m/s overstepped the threshold to 
breach the stratum corneum of the skin. Thus, these results confirm the theory that a 
threshold value of at least 7 kg m-1 s-1, calculated from the density, velocity and radius 
of the particles, is needed to penetrate into the skin [3]. According to this function a 
value of 9 kg m-1 s-1 was achieved (calculated using the true density of the particles).  
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Figure 7.24: CLSM pictures of excised pig skin after bombardment with FITC-labeled 
polystyrene particles (40 µm). Skin surface was marked with red fluorescent dye (TRITC). 
Top view of the skin surface and orthogonal sections are shown. 
 
Figure 7.25: Penetration of 40 µm FITC-labelled polystyrene particles into excised pig 
skin as determined by CLSM measurement. Skin surface was marked with red 
fluorescent dye (TRITC). Visualization of multiple depths in 10.0 µm-steps per recording. 
Mean penetration depth 30-40 µm. 
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Though the above mentioned thesis was drawn out of experimental data using a 
needle-free injection device accelerating particles by entrapping them into a high speed 
helium gas flow [3, 22, 23], the obtained data indicate that this function is also valid 
using the prototype pyrotechnical device, accelerating particles by momentum transfer 
in a static environment. As polystyrene particles exhibit similar particle density and size 
as the final vaccine payload based on sugar particles, similar penetration of sugar 
particles is expected.  
 
5.2 CRYO-SECTIONING 
Cryo-cross sections of the pig skin samples confirmed the results obtained by CLSM 
(figure 7.26). Polystyrene particles (40 µm) breached the stratum corneum and were 
found 30 to 40 µm deep in the skin tissue.  
 
Figure 7.26: Slices of excised pig skin prepared by cryo-sectioning after particle 
bombardment using 40 µm FITC-labelled polystyrene particles. Particles were 
accelerated to 404 ±16 m/s using the prototype pyrotechnical device. Scale bars 50 µm.  
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6 SUMMARY AND CONCLUSION 
 
The surrogate accelerator LWB enabled the evaluation of basic principles for the 
acceleration of particles by momentum transfer in a static environment. A method for 
the measurement of the velocity of particles using high speed cameras was developed 
and the dependency of particle velocity on particle parameters like size, density and 
shape was evaluated. It was shown that particle velocity increases with increasing size 
and density of the particles. The shape of particles had no significant influence on 
particle velocity in the range of 80-180 m/s. However, limitations were given using this 
system in terms of the maximal achievable particle velocity, dependent on the type of 
particle, at approximately 300 m/s.  
Gel models, simulating the mechanical properties of skin, were used to analyze particle 
penetration after acceleration using the LWB. The maximum achieved velocity of 
≤ 275 m/s of 40 µm polystyrene particles, using an optimized set-up of the LWB for the 
acceleration of the particles, was not sufficient to penetrate into the gel models. Proof of 
concept in excised skin confirmed the results obtained after particle bombardment in 
different gelatin gels. The treshold of particle velocity to breach the stratum corneum 
and penetrate into excised skin samples was not exceeded using the LWB. 
In a number of development steps a prototype pyrotechnical device was built which 
enabled the acceleration of particles to supersonic velocity. The functional principle of 
the device based on a pyrotechnical core which generated a shock wave in a burning 
chamber and transferred kinetic energy on a membrane. Several optimization steps 
involved the filling of the burning chamber with an oleogel in order to regulate the 
transfer of the shock wave to the particle coated membrane. Furthermore a highly 
robust and flexible pre-formed membrane material was identified which was compatible 
with the pharmaceutical payload. Velocity measurements of different model particles 
revealed that particles breached the supersonic speed barrier with a median velocity of 
380-461 m/s, dependent on the type of particle. The accuracy of velocity measurement 
in this high speed range was re-evaluated.  
The penetration of 40 µm FITC-labelled polystyrene particles in excised pig skin 
accelerated to supersonic speed using the prototype pyrotechnical device was 
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experimentally demonstrated. Particles reached a medium velocity of 404 ±16 m/s. 
CLSM measurements as well as cryo-sectioning of the skin samples showed that 
particles breached the stratum corneum and were deposit in an average penetration 
depth of 30-40 µm. Hence, the prototype pyrotechnical device fulfilled the scope of the 
project to inject low density particles successfully into the skin.  
Penetration of vaccine loaded particles into skin, quantification of the injected vaccine 
dose as well as evaluation of the immunization efficacy of this innovative needle-free 
injection device in an animal model was beyond the scope of this thesis and will be 
discussed in further work.  
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CHAPTER 8  
 
FINAL SUMMARY, CONCLUSION AND OUTLOOK 
 
The increasing knowledge of immune responses induced by targeting the intradermal 
layers of the skin has driven the engineering of devices for intradermal vaccination. 
Needle-free delivery devices injecting dry vaccine particles into the skin combine 
considerable advantages as (i) it eliminates the possibility of needle-stick injuries und 
re-use of needles, (ii) ease of handling, so that vaccine administration may be carried 
out after minimal operator training [1], (iii) dry powder vaccine formulations can offer 
improved stability, opening up the possibility for independence from cold-chain transport 
and storage [2-4] and (iiii) offer the potential for vaccine dose reduction [5-10]. 
 
The objective of the present thesis was to develop a dry powder formulation with 
appropriate characteristics for intradermal injection and superior stabilizing effect on 
antigens during storage at elevated temperatures. Furthermore a ballistic device system 
was developed to accelerate powder particles to high velocities in order to deliver the 
particles to the target site of vaccination, the epidermal layers of the skin. 
 
In Chapter 1 a general introduction to needle-free vaccination targeting the skin and an 
overview of formulations strategies and drying techniques for the generation of dry 
powder vaccine formulations is given. A second focus is set on delivery devices 
targeting for the intradermal application of vaccines, evaluating the pros and cons of 
each system. Closing Chapter 1 the objectives of the thesis are summarized and the 
materials and methods used throughout this thesis are described in Chapter 2. 
 
In Chapter 3 it was shown that a two-step approach combining collapse freeze-drying 
and cryo-milling was successful to generate particles with appropriate characteristics for 
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ballistic injection, including a narrow particle size distribution in the desired range of 20-
70 µm and a highly dense matrix structure exhibiting a low specific surface area. 
Remarkably, these particle characteristics could be achieved by this approach 
independent of the formulation composition (in particular polymers like dextran) or the 
solid content of formulation, which was stated to be crucial for these features. 
Furthermore it could be shown, that the stability of the model antigen ovalbumin was 
preserved in formulations based on trehalose during collapse freeze-drying and cryo-
milling as well as after 12 months of storage at 2-8°C and after 12 weeks of storage at 
50°C. 
 
In Chapter 4 the cryo-milling process for the production of vaccine loaded powder 
particles was optimized. Cooling of the samples prior to milling was shown to be 
necessary to prevent local melting of the particles during milling.  
A fast, efficient and gentle process tailored according to the respective rigidity of the 
formulation was established, resulting in a high yield in the targeted particle size range 
and a narrow particle size distribution. Furthermore it was possible to set up a sterile 
production process. This is very promising and it will be interesting to evaluate it the 
cryo-milling process can be scaled-up to industrial standards and if this at least two-step 
process will be competitive with other particle manufacturing process like spray-drying 
or spray-freeze-drying. The applicability of the cryo-milling process on the model protein 
rh-GCSF could be demonstrated, however not for IFN-α-2a. The formation of insoluble 
aggregates was observed in IFN-α-2a formulations after collapse freeze-drying as well 
as after cryo-milling. As the formulation composition determines decisively protein 
stability, stability after cryo-milling has to be evaluated for each antigen individually. 
Future studies will certainly lead to a better understanding of applicability of this two-
step process on other vaccines and antigens. 
 
Formulation screening and an accelerated storage stability study of the model antigen 
ovalbumin formulations at 2-8°C, 25°C and 50°C was scrutinized in Chapter 5. In the 
course of these studies, the effect of collapse freeze-drying and subsequent cryo-milling 
on antigen stability and powder characteristics was thoroughly investigated by 
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comparing different formulations. Formulations containing higher molecular weight 
dextran (40 and 70 kDa) showed aggregation of ovalbumin at 50°C with an onset after 8 
weeks. Formulations based on a binary combination of trehalose and mannitol exhibited 
excellent protein stability throughout storage at elevated temperatures and showed 
superior physico-chemical and morphological characteristics of the powder regarding 
the requirements for ballistic injection. Furthermore, it could be demonstrated that an 
increase of the antigen load of the powder formulation from 25 µg/mg to 200 µg/mg 
ovalbumin in several formulation compositions was possible without affecting physical 
characteristics of the particles or having a negative influence on antigen stability. 
 
In Chapter 6 several oily adjuvants were explored as adhesives at the interface 
between particles and the surface of a ballistic device for intradermal injection. In order 
to simulate the mechanical stress exerted during handling, shipping and storage of the 
device, the adhesive strength in between the device surface and the particles (model 
glass particles) was investigated and was outstanding for several oily substances, 
including the oily components of MF59 and Freund’s incomplete adjuvant, also after 
storage at elevated temperature. It could be shown that approximately the tenfold higher 
mass of particles in comparison to the mass of the adhesive (10 µl) could be attached 
onto the membrane surface, enclosing the particles into a thin film of the oily substance. 
Proof of concept was given by the release of the particles from the membrane surface 
upon actuation of the ballistic device. Thereby the adhesive was entrained together with 
the particles, offering the possibility to be co-injected into the skin and herein to exert an 
adjuvant effect. 
In addition to the experiments investigating the adherence strength of particles at the 
interface to the device surface, the storage stability and possible interaction between 
selected oily substances and ovalbumin loaded powder particles was explored in a 
short term stability study at elevated temperatures. 
A comprehensive investigation of the stability of ovalbumin demonstrated that antigen 
stability was maintained during storage at 40°C for 12 weeks in samples incubated with 
squalane, squalene, or paraffin oil. Only a slight decrease in protein stability was found 
for samples incubated with Freund’s incomplete adjuvant. In contrast, the occurrence of 
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higher-ordered aggregates and significant perturbations of the secondary protein 
structure were observed in samples incubated with the oily components of MF59 with 
an onset after 8 weeks of storage at 40°C. Therefore, preference should be given to its 
component squalene in the selection as oily adjuvant.  
In Chapter 7 a highly versatile and controllable surrogate apparatus, the Lell’s Foucault 
accelerator (LWB), was used to evaluate basic principles for the acceleration of 
particles by momentum transfer in a static environment. A method was developed for 
the measurement of particle velocity using high speed cameras and the dependency of 
particle velocity on particle parameters like size, density and shape was evaluated. 
It was shown that particle velocity increases with increasing size and density of the 
particles. The threshold of particle velocity (model particles polystyrene, 40 µm, 
1.1 g/cm³) to breach the stratum corneum and penetrate into gel models, simulating the 
mechanical properties of skin, or excised skin samples was not achieved with the 
maximum achieved velocity of ≤ 275 m/s using the LWB. 
In a number of development steps a prototype device based on a pyrotechnical principle 
was built (by our cooperation partner Dr. Lell, Pyroglobe, Hettenshausen, Germany), 
which enabled the acceleration of particles to 380-461 m/s, breaching the supersonic 
speed barrier. The penetration of FITC-labelled polystyrene particles (40 µm, 1.1 g/cm³) 
into excised pig skin in an average penetration depth of 30-40 µm was demonstrated by 
CLSM measurements and cryo-sectioning. Hence, the prototype pyrotechnical device 
fulfilled the scope of the project to inject low density particles successfully into the skin.  
 
In conclusion, following major achievements were reached within this thesis: 
 A dry powder antigen formulation based on a binary combination of trehalose 
and mannitol with appropriate characteristics for intradermal injection was 
developed by applying a two-step approach combining collapse freeze-drying 
and cryo-milling. The powder formulation showed excellent antigen stability 
throughout storage at elevated temperatures. A cryo-milling process for the 
production of vaccine loaded powder particles was established which is fast, 
efficient and opens up the possibility to up-scale the process to industrial 
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standards, resulting in a high yield of particles in the targeted size range and a 
narrow particle size distribution. 
 The use of oily adjuvants as adhesives at the interface between particles and the 
surface of a ballistic device for intradermal injection was shown to successfully 
attach particles onto the device surface by enclosing them into a thin film of the 
oily substance. The adherence strength between particles and device surface 
was sufficient to fix the particles on the device surface during handling, shipping 
and storage of the device, but likewise the particles could also be released from 
the membrane surface upon actuation of the ballistic device. The entrainment of 
adhesive together with particles offers the possibility to be co-injected into the 
skin and herein to exert an adjuvant effect. Furthermore, it was proven that 
antigen stability could be preserved in the combination of ovalbumin loaded 
powders with selected oily adjuvants like Freund’s incomplete adjuvant or 
squalene during storage at elevated temperatures. 
 A prototype device based on a pyrotechnical principle was built which enabled 
the acceleration of particles to supersonic speed. Proof of concept was given by 
the penetration of the particles into excised pig skin.  
 
In summary, the conducted studies provided the basis for needle-free ballistic delivery 
of a powdered vaccine. Further studies demonstrating the ability of the delivery device 
to inject vaccine powder particles together with oily adjuvants into the skin are 
necessary and it would be still of interest to investigate the ability of this application 
method to provoke an adequate immune response in an animal model. In this context, 
the transferability of the presented results to other vaccines, which are in the focus of 
mass vaccination programs (e.g. influenza), is of great interest, as mass vaccination 
programs would capitalize the most from a needle-free and cold chain independent 
vaccination method. 
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1 ADDITIONAL FIGURES 
 
 
Figure 9.1: Recovery of ovalbumin protein species (%) as determined by size 
exclusion chromatography in cryo-milled powders after 0, 8 and 12 weeks of storage 
at 25°C. Trehalose/mannitol/dextran 70 kDa formulations are depicted in A, 
trehalose/mannitol/dextran 40 kDa formulations are depicted in B. Black bars 
represent higher molecular weight aggregates, light grey bars represent dimers, dark 
grey bars represent fragments. Open circles represent the total protein recovery, filled 
circles represent monomer recovery (average +/- SD, n=3). 
 
 
Figure 9.2: Recovery of ovalbumin protein species (%) as determined by size 
exclusion chromatography in cryo-milled powders after 0, 8 and 12 weeks of storage 
at 25°C. Trehalose/mannitol/dextran 6 kDa formulations are depicted in A, 
trehalose/mannitol/hydroxyethylstarch formulations are depicted in B. Black bars 
represent higher molecular weight aggregates, light grey bars represent dimers, dark 
grey bars represent fragments. Open circles represent the total protein recovery, filled 
circles represent monomer recovery (average +/- SD, n=3).  
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Figure 9.3: Recovery of ovalbumin protein species (%) as determined by size 
exclusion chromatography in cryo-milled powders after 0, 8 and 12 weeks of storage 
at 25°C. Trehalose/mannitol formulations are depicted in A, trehalose/phenylalanine 
formulations are depicted in B. Black bars represent higher molecular weight 
aggregates, light grey bars represent dimers, dark grey bars represent fragments. 
Open circles represent the total protein recovery, filled circles represent monomer 
recovery (average +/- SD, n=3).  
 
 
Figure 9.4: Recovery of ovalbumin protein species (%) in trehalose formulations as 
determined by size exclusion chromatography in cryo-milled powders after 0, 8 and 12 
weeks of storage at 25°C. Black bars represent higher molecular weight aggregates, 
light grey bars represent dimers, dark grey bars represent fragments. Open circles 
represent the total protein recovery, filled circles represent monomer recovery 
(average +/- SD, n=3). 
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2 REVIEW ARTICLE: DEVICES FOR INTRADERMAL VACCINATION 
 
The review was published in Vaccine: 
Kis EE, Winter G, Myschik J*. Devices for intradermal vaccination. Vaccine 2012; 
30(3):523-38. 
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ABSTRACT 
New insights in vaccine development, the need for safe, economic and efficient 
vaccine administration and the increasing mechanistic knowledge of immune 
responses induced by targeting the intradermal layers of the skin have all driven the 
engineering of devices for intradermal vaccination. In this review we highlight 
different delivery devices that make the epidermal and dermal layers of the skin 
accessible for vaccine administration. Depending on the device the desired vaccine 
can be applied either as a liquid formulation or as solid, powdered vaccine particles. 
The process of intradermal injection employs micron-sized needles that are inserted 
1.5 mm perpendicularly into the skin, and which inject approximately 100-200 µl of a 
liquid vaccine formulation into the dermal skin layers. Tattoo devices, on the other 
hand, can be used to deliver liquid vaccine formulations into the dermal layer of the 
skin by the use of oscillating needles. Microneedle arrays are made of vaccine-
coated solid microneedles or biodegradable microneedles. These are inserted into 
the dermal layers of the skin where either the vaccine coating is dissolved, or the 
microneedle itself dissolves in place. Jet-injectors operate by generating a high 
pressured stream, which flushes the liquid vaccine formulation into the deeper skin 
layers. Delivery devices using liquid vaccine formulations are advantageous, as 
established vaccine formulations can be used as provided without the need for 
reformulation. However, approaches that deliver vaccines in a solid form may also 
prove to be promising. One such method is the ballistic approach, in which solid 
vaccine particles or vaccine-coated gold particles are accelerated towards the skin by 
needle-free devices, so that the particles are deposited in the epidermal and dermal 
layers of the skin. These various delivery devices are explored in this review with 
regard to their delivery mechanism and ease of handling, their efficacy in clinical trials 
and their suitability for practical use.  
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2.1 INTRODUCTION 
Vaccination is the core principle for the prevention of life-threatening infectious 
diseases, and can be dated back to the first vaccination carried out by Edward 
Jenner in 1796 [1-3]. Despite the availability of a wide range of vaccines for many 
and varied applications, infectious diseases remain a major global problem, 
especially in developing countries [4-6].  
One reason for this fact is that many vaccines still require the use of needles and 
syringes for administration. Particular in developing countries, the application of 
vaccines via needles and syringes carries significant risk. Professional healthcare 
workers are needed for the administration of vaccines to patients, and these persons 
are potentially exposed to needle-stick injuries. Furthermore, sharps waste 
management and the reuse of needles are both considerable problems. 
Novel vaccination strategies should ideally allow for safer injection practices, while 
still being cost-effective and capable of evoking sufficient immune responses in 
patients [4, 7]. As a safe injection practice is the primary priority postulated by the 
World Health Organization (WHO) [8], the development of needle-free technologies 
has experienced a significant upturn in the past years [9]. Needle-free injection 
devices avoid unsafe injection practices and can enhance patient compliance by 
evoking less pain and stress. 
The skin is an attractive target for vaccination as it constitutes the major barrier for 
the entry of environmental pathogens, while at the same time being easily accessible 
for vaccine administration [10-15]. Immunocompetent antigen presenting cells 
(APCs) such as the Langerhans cells (LCs) in the epidermis and dendritic cells in the 
underling dermis are able to capture and process foreign antigens. APCs are able to 
migrate to lymph nodes and here present processed antigens on their surface to 
other cells of the immune system [15, 16]. In addition, the lack of sensory nerve 
endings and blood vessels in the epidermal layer of the skin provides the possibility 
of application of the vaccine without causing any pain or bleeding. In terms of 
efficiency, the intradermal route of vaccine application has been stated to induce 
protective immune responses superior to those induced after intramuscular injection 
and in the case of some vaccines, allow for the use of smaller quantities of antigen 
[17-33]. 
A broad review of clinical trials comparing the intradermal and subcutaneous (s.c.) or 
intramuscular (i.m.) route of administration of several licensed vaccines is given in a 
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publication by the Program for Appropriate Technology in Health (PATH) [34]. 
Several clinical trials have been conducted to evaluate whether equivalent or 
superior immune responses could be elicited by administering vaccines via the 
intradermal route in comparison to intramuscular or subcutaneous injection. Clinical 
trials with influenza [25, 35, 36] and rabies [37] vaccines verified that intradermal 
vaccination was able to elicit equivalent immune responses to the vaccine given 
intramuscularly or subcutaneously, while utilizing only 10-20% of the antigen dose. 
Similar results were obtained for hepatitis B vaccines [38, 39], while only limited 
clinical trials have been carried out for other commercially available vaccines such as 
the polio, measles, tetanus toxoid and hepatitis A vaccines [34, 40-43]. 
However, most of these studies were not designed to compare identical vaccine 
doses given by the intradermal and the s.c. or i.m. route. Therefore, it is unclear 
whether the antigen dose contained within the s.c. and i.m. injection could also have 
been reduced, with continued vaccine efficacy. A further point of concern is that 
many of the conducted trials used conventional needles and syringes for injection via 
all three routes of administration. It can therefore be brought into question if the LCs 
in the epidermal and dermal layer of the skin were effectively targeted. 
 
The traditional administration of vaccines via needle and syringe cannot effectively 
target the LCs in the epidermis of the skin, as deeper subcutaneous regions or 
muscle tissue will be reached due to the length of the needle and the applied 
standard technique [13, 44]. Intradermal injection methods using needles and 
syringes, such as the Mantoux technique, require considerable expertise and are 
seldom used for intradermal vaccinations and only for bacilli calmette guérin (BCG 
vaccination), for tuberculosis and for post-exposure rabies vaccination [45]. 
Therefore, there is an urgent need for devices to facilitate correct and accurate 
intradermal administration. This need is attempted to be met by the development of a 
variety of  delivery systems intended specifically for the intradermal administration of 
vaccines [46].  
Vaccines may pass through the skin passively via diffusion (transcutaneously) or by 
penetration through the stratum corneum (SC) into the deeper skin layers 
(intradermally) [9, 47-49]. The terminology used to describe vaccination via these 
mechanisms has not always been used consistently, with the process of introducing 
vaccines into the skin sometimes referred to as transdermal, epidermal or 
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percutaneous delivery interchangeably. Only molecules smaller than 500 Dalton [50] 
can pass the SC by diffusion or permeation. Glenn et al. proposed the use of 
diffusion patches to enhance the permeability of the SC and thereby enable the 
delivery of large recombinant antigens greater than 1 Mega Dalton (MDa), leading to 
the introduction of systemic immune responses [51]. Other methods used to breach 
the SC such as tape stripping, brushing with sandpaper, application of depilatory 
agents, ultrasound, electroporation, microporation or ablation by laser or heat are 
widely described in literature, however only a few of these methods have been tested 
in clinical trials [52-57]. Most of these approaches are furthermore associated with 
disadvantages such as difficulties in handling, the need for expensive tools and the 
induction of considerable pain in the vaccination subject. Some such approaches 
may even combine these disadvantages. 
Ballistic approaches however have already reached the stage of clinical trials in 
humans [58], and recently a microinjection system delivering a seasonal influenza 
vaccine has gained approval [59]. 
As mentioned, a major requirement for such delivery devices is ease of handling, so 
that vaccine administration may be carried out after minimal operator training, 
already. The cost of the device should prove to be competitive with that of 
conventional needle and syringe systems, and a superior long term stability of the 
vaccine would also be desirable, allowing for avoidance of a cold chain and so 
increasing the ease with which vaccines may be distributed.  
 
In this review we highlight delivery systems that facilitate the intradermal application 
of vaccines (see table 9.1) and thereby target the LCs (figure 9.5). We focus on 
methods that apply the vaccine directly into the skin; methods involving application of 
the vaccine onto the skin surface or enabling vaccine penetration by other means 
(e.g. penetration enhancers, or SC ablation methods such as tape stripping or 
abrasion) have been well described elsewhere [60] and are therefore not discussed 
in the current review.  
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Table 9.1: An overview of different devices for liquid and solid formulation 
administration 
 Type of device Reference examples 
Devices for liquid formulation 
administration 
Needle and syringe 
Mantoux technique 
[45, 61-64] 
Intradermal microinjection 
BD Soluvia™ 
[35, 36, 65-71] 
Tattoo devices for vaccination [72-77] 
Hollow microneedle arrays [78-81] 
Liquid jet injectors 
Biojector™ 2000 
PharmJet® device 
Vitajet 3® device (polymer particles 
in liquid) 
Iject® device 
[33, 82-84] 
Devices for solid formulation 
administration 
Solid microneedle arrays [78, 81, 85-89] 
(see also table 2) 
Ballistic injectors 
Gene gun 
Powderject XR device 
Convergent-divergent supersonic 
nozzle (CDSN) device 
Contoured shock tube (CST) device 
Venturi device 
[90-99] 
 
 
 
Figure 9.5: Delivery systems enabling the intradermal application of vaccines: Liquid 
jet injection, microinjection, microneedles, tattoo vaccination, powder particle 
injection, gold particle injection. Adopted after Mitragotri S. [9].  
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2.2 DEVICES 
2.2.1 NEEDLE AND SYRINGES 
The intradermal injection of vaccines using the Mantoux technique dates back to 
Charles Mantoux, a French physician, who first used this technique for tuberculosis 
diagnostics [100]. Using the Mantoux technique, the skin must be stretched and the 
needle is inserted parallel to the skin surface (figure 9.6).  
 
 
Figure 9.6: The Mantoux technique. The skin has to be stretched and the needle has to 
be inserted parallel to the skin surface, a technique which can only be carried out by 
trained personnel. Figure originates from the Centers for Disease Control and 
Prevention's Public Health Image Library (PHIL), identification number 6806. 
 
The experience of the person carrying out the injection is crucial for successful 
targeting of the dermal tissue. Today this technique is still used for the intradermal 
administration of BCG vaccines and rabies [45], however, due to difficult handling 
and inconsistency of the delivered vaccine dose, the Mantoux technique has not 
been established for routine use [61-64]. The use of bifurcated or pronged needles, 
first introduced by Benjamin A. Rubin [101, 102], or the application of multiple 
puncture injections [103] are considered to lead to inaccurate dosing and loss of 
vaccine [7, 104]. 
 
2.2.2 INTRADERMAL MICROINJECTION 
The BD Soluvia™ (Becton Dickinson, Franklin Lakes, NJ, USA) is an intradermal 
microneedle injection system that consists of a 30 gauge needle of 1.5 mm in length, 
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and a syringe which has the capacity to hold 100 to 200 µl of a liquid formulation. 
This system enables intradermal vaccination [65]. The needle must be inserted 
perpendicular to the skin surface. A specially designed needle-penetration depth 
limiter ensures an appropriate insertion depth. An additional mechanism integrated 
into the syringe serves for the prevention of reuse or injury. After vaccine 
administration, the microneedle is covered with a plastic shield by pressing the 
plunger further [66]. The advantage of such a system is the ease of handling, 
allowing the vaccine to be administered also by untrained staff. The intradermal 
microinjection system ensures consistent vaccine dosing and is compatible with 
conventional liquid vaccine formulations. Due to the low penetration depth of the 
needle almost no sensation of pain can be perceived.  
Laurent et al. investigated various performance criteria of the BD microinjection 
system, including the fluid distribution and histological changes at the injection site, 
as well as the accuracy of the volume of the injected fluid in comparison to the 
Mantoux technique. Such investigations were performed by the use of different 
techniques like X-ray and 3D-ultrasound echography [61]. The authors observed a 
larger fluid distribution at the injection site using the BD microinjection technique as 
the liquid infiltrated the papillary and reticular dermis, indicated by the visible 
formation of a skin wheal at the injection site. In comparison to considerable pain 
often resulting from employment of the Mantoux technique, the procedure of needle 
insertion with the BD microinjection system was observed to be almost pain free. The 
Mantoux technique caused in general more pain and tissue damage because of the 
right angle and upward position of the needle during injection. Furthermore, the 
intuitive handling of the BD microinjection system may mean that operation solely by 
highly trained healthcare personnel is unnecessary. However, while significant 
advantages were associated with the operation and needle insertion phase of the 
system, pain was perceived during fluid injection. Local adverse events such as 
blood at the injection site, redness and itching were also reported. A mean fluid 
leakage volume of 2-3 µl was observed due to back-flow from the injection site. The 
group of Gupta et al. investigated parameters affecting infusion pressure and 
associated pain perceived during microneedle injection, using glass microneedles 
[105]. Whilst the insertion depth had no bearing on the infusion pressure, an increase 
in pressure was observed by increasing the volume of the liquid delivered into the 
skin. However, a typical intradermal injection volume of 100 µl required a pressure of 
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less than 100 mmHg, similar to s.c. injection. This can be explained by compression 
of the dense fibers in the dermis, caused by perpendicular microneedle insertion. It 
could be also observed, that microneedle-based intradermal insertions were less 
painful than hypodermic needle insertion, which led to the formation of skin wheals at 
the injection site. The group of Laurent et al. studied the appropriate microneedle 
length for intradermal injection by echographic measurements [65]. They evaluated 
skin thickness at different body sites, such as the deltoid, suprascapular, waist and 
thigh area in different ethnic groups (Caucasian, Asian, and Black) as a function of 
gender, age and body mass index. Gender and body mass index were found to have 
an impact on impact on skin thickness, whereas average thickness of the skin was 
seen to remain constant in the age range of 18 to 70 years, independent of ethnic 
origin. No differences in skin thickness among ethnic groups were measured at the 
deltoid and suprascapular region, having a mean thickness of 2.02 mm and 2.54 mm 
respectively; both areas are therefore considered as being appropriate sites for 
intradermal injection [65, 106]. Furthermore it was found that a needle length of 1.5 
mm was suitable to target the dermal skin layer, with this length being independent of 
the patient’s gender, age, ethnicity or body mass index. 
Several preclinical and clinical trials applying rabies, anthrax recombinant protective 
antigen vaccine and influenza vaccine have been conducted using the BD SoluviaTM 
microinjection system [35, 36, 66-68, 70, 107]. Laurent et al. observed that 
intradermal delivery of a reduced dose (25% of the standard i.m. dose) of a rabies 
vaccine in humans, using the BD microneedle, resulted in similar humoral immune 
responses as immunization with the full dose via the i.m. route [108]. This underlines 
the potential for dose sparing if vaccination is carried out intradermally. The group of 
Mikszta et al. investigated the intradermal delivery of an adjuvanted anthrax vaccine 
at several dose levels in rabbits, using the BD microneedle in comparison to i.m. 
vaccination [68]. A superior immune response after intradermal injection over i.m. 
injection was found during the first two weeks following primary and booster 
vaccination, though the immune response equalized at the later stages. Higher 
protection levels were found after aerosol challenge in the groups immunized 
intradermally than in the groups immunized using the i.m. route.  
Immunogenicity of a trivalent inactivated seasonal influenza vaccine, delivered by 
i.m. or intradermal injection using the same quantity of antigen was investigated in a 
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three year, randomized phase 3 trial in 3707 elderly persons [66]. The intradermal 
vaccine contained 15 µg HA/strain per 0.1 ml whereas the i.m. vaccine contained 15 
µg HA/strain per 0.5 ml dose. Neither of the vaccines contained adjuvants. A superior 
seroprotection rate was observed using the intradermal injected vaccine. Visible, 
local injection site reactions like pruritus, erythema, swelling, indurations and pain 
were more frequent after intradermal vaccine delivery, whereas systemic reactions 
induced by intradermal and i.m. injections were comparable [66, 108]. Whether the 
greater incidence of local inflammation resulting from intradermal injection may 
potentially lead to an enhanced efficiency of immunization is a point for discussion. 
As the elderly are in general poorly immunoresponsive, different immunization 
strategies have to be chosen to optimize responses to vaccination. Potential 
strategies include the use of adjuvanted formulations, or other application routes 
such as intradermal administration. The group of Van Damme et al. compared the 
immunogenicity of an adjuvanted seasonal influenza vaccine administered by i.m. 
injection and a non-adjuvanted influenza vaccine administered by intradermal 
microinjection, using a pre-filled microneedle injection system (Becton Dickinson; 
Franklin Lakes, NJ, USA). The intradermal influenza vaccine compared favorably 
with the i.m. vaccine in this study – both routes were well tolerated and fulfilled  the 
European Medicines Agency (EMA) immunogenicity criteria for influenza vaccines in 
the elderly [107]. Similar results were obtained using a MicronJet device (NanoPass 
Technologies Ltd., Nes Ziona, Israel), which is mounted on a commercial syringe, 
having an array of 0.45 mm long microneedles [69]. The MicronJet device from 
NanoPass Technologies gained FDA clearance in 2010, intended for the use of 
commercially available vaccines [109]. 
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Figure 9.7: Intanza® (Sanofi Aventis, Germany), a microinjection device, was approved 
and released on the market for a seasonal influenza vaccine for elderly patients by 
Sanofi Pasteur, Lyon, France in 2009. Figure reprinted courtesy of Sanofi Pasteur MSD 
GmbH, Leimen, Germany. 
 
In 2009, Intanza® (figure 9.7), also known as both ID flu® and Fluzone®, was 
approved and released on the market as a seasonal influenza vaccine for elderly 
patients administered using the BD SoluviaTM microinjection system [59, 71]. A full 
dose of 15 µg hemagglutinin per strain is approved for the prevention of seasonal 
influenza in the elderly population (aged 60 years), whereas a reduced dose of 9 µg 
hemagglutinin per strain is approved for adults up to the age of 60 years [59]. 
 
2.2.3 MICRONEEDLE ARRAYS 
Microneedle arrays are small, minimally invasive devices consisting of an 
arrangement of micron-sized needles. In contrast to microneedles used for 
intradermal injection of fluids (see section 2.2.), microneedle arrays are usually solid 
needles coated with drug or biodegradable solid needle arrays that dissolve upon 
insertion. 
The development of microneedle arrays for transdermal drug delivery dates back to 
the early 1970s, but not until the advancement of microelectronics technology in the 
1990s was the preparation of microneedle arrays of defined needle sizes and lengths 
made possible. From the late 1990s onwards there has been rapid progress in the 
evaluation of different materials and approaches that can be used for microneedle 
array fabrication. An overview is given in table 2, showing some examples of the 
variety of different materials and preparation techniques that may be employed for 
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fabrication of microneedle arrays, as well as needle shapes and lengths, additional 
features, and loading procedures for drugs, antigens, or vaccines.  
Microneedle arrays can be broadly divided into the following different groups: solid 
microneedles made from non-degradable, solid material such as titanium [110], 
silicon [78, 111, 112], stainless steel [113, 114] or glass [85]; and, or solid, hollow 
microneedles made from similar materials but being equipped with a hole in the 
needle center [78-80] (figure 9.8). Both types can be attached to an adhesive patch 
[81, 115-118]. In addition, microneedles can be made from polymers that are either 
degradable (such as PLG, PLGA) [86] or non-degradable (e.g. polystyrene) [85]. 
Lastly, self-dissolving microneedles can be prepared from sugars [87, 88, 119] or 
other rapidly dissolving materials [120].  
The first microneedle arrays were prepared from non-degradable, solid materials. 
Research groups have successfully shown that microneedles of different shapes, 
geometries and lengths [78, 113, 121, 122] can be prepared using techniques such 
as chemical etching, alone or laser etching [123] followed by a cleaning technique 
such as electro-polishing. The importance of needle geometry for penetration 
efficiency and mechanical stability of the needles has also been reported. Drug 
loading of liquid formulations has been carried out by dip coating [113, 114], surface 
coating after chemical treatment of the microneedles [113], or layer coating. As dip 
coating is strongly influenced by factors such as the wetting behavior of the liquid on 
the needle surface, the viscosity of the formulation, and the surface tension, these 
factors have also been investigated. In order to circumvent some of the above 
mentioned influencing factors, needles have been pre-coated with silicon oxide or 
PLGA, to increase the surface energy [113]. A variety of drugs, peptides, protein, 
antigens and even vaccines have been coated onto solid microneedles and have 
been successfully tested in vivo [114, 124-126]. In addition to coating the drug on the 
microneedle surface, the simple induction of microchannels by the microneedles has 
also been explored and shown to result in enhanced penetration of drugs or 
nanoparticles. 
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Table 9.2: An overview of different microneedle arrays 
 Solid microneedles Hollow microneedles Polymers Self-dissolving microneedles 
Material Titanium [85] 
Silicon [78, 111, 112] 
Stainless steel [113, 114] 
Stainless steel or titanium sheets 
[122, 126] 
Glass [78, 85] 
Nickel [85] 
Copper [85] 
Silicon [78] 
Metal [78] 
Glass [78, 79] 
Radel R (PPSU) [80] 
PLGA [78, 86] 
Polycarbonate [85, 127] 
PLA [78, 128] 
PGA [78] 
PLA microneedle roller (2D array) + 
CMC [129] 
Polystyrene [85] 
Maltose [87, 88, 130] 
Carboxymethylcellulose [128, 131] 
Amylopectin [128] 
Methylvinylether maleic anhydride 
(PVEIMA) [132] 
Sodium hyaluronate + dextran [120] 
Chondroitin sulphate + dextran 
[120, 133] 
Preparation technique Chemical etching [78] 
Electropolishing [113] 
Laser cutting [113] 
Electrodeposition on polymer mold 
[78] 
Micropipette puller for glass 
needles [78] 
Plasma etching (of silicon) [134] 
Micromolding [78, 129] Molding process (e.g. for maltose), 
heat (140°C), followed by curing 
step  
Simultaneous formation and curing 
[130] 
Preparation of concentrated 
hydrogel, filling in molds followed by 
centrifugation [128] 
Shape / Geometry Conical 
Pyramidal 
Octagonal-pyramidal [135] 
Tapered, beveled [78] 
Beveled [80] 
Conical shape [128] 
Pyramidal shape [136] 
Beveled tip [86] 
Tapered cone [86] 
Conical cone shape [128, 130] 
Tetrahedron shape [88] 
Length ~ 150 µm, radius at tip ~ 1 µm [78] 
430 µm 
1000 µm, sharp tip [121] 
700 µm [113, 126] 
700 µm, 160 µm width at base [85, 
114] 
480-1450 µm; width 160-245 µm 
[122] 
225, 400, 600 µm [62] 
500 – 800 µm, tip 60 µm [78] 
150 – 1000 µm [78] 
1200 µm long, 250 µm at base [80] 
600 µm height, 10 µm diameter tip 
[137] 
200 – 500 µm [127] 
1200 µm, 60 µm flat tip diameter 
[130] 
600 µm, tip radius 100 µm [130] 
~ 500 µm [88, 120, 138] 
500 µm needles with a pitch of 350 
µm [87] 
~ 115 µm [131] 
Special feature Microneedle induced microchannels 
can be used for enhanced 
penetration of drugs or 
nanoparticles. Adhesive patch 
backing [115, 124]can be added  
Enables active fluid flow  
Vibration of microneedle arrays 
used to increase microinjection, 
partial retraction increases flow rate 
[79, 80] 
Biodegradable polymers are slowly 
degrading 
Microparticles incorporated into 
polymer microneedle [139] 
Fast dissolving within 20 min [119] 
Tips of needles dissolved in 10 s, 
after 1 h microneedles fully 
dissolved [128] 
No sharp waste [130] 
Low cost of material [132] 
Loading Coating with liquid formulation 
(1) dip coating (factors: wetting 
behavior, viscosity, surface tension) 
[113, 114] 
(2) surface coating of stainless steel 
needles with silicon oxide [113] 
(3) surface coating with PLGA [113] 
(4) layer coating [113] 
(5) Coating with adjuvant[140] 
 (1) Coating with liquid formulation 
2) Incorporation of drug into matrix 
3) Microneedle completely made of 
drug 
(4) Casting of drug into mold 
followed by drying and subsequent 
addition of polymer [136] 
(1) Incorporation of drug into matrix 
(2) Microneedle completely made of 
drug 
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Table 9.2 (Continued) 
 Solid microneedles Hollow microneedles Polymers Self-dissolving microneedles 
Drug/fluorescent 
marker/antigen/vaccine 
OVA [124] 
OVA, OVA + TMC [125] 
Oligonucleotides [81] 
Insulin [78, 81, 113] 
Protein and DNA vaccines [81] 
BSA [78, 113] 
Latex nanoparticles 
Plasmid DNA [111] 
Riboflavin [113] 
Virus-like particles [85, 114, 126] 
Influenza [141] 
Hepatitis B [111] 
Hepatitis C [142] 
HPV 
BCG [118] 
Desmopressin [116] 
Parathyroid hormone [143] 
Insulin [78, 79, 81] 
OVA [80] 
Luciferase [80] 
DNA [80] 
Influenza 
Anthrax [144] 
Rabies vaccine 
Calcein [127] 
BSA [86] 
Phenylephrine [137] 
BSA [128] 
Lysozyme [128] 
Low molecular weight heparin [145] 
EPO [133, 138] 
Ascorbic-acid-2-glucoside [119] 
Ascorbate-2-glicoside [87] 
Sodium salicylate [87] 
Calcein [87, 88] 
Niacinamide [128] 
Insulin [89, 132] 
Sumatriptan [120] 
Interferon  
Human growth hormone (HGH)  
Fluvax2008 [131] 
OVA [131] 
 
 
 
258 
 
 
Figure 9.8: (A) Hollow microneedle (500 µm tall) formed by electrodeposition of metal 
onto a polymer mold next to the tip of a 27 gauge hypodermic needle. Image was 
adapted and reproduced with permission from Davis et al. [146]. (B) Stainless steel 
microneedle array fabricated using laser cutting and electropolishing next to a 20 
gauge hypodermic needle (scale bar = 150 µm). Image was adapted and reproduced 
with permission from Kim et al. [147]. (C) Image of glass microneedles assembled into 
an array using epoxy resin. (D) Poly-lactide-co-glycolide polymer microneedle array 
and (E) poly-glycolide polymer microneedle molded from glass microneedle masters 
(scale bars = 100 µm).Image (C), (D) and (E) was adapted and reproduced with 
permission from Wang et al.[79]. 
 
Hollow microneedles have been prepared from silicon, metal, glass [78, 79, 148] or 
polymers [80] using either electrodeposition of a metal on a polymer by the use of a 
mold [78], using a micropipette puller in the case of glass needles, or etching of 
silicon [134]. Again, different lengths and shapes (tapered, beveled tip) [78, 80] have 
been prepared. The special feature of hollow microneedles is the possibility to allow 
for active fluid flow through the needle hole [81]. This can be even further enhanced if 
the needle array is partially retracted after insertion [79]. In addition, vibration of the 
arrays has been explored and used to increase microinjection [80]. The group of 
Zahn et al. investigated the use of polysilicon micromolding for the fabrication of 
hollow microneedles, allowing for the implementation of complicated geometries in 
the needle as well smaller, sharper and smoother microneedles [149]. Additional 
functionalities such as continuous micropumping are also facilitated by this 
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fabrication process [150]. The ability of hollow microneedle injection to penetrate the 
SC and deliver small molecule drugs was tested by Sivamani et al. [151, 152]. It was 
proven, that hollow glass microneedles were able to effectively penetrate the SC and 
deliver drugs directly into the epidermis, despite the hindrance of skin elasticity. 
More detailed reviews of hollow microneedles are provided by Sivamani et al. [153] 
and Kim et al. [154]. 
Another intradermal injection system, the 3M’s hollow Microstructured Transdermal 
System (hMTS), is a device containing 18 polymeric, hollow microneedles/cm² which 
is connected to a conventional glass cartridge, containing the drug reservoir. The 
liquid formulation is forced through the hollow microneedles by the power of a spring. 
The patch requires a wear time of 3 to 40 min, depending on the formulation injected. 
Burton et al. used this system to perform intradermal injections delivering small 
molecule salts and proteins from 0.5 ml up to 1.5 ml in domestic pigs [155]. The 
pharmacokinetic profiles and relative bioavailability achieved using the hMTS were 
comparable to profiles obtained after s.c. injection. The 3M’s hollow Microstructured 
Transdermal System has yet not gained FDA approval. 
The Macroflux® microneedle array patch is one example where solid microneedles 
are combined with an adhesive patch [115, 116]. Here, the drug can be coated onto 
the needles, and with the patch allowing for a longer residence time during which the 
drug can diffuse into the skin [124]. In addition, an occlusive effect of the patch on the 
skin can be observed. The effect of microneedle pore closure with and without 
occlusion has been investigated, with pore closure being found to occur more quickly 
under non-occlusive conditions [156, 157]. A variety of polymers have been used for 
the preparation of microneedle arrays, including the biodegradable polylactic acid 
(PLA) [78, 119], polylactic-co-glycolic-acid (PLGA) [86], polyglycolic acid (PGA) [78] 
as well as non-biodegradable polymers such as polystyrene [85]. These 
microneedles can be prepared by micromolding, which allows for the preparation of 
different needle lengths and shapes [86, 136]. In contrast to solid microneedles 
prepared from titanium, stainless steel, or silicon, the drug can not only be dip-coated 
onto the needle, but also directly incorporated into the needle matrix. In addition, 
needles can be prepared from drug, or microparticles can be incorporated into the 
polymer microneedle [86]. 
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The largest and fastest growing group of microneedle arrays investigated in the last 
years is the group of self-dissolving needles. These can be prepared from sugar or 
sugar derivatives such as maltose [87, 88, 119], carboxymethylcellulose [131], or 
amylopectin. These needles have the obvious advantage that they dissolve rapidly 
within minutes after insertion into the skin, leaving no sharp waste to be disposed of 
[130]. The material for preparation of self-dissolving needles can be obtained at low 
cost [132], and many excipients employed in the preparation process are already 
used in pharmaceutical products without any safety concerns. Additionally, if the self-
dissolving needles break upon insertion, no residuals will remain in the skin due to 
the fast dissolution of the material. The drug to be administered can be incorporated 
directly into the matrix, or microneedles can be prepared consisting theoretically 
solely of drug. Again, factors such as mechanical stability must be kept in mind when 
preparing needles using such readily degradable substances. Some preparation 
procedures require a curing step to achieve sufficient mechanical stability, which may 
result in volume loss of the needle and may complicate the production process.  
The group of Bal et al. investigated the immunization efficiency of N-Trimethyl 
chitosan (TMC) adjuvanted diphtheria toxoid (DT) vaccines in mice before and after 
microneedle treatment of the skin [158]. The vaccine was formulated either as 
solution or DT was loaded onto TMC nanoparticles. Alum adjuvanted DT served as a 
positive control and was applied s.c. Two different types of microneedles were used, 
either microneedles that were manufactured from commercially available 30G 
needles or stainless steel microneedles prepared by electrical discharge machining. 
Both, TMC/DT nanoparticles as well as the solution induced equally strong immune 
responses as the positive control, independent of the microneedle array used or the 
sequence of the microneedle treatment. However, 8-fold higher IgG titers were 
obtained after immunization with the TMC/DT solution in comparison to the TMC/DT 
nanoparticles. It was discussed that the distribution of the TMC/DT solution was 
broader compared to the TMC/DT nanoparticles due to electrostatic interactions 
between the positively charged nanoparticles and the negatively charged skin, 
leading to a blockage of the conduits which were formed by the microneedles. Similar 
results were obtained by Ding et al after immunization of mice against diphtheria 
toxoid combined with several adjuvants after microneedle array pre-treatment [159]. 
A 1000-fold increase of diphtheria toxoid specific serum IgG levels were obtained 
after microneedle array pre-treatment compared to administration of the vaccine onto 
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intact skin. A further enhancement of the immune-response could be obtained by co-
administration of adjuvants such as lipopolysaccharides, Quil A, CpG 
oligodeoxynucleotide or cholera toxin. Contrary to the use of DT, the application of 
influenza vaccine onto intact skin as well as on skin pre-treated with microneedles 
failed to evoke appropriate immune responses [141]. The group of Hiraishi et al. 
demonstrated that vaccination of guinea pigs using a BCG vaccine coated 
microneedle array patch resulted in robust antigen-specific cellular immune 
responses, comparable to those induced by traditional intradermal BCG vaccination 
using a 26G needle [118]. Immunogenicity of microneedle patches coated with 4 µg 
of an influenza virus like particle (VLP) vaccine in mice was investigated by the group 
of Kim et al [85]. Virus specific IgG was significantly increased after immunization 
using the microneedle patch in comparison to naïve mice and was further enhanced 
in the case of vaccine formulation coatings, which were stabilized with trehalose. 
After challenge with a lethal dose of the influenza virus only those mice survived, 
which were immunized with trehalose-stabilized influenza VLP coated microneedles. 
These results point out that the stabilization of the coated vaccine is crucial in order 
to preserve the protective efficacy of the vaccine. 
In summary, a large number of drugs, proteins, model antigens and vaccines have 
been tested with regards to the physical/chemical stability of the microneedle array 
and/or the bioactive, together with the effect in vivo [67, 108, 114, 125, 126, 142, 
147, 158-164]. Microneedle arrays are a promising novel device, targeting the 
intradermal layer of the skin. 
 
2.2.4 TATTOO DEVICES FOR VACCINATION 
The use of tattoo devices to introduce DNA and peptide vaccines into the dermal 
layer of the skin has been investigated as a new approach for puncture-mediated 
gene transfer [72-77].  
For this purpose a short needle or a bundle of needles oscillate at high frequency, 
thereby puncturing the skin and introducing the vaccine formulation. The major 
advantage of this technique would be that the vaccine is distributed over a large 
surface area, which is thought to facilitate the transfection of a broad cell population.  
The group of van den Berg et al. determined the influence of several tattoo setting 
parameters on antigen expression and transfection efficiency in an ex-vivo human 
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skin model, in order to optimize this technique for clinical application. An increase in 
needle depth, tattoo duration time, and DNA concentration were seen to lead to an 
increase in antigen expression, although the transfection efficiency was very low [72]. 
Pokorná et al. delivered human papillomavirus type 16-derived peptides adjuvanted 
with CpG motifs by the use of a tattoo device, and compared the immune responses 
to s.c. delivered peptides or gene gun mediated transfection. Vaccine delivery by 
tattooing elicited higher specific cellular and humoral immune responses than s.c. 
needle injection. DNA tattoo vaccination stimulated immunity comparable to 
immunizations delivered by the gene gun, however a 10-fold higher dose was used 
for tattoo vaccination in comparison to gene gun delivery [75]. Quaak et al. 
investigated the potential for damage to a DNA vaccine as a result of the tattoo 
procedure. The authors observed a reduction of only 3% of the supercoiled pDNA 
content and formation of open circular pDNA; the impact on the induction of immune 
responses was marginal [77]. 
With regard to patient compliance, it is very questionable if tattooing will be widely 
accepted given that it causes local tissue damage and involves a painful and 
complex vaccination procedure.  
 
2.2.5 LIQUID JET INJECTORS 
Jet injectors were developed in the 1930s and have been used in human mass 
vaccination programs for measles, polio and smallpox for over 50 years [33, 82]. The 
first generation of liquid jet injectors was developed for multiple uses. Major 
drawbacks of the multi-use-nozzle were safety hazards like the transmission of blood 
borne diseases, e.g. hepatitis B [165]. Therefore, new generations of jet injectors 
have disposable cartridges in order to avoid cross-contamination. 
The mechanism of liquid jet injectors relies on the principle of forcing fluids through a 
small orifice, generating a high pressured stream that penetrates into the skin with 
high velocity of approximately 100 m/s. The impact of the fluid on the skin generates 
a hole through which the liquid is forced into the tissue [166]. The actuation of the jet 
injector can either be spring-powered, harnessing the relaxation of a spring, gas-
powered using pressurized carbon-dioxide or helium gas, or pyrotechnically driven 
[167, 168]. The delivery of a liquid vaccine formulation by a liquid jet injector can be 
divided into three general stages. At first a peak pressure phase is observed, 
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followed by the delivery or dispersion phase, and concluding with the drop-off phase 
[169]. During the first stage, when the first stream of liquid pierces the skin, small 
amounts of the liquid can splash back and leave some product residues on the skin 
surface. While any resulting loss of vaccine is negligible, such an occurrence may 
serve to alert the operator to an incorrectly performed administration. The second 
stage provides a wide dispersion of the liquid into the tissue as it forces a path 
through low resistance regions [170]. The depth and shape as well as the 
completeness of the injection is dependent on several technical parameters such as 
the stand-off distance of the device from the skin, the nozzle diameter, the velocity of 
the liquid stream, the mechanical properties of the skin, and the properties of the 
liquid formulation including volume, viscosity and surface tension [82, 166, 171]. It 
has been found, that for the velocity of the liquid stream, a threshold value of at least 
60 to 80 m/s must be reached in order to achieve penetration into the skin. For a 
complete optimal penetration the velocity of the liquid stream has to be approximately 
150 m/s [166]. 
Conflicting opinions exist as to whether the equal or even enhanced immune 
response evoked by the use of liquid jet injectors in comparison to i.m. injections can 
be attributed to the large dispersion pattern of the vaccine and the targeting of more 
APCs located in the superficial layers of the skin [9, 33, 172-175]. Also the possibility 
of a slight inflammation at the injection site might be the reason for enhanced 
immune responses [7, 173, 176]. However, liquid administered by a liquid jet injector 
is flushed through the epidermal and dermal layer of the skin down to the 
subcutaneous fatty tissue, and even to the muscular tissue. Hence, depending on the 
site of the delivery, an effective targeting of LC might not be reached, as such cells 
are generally resident in the epidermal layer of the skin [44]. 
Immunogenicity of a malaria DNA vaccine in rabbits after intramuscular injection 
using a needle and syringe or intramuscular and intradermal jet injection using a 
Biojector™ 2000 (Bioject Inc., Portland, OR, USA) device was investigated by the 
group of Aguiar et al. [177]. Enhanced immune responses were observed using the 
jet injection device in comparison to i.m. needle-injection. Similar antibody responses 
were observed comparing i.m. or a combination of i.m. and intradermal jet injection, 
suggesting that both application methods are equivalent.  
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Fractional doses of an inactivated poliovirus vaccine were given to children in Oman 
using either the Biojector™ 2000 (Bioject Inc., Portland, OR, USA) device, which was 
additionally equipped with a spacer for intradermal administration, or the full dose of 
the vaccine using a conventional needle and syringe system for i.m. administration 
[40]. Similar levels of seroconversion were achieved after the intradermal vaccination 
with fractional doses as after i.m. vaccination with the full dose. However, significantly 
lower median titers were found in the fractional dose group in comparison to the full 
dose group. In contrast to this study significantly lower seroconversion rates were 
found after immunization with fractional doses of an inactivated poliovirus given 
intradermally with the Biojector™ 2000 -device, equipped with an intradermal spacer, 
in comparison to the full dose given i.m. [41]. 
The Biojector™ 2000 has FDA clearance for i.m. and s.c. injection of liquid 
medicines, including vaccines; however intradermal injections are at the moment just 
performed in clinical trials. 
The possibility to deliver polystyrene and PLGA polymer particles into the skin by 
liquid jet injection using a Vitajet 3® device (Bioject Medical Technologies Inc., 
Tualatin, OR, USA) was explored by Michinaka et al. [83]. It was found that the 
effectiveness of particle penetration into the skin was proportional to the injection 
volume. The dispersion area of the polystyrene particles was also observed to 
decrease with increasing particle size. 
Needle-free jet-injection devices have some drawbacks in comparison to the use of a 
needle-syringe system. These include higher costs per unit, the need for 
maintenance of multi-use devices, and a greater complexity of the device in 
comparison to needle and syringe systems. Drawbacks of spring-powered devices 
are the limited range of force and versatility, which do not take into account the broad 
differences in skin thickness occurring as a function of gender and age; gas-powered 
devices also have a distinct disadvantage as they are dependent on an exhaustible 
energy source [169].  
A further disadvantage of liquid jet injection is that pain is caused, both by 
penetration of the liquid into deeper skin layers and by disturbance of sensory nerve 
endings. Blood vessels may also be disrupted as a result of liquid jet administration, 
meaning that bleeding can occur. Local reactions like swelling, erythema, hematoma 
and pain have been reported after vaccination with liquid jet injectors, however the 
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occurrence of these adverse effects might also be dependent on the type of vaccine 
administered and the presence of adjuvants in the formulation [61, 172, 174, 178].  
It has also been discussed, whether shear forces, generated as a result of forcing 
liquid through a small orifice, could damage the administered product. The group of 
Benedek et al. investigated the effects of liquid jet injection using the Iject® system 
(Bioject Inc., Portland, OR, USA) on different model proteins, with a particular focus 
on degradation and aggregation. No damaging effects were observed for the 
selected proteins using the Iject® device. However, these results cannot be 
generalized to all vaccine formulations or to all jet injector devices – each device and 
vaccine formulation must be evaluated individually [84]. The Iject® device as well as 
the Vitajet 3® device from Bioject Medical Technologies Inc. are not readily available 
and proposed only for investigational use.  
The spring powered PharmaJet® device (PharmaJet Inc., Golden, CO) has been 
used for s.c./ i.m. vaccination of pigs, administering a DNA vaccine against swine 
influenza [179]. In comparison to the i.m. vaccination applying a conventional needle 
and syringe injection, the needle-free delivery method using PharmaJet® elicited 
improved immune responses and comparable post-challenge results. 
In 2011 PharmaJet® Inc. (Golden, CO) gained FDA marketing clearance for their 
0.1 ml intradermal needle-free injection system [180]. This device can be used with 
standard off-the-shelf licensed vaccines. 
Major advantages of the liquid jet injection technique are the eradication of hazards 
associated with needle-stick injuries, as all devices provide a needle-free injection 
technique; the potential of liquid jet injections for mass vaccination campaigns using 
existing, approved liquid vaccines is also a considerable positive factor [169].  
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2.2.6 BALLISTIC INJECTORS 
In comparison to liquid jet injectors, ballistic injectors do not accelerate a liquid 
stream towards the skin, but dry, solid particles. 
 
GENE GUN 
The first “gene gun” for particle mediated gene transfer was developed in 1987 by 
Sanford and colleagues [90]. Initially, the gene gun was used to deliver DNA coated 
metal particles of 1 µm diameter into plants in order to modify these genetically. In 
the early 1990s, conventional vaccines and DNA vaccines were delivered to humans 
using the gene gun [91, 92]. A commercially available bench top device, the so called 
Helios device (Bio-Rad, Hercules, CA, USA), is mainly used for genetic immunization 
research and is restricted to research purposes. An adjustable helium pulse of 100 to 
600 psi propels DNA-coated gold microparticles from the inner wall of a Tefzel™ 
tubing system and accelerates them towards a target. Several parameters of the 
target bombardment process have to be optimized in order to enhance transfection 
efficacy and avoid tissue damage. 
Amongst other parameters, the helium pulse and several particle preparation 
conditions must be adjusted experimentally depending on the target. In addition, cells 
containing gold particles may undergo cell death, thereby limiting the effectiveness of 
gene gun-mediated immunization. The costs and complexity of the gene gun 
prohibits its use as a vaccination device for clinical human use or in mass vaccination 
programs. 
 
DEVICES AND VACCINE CARRIER PARTICLES FOR PARTICLE-MEDIATED EPIDERMAL 
DELIVERY (PMED) AND EPIDERMAL POWDER IMMUNIZATION (EPI) 
The following section gives an overview of different devices utilized for PMED, i.e. 
injecting gold particles into the skin or for EPI, where vaccine/sugar particles are 
injected into the skin. A brief summary of preclinical and clinical studies applying 
these techniques is also given. 
On the basis of the gene gun principle, PowderMed Vaccines Inc. (former 
PowderJect, acquired by Pfizer in 2006) and the Bellhouse group at Oxford 
University have developed the PowderJect XR device. This is a multi-use research 
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device that has been used in several preclinical trials, suitable for PMED. The device 
is dependent on an external power and gas source [91]. The device is actuated by 
pressing a trigger, thus opening an electric solenoid valve that controls the release of 
pressurized helium from an external tank. A disposable plastic nozzle containing the 
vaccine cartridge is attached with a snap lock on the device. The vaccine is 
precipitated onto gold particles, which are resuspended in ethanol and filled into the 
tubing of the vaccine cartridge. After drying, the gold particles cover the inner walls of 
the tubing [93]. Upon release of the pressurized helium gas, vaccine coated gold 
particles are entrained in the gas flow, removed from the tubing of the vaccine 
cartridge and accelerated to high velocities. 
Convergent-divergent supersonic nozzle (CDSN) devices 
The same Oxford University group has also developed a hand-held, single use, 
disposable device which is suitable for clinical research and the delivery of vaccine 
powders for EPI, the PowderJect ND device. The design of the nozzle is convergent 
– divergent (Laval nozzle), which allows for acceleration of the vaccine particles to 
supersonic speed. [94]. This device comprises a cartridge with pressurized helium or 
nitrogen of 2-6 MPa and a vaccine cassette made up of two rupture polyurethane or 
polycarbonate membranes of approximately 20 µm thickness. The vaccine cassette 
can hold a powdered payload of approximately 0.5- 5 mg [94]. Upon actuation of the 
delivery device, the compressed helium rapidly expands, rupturing the diaphragms of 
the vaccine cassette and drawing the particles into the helium gas flow. The particles 
are propelled down the convergent-divergent nozzle towards the skin with high 
velocity. A silencer, attached around the nozzle, dampens the noise level by laterally 
venting the gas. The forward momentum of the particles allows them to penetrate into 
the superficial layers of the target skin site [58, 181-183]. 
Investigations of the gas and particle dynamics of this device revealed that after the 
starting process the emergent gas flow undergoes flow separation before converting 
to a quasi-steady supersonic flow. Large variations in gas density and velocity induce 
non-uniformities in the resulting particle velocity, which ranges from 200 m/s to 800 
m/s. Inconsistent spatial particle distributions are a further result of gas density and 
velocity variations [95, 184, 185]. 
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Contoured shock tube (CST) - devices 
The convergent-divergent nozzle design of the first prototype devices was replaced 
by a CST design (figure 9.9) enabling the acceleration of vaccine particles to more 
uniform velocity (> 700 m/s [96]) and spatial particle distribution. Employing this 
approach led to drastic reduction in variations in the free-jet particle velocity at the 
device exit [95]. 
 
Figure 9.9: Hand-held PowderJect device with a convergent-divergent supersonic 
nozzle design. Figure reprinted from Liu Y et al. [186]. 
One of the drawbacks of a vaccine cartridge comprising rupture membranes is the 
potential risk that fragments of the sealing membranes are incorporated together with 
the particles in the gas flow and are also accelerated towards the target. However, no 
damage to the target was found as a result of membrane fragments in in vitro and in 
vivo experiments [187]. 
Another initial disadvantage of the CST device was the noise level of the device. A 
silencer was therefore attached around the nozzle [95]. The addition of a silencer and 
the creation of a standing-off shock wave in the impingement region reduced the 
particle impact velocity from 699 ± 4.7 m/s as simulated in a free jet to 504.5 ± 64.46 
m/s [186, 188].  
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Additionally drawbacks, such as unsatisfactory spatial particle distributions with 
particle overload in the central target area, and the entrapment of considerable 
volumes of vaccine powder on the rupture membranes and on the inner walls of the 
device, led to further optimization of the device and vaccine cartridge design [98, 99, 
185]. 
Venturi devices 
The development of devices called Venturi devices has been described by Liu and 
co-workers [97-99]. In this setup, the vaccine particles are not enclosed in 
polycarbonate membranes but are loosely packed in the cavity of the device. Upon 
actuation a high speed gas flow is generated that carries the particles down a conical 
nozzle. The authors state that the Venturi device provides more uniform velocity 
distributions compared to earlier developed devices. The computed particle velocities 
in a free jet covered a range from 400 – 800 m/s, with a mean velocity of 654.4 m/s ± 
11.96 m/s [98].  
Gold particles for PMED 
Different physical particle characteristics such as size, density, shape and 
morphology determine whether particles are able to breach the SC of the skin and 
have an influence on the penetration depth of the particles. A tight mono-modal 
particle distribution as well as a high rigidity of the particles is necessary for efficient 
and targeted particle delivery. 
Gold particles of 1-3 µm in size have a high density and can be introduced into the 
skin by ballistic injection. These particles are mainly deposited intracellularly [189]. 
For the delivery of DNA vaccines, gold particles are generally used for direct 
targeting of immunocompetent cells in the epidermal layers of the skin [91, 190, 191].  
Deceleration of the particles within the tissue leads to stress and shock waves within 
the tissue. Direct impact of the gold particles can result in cell death [187, 192].  
Proponents of PMED vaccination emphasize that PMED is a quick and easy 
procedure, applicable for all types of cell targeting and requiring only small amounts 
of DNA. However, the amount of DNA that can be precipitated onto the gold particles 
is limited by the surface capacity of the particles. Gold particles tend to agglomerate if 
higher amounts of vaccines are used. Furthermore, dependent on the type of DNA 
vaccine, the amount of DNA delivered within one payload might not be sufficient to 
evoke an appropriate immune response and therefore multiple shots at multiple 
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delivery sites may be necessary [183, 190, 193]. Advantages of the PMED method 
using gold particles are that with one vaccine particle payload a large number of cells 
are directly targeted. This offers higher transfection efficiency, unlike other 
approaches that perfuse the extracellular space with liquid vaccine formulation [91, 
194, 195]. The use of gold particles as carrier particles may also prove too costly for 
mass vaccination campaigns. 
Preclinical and clinical studies applying PMED 
Tacket et al. investigated the safety and immunogenicity of a DNA vaccine encoding 
for hepatitis B surface antigen delivered by a PowderJect XR1 device in a phase I 
study to seven healthy volunteers [193]. Two administrations of vaccine were given 
onto two skin sites on the posterior upper arm, choosing one of three different helium 
pressure levels of the PowderJect XR1 device. The schedule was repeated after 56 
days. Local site reactions appeared within minutes following vaccine delivery, their 
severity correlated to the used helium pressure level. Local site reactions generally 
lasted for minutes, with a faint area of erythema persisting for 56 days in some 
volunteers. No primary immune responses were observed.  
The dose-response relationship of hepatitis B virus DNA vaccine coated on gold 
microparticles and administered using the PowderJect device was investigated by the 
group of Roy et al. All three dose levels (1, 2 or 4 µg) administered at two to four 
delivery sites induced protective antibody responses and proliferation of antigen 
specific CD8+ and CD4+ T cells after three immunization intervals [183]. Rottinghaus 
et al. found similar results when comparing a Hepatitis B DNA vaccine to a 
conventional vaccination in non-responders [196]. Chen et al. demonstrated that skin 
bombardment with antigen coated gold particles using the PowderJect XR1 device 
was able to induce both augmented antibody and CTL responses against several 
viral protein antigens in mice. Histological examinations of the skin vaccination sites 
revealed intracellular localization of the gold particles in keratinocytes and also in LCs 
in the draining lymph nodes. In a skin target area of approximately 113 mm² 
approximately 50% of the LCs were directly targeted [189].  
A prophylactic nucleic acid vaccine against Hepatitis B virus was coated on gold 
particles and delivered using either a PowderJect XR-1 device or the commercial 
prototype device ND 5.5. The vaccine was administered as a single boost in 
previously immunized healthy adults. A 2 µg amount of DNA was precipitated onto 1 
mg gold particles and was administered to two or four skin sites, resulting in a total 
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dose of 4 µg or 8 µg DNA respectively. Both devices demonstrated similar 
performance and were able to boost both antibody and cell-mediated immune 
responses [93]. 
A dose escalation trial was conducted by the group of Drape et al. evaluating a 
monovalent influenza DNA vaccine delivered by PMED. All three dose levels studied 
led to serum haemagglutination inhibition (HAI) antibody responses. However, only 
the highest dose level, administered four times, met the requirements of the 
Committee for Proprietary Medical Products (CPMP) [197].  
 
Powdered sugar particles for EPI 
In addition to gold particles, vaccine antigen can also be delivered in the form of 
powdered sugar particles. In this case vaccine antigen is mixed with excipients like 
trehalose, mannitol or dextran and formulated into dry particles by applying different 
processes such as spray drying, spray freeze-drying, freeze-drying, spray coating or 
simple desiccation [198-203]. Applying freeze-drying or desiccation requires a 
subsequent pulverizing step where particle sizes are reduced to diameters of 20 to 
70 µm [182, 199]. As in the case of gold particles, the powdered sugar particles are 
accelerated to high velocities by the use of appropriate ballistic devices in order to 
penetrate the superficial layers of the skin. Sugar particles are generally larger in 
size, approximately 20-70 µm or 25-100 µm, as compared to gold particles. Larger 
sizes are used to achieve the necessary impact to penetrate skin due to their lower 
density (~700-1,200 kg/m³) compared to gold [204, 205].  
Due to their size and high water solubility, sugar particles are predominantly 
deposited in the extracellular region, and dissolve rapidly [190]. Antigen entrapped 
within these particles can therefore be endocytosed by immunocompetent APCs in 
targeted tissue. 
Advantages of powdered sugar particles include a cheap and easy manufacturing 
process, a high loading capacity of the sugar matrix with vaccine antigen, and the 
ability to store the formulation at room temperature without cooling [15]. However, as 
mentioned above sugar particles have a markedly lower density (~1,000 kg/m³) in 
comparison to gold particles [206], which may hinder ballistic delivery. Furthermore, 
the hygroscopicity of the sugar particles requires gas-tight packaging of the vaccine 
cartridge. 
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Preclinical and clinical studies applying EPI 
Chen et al. investigated the immunogenicity of an influenza vaccine and protection 
responses induced following challenge in a mouse model [182]. The vaccine was 
formulated with trehalose and prepared by desiccation, grinding and sieving in order 
produce powder particles of 20 to 53 µm in size. The powdered vaccine particles 
were administered using a PowderJect ND device, and the results were compared to 
conventional i.m. or s.c. injection. Prime immunization using powder injection elicited 
higher serum immunoglobulin titers to influenza virus than i.m. or s.c. injection. After 
boosting, the powder immunization elicited antibody titers 300% and 700% higher 
than after boosting by i.m. or s.c. injection. Challenge experiments showed that EPI 
also resulted in protection against mortality, weight loss and virus replication in the 
lungs of the mice [182].  
In a phase I clinical trial, a trivalent influenza vaccine was administered by EPI using 
the PowderJect ND5.2 device and compared to conventional i.m. injection. The 
powdered vaccine was prepared by spray freeze-drying, and contained 45 µg 
haemagglutinin (HA)/ mg powder. Subjects received EPI on either one or two skin 
sites. Strong antibody responses were elicited using EPI, meeting the requirements 
of the CPMP. Results were comparable to i.m. injection. Local site reactions like 
erythema, petechiae, oedema and skin discoloration were prominent after EPI [58]. 
The immunogenicity of recombinant envelope protein gp20 (rgp120), a human 
immunodeficiency virus (HIV) component, was investigated, following either 
precipitation onto gold particles or formulation together with trehalose as powder 
particles. Both such formulations were administered to mice by EPI, and compared to 
conventional administration via i.m. injection. Higher antibody responses were 
achieved as a result of HIV rgp120 administration by EPI in comparison to i.m. 
injection. Trehalose-formulated rpg120 powder particles induced IgG1 antibody 
responses, whereas rpg120 precipitated onto gold particles induced IgG1, IgG2a and 
IgG2b subclass antibody responses and CTL responses. The type of vaccine 
formulation as well as the deposition of the particles (intra- or extracellular) may have 
an impact on the observed differences in immune responses [207]. Osorio et al. 
demonstrated that administration of hepatitis B surface antigen (HBsAg) in mice via 
EPI resulted in superior immune responses in comparison to i.m.-injected, non-
adjuvanted HBsAg. Similar immune responses were obtained in comparison to alum-
adjuvanted HBsAg injected i.m.  Adjuvantation of HBsAg with CpG DNA and 
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administration by EPI induced more efficient immune responses than a 
corresponding i.m. injection, and resulted in activation of T-helper cells [208]. 
Ballistic injectors have not gained regulatory approval for use in humans but are 
widely used in preclinical and clinical studies.  
 
 
2.3 TECHNICAL AND REGULATORY CHALLENGES  
Several technical challenges have to be overcome in order to bring a novel device 
targeting the intradermal layers of the skin to the level of clinical studies, and further 
to market release. Firstly, the device must reach the targeted region - the intradermal 
tissue with resident immunocompetent LCs. The potential for dose-sparing by 
intradermal delivery has to be determined case-by-case, for each individual vaccine 
and corresponding delivery device, so that adequate immunogenicity and sufficient 
protection is ensured. For optimal patient acceptance and widespread use, for 
example in mass vaccination programs, the device should be easy and intuitive to 
use, and should be effective for delivery to a variety of patient groups with different 
skin types (children, adults and people with different ethnical heritage). Furthermore, 
the device has to be competitive in terms of cost with conventional vaccination 
systems such as needles and syringes. In order to facilitate regulatory approval, it is 
advantageous if the device permits the use of standard off-the-shelf licensed 
vaccines. In this case, an application for marketing clearance may be made for the 
device under the regulations of the medical device directive, a pre-market notification 
(510(k)) or pre-market approval (PMA). In such a case, it must be proven that the 
vaccine is compatible with the injector, and that the use of the device in question will 
not change the characteristics of the marketed vaccine. In some cases it might be 
necessary to concentrate the vaccine so that it can be delivered in a reduced volume 
appropriate for intradermal injection (around 100 µl per dose). Such reformulations as 
well as the use of fractional doses of vaccines would require a licensing amendment. 
If the injector is intended for use with a specific vaccine formulation, and is therefore 
pre-filled or co-packaged with that product, a new drug application (NDA) or 
biological licensing application (BLA) is required for FDA clearance. Furthermore, it 
has to be defined if the injector is intended for self-administration, or use by a health 
care provider, and if the device is designed for single-use or can be reused.  
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2.3.1 Issues and challenges surrounding the stability of vaccines 
Dry powder vaccine formulations can offer improved stability [15, 209, 210], opening 
up the possibility for independence from cold-chain transport and storage. However, 
approved vaccines are mostly provided as liquid formulations. Microinjection devices, 
liquid jet injectors and hollow microneedles can be used with approved liquid vaccine 
formulations, whereas a reformulation of the vaccine is required for solid 
microneedles and ballistic delivery of dry powders. Significant research has to be 
undertaken in order to stabilize vaccines coated on microneedles [147] or to develop 
dry powders for ballistic injection which are capable of achieving regulatory 
clearance. 
 
 
2.4 CONCLUSION 
Delivery systems targeting the skin have attracted growing attention during the last 
years. Needle-free delivery systems are associated with significant advantages, 
particularly with regard to safety issues and application in mass vaccination 
programs. Also, the potential for vaccine dose reduction by targeting the intradermal 
layers of the skin strengthens the position of intradermal vaccination devices and 
offers savings in delivery costs and coverage of a broad population with vaccines in 
limited supply. An effective targeting of immunocompetent cells in the epidermal layer 
of the skin has been made possible due to considerable progress in device 
development. Even though the potential of needle-free injections and the targeting of 
the epidermal layer of the skin is the focus of a lot of research groups, only a few 
delivery devices have progressed to clinical trials and are currently approved for 
commercial use.. These include devices which are compatible with existing liquid or 
lyophilized formulations, such as the liquid jet injector PharmaJet®, the MicronJet® 
device, and the intradermal microinjection system BD Soluvia®. 
So far, there is no device approved for intradermal vaccination delivering a dry solid 
vaccine, although promising development in this field has been made by PMED and 
EPI techniques. Dry solid vaccine formulations offer considerable advantages, in 
terms of enhanced stability and the potential for cold chain independency. The ability 
to deliver such vaccines via an intradermal device may therefore be preferable to 
delivery of liquid vaccine formulations by conventional needles and syringes. 
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However, reformulation of existing vaccines might be required using solid injection 
systems. 
Recent technologies like tattoo vaccination are not likely to surpass the experimental 
stage, as they are associated with a painful and complex vaccination procedure.  
Microneedle arrays are still in a development process but encouraging data has been 
reported. Operational challenges like the reproducibility of the coating procedure and 
of antigen delivery must be overcome in order to gain regulatory approval for such 
systems.  
In conclusion, while there has been considerable development of intradermal 
vaccination devices in the past years, there is still a need for further improvement to 
the design of devices for intradermal administration in order to fulfil their potential to 
be competitive with conventional needle and syringe forms of administration. 
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